

Diseases of Poultry

13th
EDITION

Editor in Chief: David E. Swayne

Associate Editors: John R. Glisson,
Larry R. McDougald, Lisa K. Nolan,
David L. Suarez, and Venugopal Nair

Contents

<i>Contributors</i>	xi		
<i>Preface</i>	xix		
<i>Introduction</i>	xxv		
SECTION I: GENERAL CONCEPTS OF POULTRY DISEASES			
1 Principles of Disease Prevention, Diagnosis, and Control	1		
Introduction, <i>S.R. Collett</i>			
Principles of Disease Prevention, Diagnosis, and Control Introduction, <i>S.R. Collett</i>	3		
Antimicrobial Therapy (Including Resistance), <i>C.L. Hofacre, R.S. Singer and T.J. Johnson</i>			
Public Health Significance of Poultry Diseases, <i>R.D. Berghaus and B. Stewart-Brown</i>			
2 Host Factors for Disease Resistance	61		
Introduction, <i>J.M. Sharma</i>			
The Avian Immune System, <i>J.M. Sharma and S. Rautenschlein</i>			
Genetics of Disease Resistance, <i>H.H. Cheng and S.J. Lamont</i>			
SECTION II: VIRAL DISEASES			
3 Newcastle Disease, Other Avian Paramyxoviruses, and Avian Metapneumovirus Infections	87		
Introduction, <i>D.L. Suarez</i>			
Newcastle Disease, <i>P.J. Miller and G. Koch</i>	89		
Avian Paramyxoviruses 2-11, <i>E. Mundt</i>			
Avian Metapneumovirus, <i>R.C. Jones and S. Rautenschlein</i>			
4 Infectious Bronchitis, <i>M.W. Jackwood and S. de Wit</i>	139		
5 Infectious Laryngotracheitis, <i>M. Garcia, S. Spatz, and J.S. Guy</i>	161		
6 Influenza, <i>D.E. Swayne, D.L. Suarez, and L.D. Sims</i>	181		
7 Infectious Bursal Disease, <i>N. Etteradossi and Y.M. Saif</i>		219	
8 Chicken Infectious Anemia Virus and Other Circovirus Infections		247	
Introduction, <i>K.A. Schat and L.W. Woods</i>			
Chicken Infectious Anemia, <i>K.A. Schat and V.L. van Santen</i>			
Circovirus Infections of Avian Species, <i>L.W. Woods and K.S. Latimer</i>			
9 Adenovirus Infections		289	
Introduction, <i>S.D. Fitzgerald</i>			
Aviadenovirus Infections, <i>M. Hess</i>			
Atadenovirus (Egg Drop Syndrome and Related Infections), <i>J.A. Smyth</i>			
Hemorrhagic Enteritis and Related Infections, <i>F.W. Pierson and S.D. Fitzgerald</i>			
Quail Bronchitis, <i>W.M. Reed and S.W. Jack</i>			
10 Pox, <i>D.N. Tripathy and W.M. Reed</i>		333	
11 Reovirus Infections, <i>R.C. Jones</i>		351	
12 Viral Enteric Infections		375	
Introduction, <i>Y.M. Saif</i>			
Turkey Coronavirus Enteritis, <i>J.S. Guy</i>			
Rotavirus Infections, <i>J.M. Day</i>			
Astrovirus Infections, <i>S.L. Schultz-Cherry</i>			
Avian Enterovirus-Like Virus Infections, <i>C.S. Hayhow</i>			
Enteric Parvovirus Infections of Chickens and Turkeys, <i>L. Zsak</i>			
13 Viral Infections of Waterfowl		417	
Introduction, <i>P.R. Woolcock</i>			
Duck Hepatitis, <i>P.R. Woolcock and H.-J. Tsai</i>			
Duck Virus Enteritis (Duck Plague), <i>S.A. Metwally</i>			
Hemorrhagic Nephritis Enteritis of Geese, <i>J.-L. Guérin</i>			
Parvovirus Infections of Waterfowl, <i>V.J. Palya</i>			

465	<i>Mycoplasma synoviae</i> Infection, <i>N. Ferguson-Noel</i> and <i>A.H. Noormohammadi</i>	
	<i>Mycoplasma iowae</i> Infection, <i>J.M. Bradbury</i> and <i>Z. Raviv</i>	
	Other Mycoplasmal Infections, <i>N. Ferguson-Noel</i>	
22	Clostridial Diseases	943
	Introduction, <i>C.M. Logue</i>	
	Ulcerative Enteritis, <i>J.G. Songer</i> and <i>F.Uzal</i>	
	Necrotic Enteritis, <i>K. Opengart</i> and <i>J.G. Songer</i>	
	Botulism, <i>H. Skarin</i> , <i>G. Blomqvist</i> and <i>V. Båverud</i>	
513	Gangrenous Dermatitis, <i>K. Opengart</i>	
23	Other Bacterial Diseases	971
	Introduction, <i>C.M. Logue</i>	
	Staphylococcosis, <i>C.B. Andreasen</i>	
	Streptococcus and Enterococcus, <i>S.G. Thayer</i> and <i>W.D. Waltman</i>	
	Erysipelas, <i>J.M. Bricker</i> and <i>Y.M. Saif</i>	
	Avian Intestinal Spirochetosis, <i>D.J. Hampson</i>	
	Tuberculosis, <i>R.M. Fulton</i> and <i>S. Sanchez</i>	
	Miscellaneous and Sporadic Bacterial Infections, <i>T. Abdul-Aziz</i> and <i>H.J. Barnes</i>	
24	Avian Chlamydiosis, <i>D. Vanrompay</i>	1055
	SECTION IV: FUNGAL DISEASES	1075
25	Fungal Infections, <i>M.J. Dykstra</i> , <i>B.R. Charlton</i> , <i>R.P. Chin</i> , and <i>H.J. Barnes</i>	1077
	SECTION V: PARASITIC DISEASES	1097
26	External Parasites and Poultry Pests, <i>N.C. Hinkle</i> and <i>R.M. Corrigan</i>	1099
27	Internal Parasites, <i>L.R. McDougald</i>	1117
28	Protozoal Infections	1147
	Introduction, <i>L.R. McDougald</i>	
	Coccidiosis, <i>L.R. McDougald</i> and <i>S.H. Fitz-Coy</i>	
	Cryptosporidiosis, <i>L.R. McDougald</i>	
	Histomoniasis (Blackhead) and Other Protozoan Diseases of the Intestinal Tract, <i>M. Hess</i> and <i>L.R. McDougald</i>	
	Miscellaneous and Sporadic Protozoal Infections, <i>A.J. Bermudez</i>	
	SECTION VI: NONINFECTIOUS DISEASES	1203
29	Nutritional Diseases, <i>K.C. Klasing</i>	1205
30	Developmental, Metabolic, and Other Noninfectious Disorders, <i>R. Crespo</i> and <i>H.L. Shivaprasad</i>	1233
31	Mycotoxicoses, <i>F.J. Hoerr</i>	1271
32	Toxins and Poisons, <i>R.M. Fulton</i>	1287

SECTION VII: OTHER DISEASES

33	Emerging Diseases and Diseases of Complex or Unknown Etiology	1317	Hypoglycemia-Spiking Mortality Syndrome of Broiler Chickens, <i>J.F. Davis</i>
	Introduction, <i>Y.M. Saif</i>	1319	Proventriculitis and Proventricular Dilatation of Broiler Chickens, <i>S. Hafner</i> and <i>J.S. Guy</i>
	Multicausal Respiratory Diseases, <i>J.R. Glisson</i>		
	Multicausal Enteric Diseases, <i>M.J. Pantin-Jackwood</i>		<i>Index</i>
			1341

93. Evaluation of cross-contam-
removal equipment. *Poult Sci.*
K.F. Snowden, C.P. Kurtzman,
genetic analysis identifies the
ovel anamorphic ascomycetous
er, gen. nov., sp. nov. *Int J Syst*
2003. Reticuloendotheliosis. In:
. Saif, H.J. Barnes, J.R. Glisson,

A.M. Fadly, L.R. McDougald, and D.E. Swayne, eds. Iowa State
University Press, Ames, Iowa. 517-539.
46. Witter, R.L., and K.A. Schat. 2003. Marek's disease. In:
Diseases of Poultry, 11th ed. Y.M. Saif, H.J. Barnes, J.R. Glisson,
A.M. Fadly, L.R. McDougald, and D.E. Swayne, eds. Iowa State
University Press, Ames, Iowa. 407-465.
47. Yu, L., Y. Jiang, S. Low, Z. Wang, S.J. Nam, W. Liu, and J.
Kwang. 2001. Characterization of three infectious bronchitis
virus isolates from China associated with proventriculitis in
vaccinated chickens. *Avian Dis.* 45:416-424.

Index

Page references followed by f denote figures.

- AAAV (avian adeno-associated virus),
316-317
- AAS (avian adenovirus splenomegaly),
309-316
- Abscess, necropsy examination
of, 32
- Acanthocephalans, 1133-1134,
1133f-1134f
- Access control
to complex, 23
to farm/site, 20-21
to poultry house, 16-17
- Acholeplasma*, 876
- Acinetobacter*, 1017
- Acquired immunity, in Marek's
disease, 544-545
- Actinomyces*, 1018
- Active immunity
avian encephalomyelitis, 492
avian leukosis/sarcoma viruses, 584
avian metapneumovirus, 116-117
beak and feather disease, 273
bordetellosis, 841-842
Borrelia anserina infection, 1020
chicken infectious anemia, 259
circovirus, 273
duck virus enteritis (duck plague),
438-439
erysipelas, 992
hemorrhagic enteritis, 314
infectious bronchitis, 147, 149
infectious bursal disease, 230
infectious laryngotracheitis, 170
influenza virus, 200-201
Mycoplasma iowae, 909
Mycoplasma meleagridis, 898
necrotic enteritis, 952
Newcastle disease, 101-102
parvovirus of chickens and turkeys,
404
rotavirus, 389-390
turkey coronavirus enteritis, 380
ulcerative enteritis, 946
- Acute reticulum cell neoplasia, 600,
600f, 601
- Adaptive immunity, 66-67
- Adenocarcinoma
alimentary, 611, 612f
lung, 614, 614f
ovary, 605, 606f
oviduct, 609-610, 609f-610f
pancreatic, 613, 613f
- Adenoma
adrenal gland, 616
alimentary, 611
hepatoma, 612, 612f
infraorbital sinus, 613
integumentary system, 619
parathyroid gland, 616
pituitary gland, 616
- Adenovirus infections, 289-320.
See also specific diseases;
specific virus
atadenovirus, 301-309
aviadenovirus, 290-300
classification, 289-290, 289t-290t
hemorrhagic enteritis, 309-316
overview, 289-290
quail bronchitis, 316-320
in waterfowl, 420-421
- Adherence to intestinal epithelial cells,
by *Salmonella*, 695
- Adhesins
Escherichia coli, 757, 758t, 759
Mycoplasma gallisepticum, 879
- Adjuvant, 35, 867
- Adrenal gland neoplasia, 616
- AEEC (attaching and effacing
Escherichia coli), 759,
773, 773f
- Aegyptianella*, 1017
- Aeromonas*, 1017-1018
- Aflatoxins, 1276-1279
etiology and toxicology, 1276
experimental disease, 1276-1279,
1278f
metabolism and residues, 1279
natural disease, 1276, 1277f
pharmacological interactions, 1279
- AFLP. *See* Amplified fragment length
polymorphism (AFLP)
analysis
- Agar gel diffusion precipitin (AGDP)
test
for duck hepatitis virus type 1, 427
for fowl cholera, 811
- Agar gel immunodiffusion (AGID) test
for Gallid herpesvirus type 1, 171
for hemorrhagic enteritis virus,
314-315
for influenza virus, 189, 202
for quail bronchitis virus, 319
for ulcerative enteritis, 948
- Agar gel precipitation (AGP) test
for infectious bronchitis virus,
150-151
for infectious bursal disease, 230, 233
for Marek's disease, 547
for *Ornithobacterium rhinotracheale*,
829, 832
for parvovirus of waterfowl, 449
for reovirus, 359, 360
for reticuloendotheliosis, 603
for *Riemerella anatipestifer*, 824

- Amoebotaenia cuneata*, 1137, 1137f–1139f, 1138, 1139
- Amoxicillin, for *Ornithobacterium rhinotracheale*, 834
- Amphimerus elongatus*, 1144
- Amplified fragment length polymorphism (AFLP) analysis
for *Campylobacter*, 742
for *E. coli*, 756
for *Mycoplasma gallisepticum*, 880
for *Mycoplasma iowae*, 908, 910
for *Ornithobacterium rhinotracheale*, 830
for *Pasteurella multocida*, 812
- Amprolium, for coccidiosis, 1159–1160, 1161, 1165
- aMPV. *See* Avian metapneumovirus (aMPV)
- AMV (avian myeloblastosis virus), 556, 556f, 559, 561–562, 563t, 564–565, 576, 580
- Amyloidosis, 1236–1238, 1237f
- Anemia, chicken infectious, 248–264
- Aneurysm, dissecting, 1251–1252
- Angara disease. *See* Hydropericardium syndrome (HS)
- Animals, access to poultry house by, 16–17
- Anthelmintic toxicity, 1292
- Antibiotics. *See* Antimicrobials
- Antibody-dependent cellular cytotoxicity (ADCC), 63
- Antibody level, measurement of, 70
- Anticoagulant toxicity, 1301
- Anticoccidials, 1159–1161
characteristics of, 1159–1160
drug resistance, 1160–1161
programs for use of, 1160
table of preventative, 1159t
toxicity, 1290–1291
in turkeys, 1165
- Antifreeze (ethylene glycol) toxicity, 1303
- Antifungal agents
for aspergillosis, 1087–1088
for mycotoxicosis prevention, 1284
- Antigen-capture ELISA
for eastern equine encephalitis, 477
for infectious bursal disease, 232
- Antigenic drift in influenza viruses, 189–190
- Antigenic shift in influenza viruses, 190
- Antigen-presenting cell (APC), 64–65
- Antimicrobials, 40–43
judicious use principles, 41–42
pharmacologic consideration, 41
for arizonosis, 713
for avian intestinal spirochetosis, 1006–1007
for bordetellosis, 834–844
for *Borrelia anserina*, 1019
for chlamydiosis, 1068
for *Clostridium botulinum*, 957
for enterococcosis, 983
for erysipelas, 994
for *Escherichia coli* infection, 784–785
for fowl cholera, 821–822
for infectious coryza, 868
for *Mycoplasma gallisepticum*, 892–893
for *Mycoplasma iowae*, 910
for *Mycoplasma meleagridis*, 899–900
for *Mycoplasma synoviae*, 906
for *Ornithobacterium rhinotracheale*, 833–834
for paratyphoid infections, 706
for *Pseudomonas*, 1025
for pullorum disease and fowl typhoid, 692–693
resistance, 42–43, 43f
for *Riemerella anatipestifer*, 828
routes of medication, 40–41
for staphylococcosis, 977
for streptococcosis, 980
toxicity, 1288–1291
aminoglycosides, 1290
antiprotozoals, 1291
arsenical and imidazole feed additives, 1291
ionophores, 1290–1291
nitrofurans, 1289–1290
sulfonamides, 1288–1289
for tuberculosis, 1017
for ulcerative enteritis, 948–949
- Antinutrients, 1292
- Antiprotozoals, toxicity of, 1291
- ANTU (alpha-naphthyl thiourea) toxicity, 1301
- Aortic rupture, 1251–1252, 1251f
- APC (antigen-presenting cell), 64–65
- APEC (avian pathogenic *Escherichia coli*), 48
- Apoptosis
beak and feather disease virus, 273
chicken infectious anemia virus, 257
infectious bursal disease and, 231
influenza virus, 193, 200
Marek's disease, 540
- Apramycin, for colibacillosis, 784
- Aproctella stoddardi*, 1124–1125, 1124f
- Aquabirnavirus, 219
- Arasan toxicity, 1299
- Arbitrary primed PCR (AP-PCR), for *Pasteurella multocida*, 813
- Arbovirus
classification, 473–474
Flaviviridae, 474
Togaviridae, 473–474, 474f
eastern equine encephalitis (EEE), 474–477, 474f, 476f
etiology, 473–474
Highlands J virus, 478
Israel turkey meningoencephalitis, 478–479
laboratory host system, 474
public health significance, 44–45, 473
nature of disease in humans, 44
occurrence, 44–45
reservoirs and sources of infection, 45
western equine encephalitis (WEE), 477–478
West Nile virus, 479–482
- Arcanobacterium*, 1018
- Argas persicus* (fowl tick), 1105, 1105f
- Arginine deficiency, 1207
- Arizonosis, 706–713
antigenic structure, 708
biochemical properties, 707–708, 708t
classification, 707
clinical signs, 709, 709f–710f
colony morphology, 707
definition and synonyms, 707
diagnosis, 711
differential diagnosis, 711
economic significance, 707
etiology, 707–708
growth requirements, 707
history, 707
incidence and distribution, 708
intervention strategies, 711–713
isolation and identification of causative agent, 711
management procedures, 711–712
morphology and staining, 707
mortality, 709
natural and experimental hosts, 708
overviews, 706–707
pathogenesis, 711
pathology, 709–711
gross lesions, 709–710, 710f
public health significance, 707
resistance to chemical and physical agents, 708
serology, 711, 712
transmission, 709
treatment, 713
vaccination, 712–713
virulence factors, 711
- Arrhenoblastoma (arrhenoma), 607–608, 608f
- Arsanilic acid toxicity, 1291
- Arsenic toxicity, 1291–1292, 1294
- ART (avian rhinotracheitis). *See* Avian metapneumovirus (aMPV)
- Arthritis
E. coli osteoarthritis, 777–778
viral arthritis, 352–361
- Arthropathy, amyloid, 1237, 1237f
- Arthropod pests, 1105–1109
Alphitobius diaperinus (lesser mealworm/darkling beetle), 1105–1107, 1106f
bed bugs, 1108, 1109f
control recommendations, 1108–1109
flies, 1107–1108, 1107f–1108f
- Articular urate deposition, 1255–1256, 1256f
- Ascaridia bonasae*, 1121
- Ascaridia columbae*, 1120f, 1121
- Ascaridia compar*, 1120f, 1121
- Ascaridia dissimillis*, 1120f, 1121
- Ascaridia galli*, 1120f–1121f, 1121
- Ascaridia numidae*, 1121
- Ascaridia* spp., 1120–1121, 1121f
- Ascarid larvae, necropsy examination and, 32
- Ascites, in colibacillosis, 771
- Ascites syndrome. *See* Pulmonary hypertension syndrome (PHS)
- Asclepidin toxicity, 1305
- Aspergillosis, 1078–1088
biochemical properties, 1079
classification, 1078
clinical signs, 1081–1083, 1081f
colony morphology, 1078, 1079
definition and synonyms, 1078
diagnosis, 1085–1087
differential diagnosis, 1087
economic significance, 1078
etiology, 1078–1080
growth requirements, 1079
history, 1078
incidence and distribution, 1080–1081
incubation period, 1082
isolation and identification of agent, 1085–1086
management procedures, 1087–1088
morbidity and mortality, 1083
morphology and staining, 1078–1079
natural and experimental hosts, 1081
pathobiology and epidemiology, 1080–1085
pathogenesis, 1085
pathology, 1083–1085
gross lesions, 1083–1084, 1083f–1084f
histopathology, 1084–1085, 1084f
public health significance, 1078
serology, 1086–1087
susceptibility to chemical and physical agents, 1079–1080
toxins, 1080
transmission, carriers, and vectors, 1082
virulence factors, 1080
- Aspergillus citrinin*, 1280
- Aspergillus flavus*, 1276, 1281
- Aspergillus ochraceus*, 1279
- Aspergillus oryzae*, 1281
- Aspergillus parasiticus*, 1276
- Asphyxiation, 1234–1235
- Aspirin, for colibacillosis, 785
- Association mapping, 74
- Astrocytoma, 614–615, 614f
- Astrovirus (AstV), 391–395. *See also* Avian nephritis
avian nephritis virus, 467–473
classification, 391, 392f, 393
clinical signs, 393–394
diagnosis, 394
etiology, 392–393
immune response, 394
incidence and distribution, 391–392
intervention strategies, 395
laboratory host systems, 393
morphology, 392, 393f
overview, 391
pathogenesis and epidemiology, 393–394
pathology, 394
gross lesions, 394
histological lesions, 394
phylogenetic tree of, 469f
susceptibility to physical and

- poor feed conversion and growth, 297
in turkeys, 297
- definitions and synonyms, 290
diagnosis, 299–300
economic significance, 290–291
etiology, 291–294
hemagglutination, 292
history, 291
immunity, 299
immunosuppression, 299
incidence and distribution, 294
incubation period, 295
intervention strategies, 300
laboratory host systems, 294
management procedures, 300
morphology, 291, 291f–293f
natural and experimental hosts, 294
pathobiology and epidemiology, 294–299
pathogenicity, 294
pathology, 298–299
Gizzard erosions, 299, 299f
hydropericardium syndrome, 298–299
inclusion body hepatitis, 296f, 298, 298f
pancreatitis, 299
respiratory disease, 299
public health significance, 291
serology, 300
strain classification, 292–294
antigenicity, 292
immunogenicity and protective characteristics, 292
molecular characteristics, 292, 294
susceptibility to physical and chemical agents, 292
transmission, 295
vaccination, 300
virus isolation, 299–300
virus replication, 292
- Avian adeno-associated virus (AAAV), 316–317
- Avian adenovirus splenomegaly (AAS), 309–316
- Avian arizonosis. *See* Arizonosis
- Avian chlamydiosis. *See* Chlamydiosis
- Avian distemper. *See* Newcastle disease
- Avian encephalomyelitis, 486–493
chemical composition, 486
classification, 486
clinical signs, 488
diagnosis, 492–493
etiology, 486
history, 486
immunity, 491–492
incidence and distribution, 487
incubation period, 488
intervention strategies, 493
laboratory host systems, 487
cell cultures, 487
chicken embryos, 487
morbidity and mortality, 488
morphology, 486
natural and experimental hosts, 487
overview, 486
pathobiology and epidemiology, 487–492
pathogenesis, 490–491
pathology, 488–490
gross lesions, 487f, 488–489
microscopic lesions, 489–490, 489f–490f
strain classification, 486–487
susceptibility to physical and chemical agents, 486
transmission, 488
vaccination, 493
virus isolation, 492
- Avian hepatitis E virus (HEV), 494–500
chemical composition, 495
classification, 494
clinical signs, 496
diagnosis, 500
differential diagnosis, 500
etiology, 494–495
immunity, 497–498
incidence and distribution, 495–496
intervention strategies, 500
laboratory host systems, 495
morbidity and mortality, 496
morphology, 494, 494f
natural and experimental hosts, 496
overview, 494
pathobiology and epizootiology, 495–499
pathogenesis, 497
pathology, 496–497, 497f–499f
strain classification, 495
susceptibility to physical and chemical agents, 495
transmission, 496
virus replication, 495
- Avian influenza. *See* Influenza
- Avian intestinal spirochetosis, 995–1007
antimicrobials, 1006–1007
biochemical properties, 997
biosecurity, 1006
clinical signs and pathology, 1001–1004, 1002f–1003f
colony morphology, 997
definition and synonyms, 995
diagnosis, 1004–1006
demonstration of spirochetes, 1004
differential diagnosis, 1005–1006
identification of spirochetes, 1004–1005
isolation of spirochetes, 1004
PCR on feces, 1005
serology, 1005
economic significance, 995
etiology, 995–999
growth requirements, 996
history, 995
intervention strategies, 1006–1007
management procedures, 1006
morphology and staining, 996, 996f
pathobiology and epizootiology, 999–1004
age influences, 1000
anatomic location, 1000
clinical signs and pathology, 1001–1004, 1002f–1003f
diet and microbiota influences, 1000–1001
host range, 999
immunity, 1004
incidence and distribution, 829–830
incubation period, 1000
prevalence of pathogenic species, 999
spirochetes in ceca, 1000
strains present, 999–1000
transmission, carriers, and vectors, 830
pathotypes, 996, 996t
probiotics, 1006
public health significance, 826
susceptibility to chemical and physical agents, 997
treatment, 833
virulence factors, 997–999
- Avian keratoacanthoma, 617–619, 618f–619f
- Avian leukosis virus (ALV), 553–592
chemical composition, 556–558
classification, 555, 557t
clinical signs, 570
definition and synonyms, 553–554
diagnosis, 585–591
differential diagnosis, 589–591
economic significance, 554
endogenous leukosis viruses, 555–566
genetic resistance, 75–76, 584–585, 585t, 592
history, 554–555
immunity, 584
incidence and distribution, 566–567
of disease, 566–567
of infection, 567
incubation period, 569–570
isolation and identification of agent, 585–589
laboratory host systems, 564–565
morphology, 555
natural and experimental hosts, 567
pathogenicity, 565–566
pathology, 570–583
connective tissue tumors, 580–582
erythroblastosis, 573–575
hemangioma, 577–578
lymphoid leukosis, 571–573
myeloblastosis, 576
myelocytomatois, 576–577
nephroma and nephroblastoma, 578–580
nonneoplastic conditions, 570–571
osteopetrosis, 582–583
prevention and control, 591–593
eradication, 591–592
selection for genetic resistance, 592
public health significance, 554
serology, 589
strain classification, 561–564
susceptibility to chemical and physical agents, 561
transmission, 567–568, 568f
vaccination, 591
virus replication, 558–559
- Avian metapneumovirus (aMPV), 89, 112–119, 417–418
chemical composition, 113
classification, 113
clinical signs, 116
definition and synonyms, 112
diagnosis, 117–118
differential diagnosis, 118
economic significance, 112
epidemiology, 112–113
etiology, 112–115
history, 112
immunity, 116–117
active, 116–117
cell-mediated, 116
humoral, 116–117
passive, 117
intervention strategies, 118–119
cell culture, 114
chicken embryos, 114
management procedures, 118–119
morbidity and mortality, 116
morphology, 113, 113f
natural and experimental hosts, 115
pathobiology, 115–117
pathogenesis, 116
pathogenicity, 114–115, 115f
pathology, 116
gross lesions, 116
microscopic lesions, 116
public health significance, 112
serology, 118
strain classification, 114
susceptibility to physical and chemical agents, 114
transmission, 115
vaccination, 119
virus isolation and identification, 117–118
virus replication, 113–114
- Avian mite dermatitis, public health significance of, 52
- Avian myeloblastosis virus (AMV), 556, 556f, 559, 561–562, 563t, 564–565, 576, 580
- Avian nephritis, 467–473
classification, 468
clinical signs, 470
diagnosis, 471–473
differential diagnosis, 472–473
etiology, 468–470, 468f–469f
genome structure, 468, 468f
incidence and distribution, 470
laboratory host systems, 469
cell cultures, 469
chicken embryos, 469
natural and experimental hosts, 470
overview, 467–468
pathogenesis and epidemiology, 470–471
pathogenicity, 469–470
pathology, 470–471, 471f–472f
gross, 470, 471f
histopathology, 470–471, 471f–472f
phylogenetics, 469f
serology, 472
susceptibility to physical and chemical agents, 468
transmission, 470
treatment, prevention, and control, 473
virus antigen demonstration, 472
virus isolation, 471

- Avian rhinotracheitis (ART). *See* Avian metapneumovirus
- Avibacterium*, differential tests for genus, 861t
- Avibacterium paragallinarum*, 859–868, 1320. *See also* Infectious coryza
- Avibirnavirus, 219
- Avicide toxicity, 1302
- Avitrol toxicity, 1302
- Avocado toxicity, 1304
- Avulavirus, 89, 107, 108
- Bacillary white diarrhea. *See* Pullorum disease
- Bacillus* spp., 1018
- Bacitracin
for avian intestinal spirochetosis, 1007
for enterococcosis, 983
for ulcerative enteritis, 948–949
- Bacteremia, necropsy examination and, 32
- Bacterial cultures, 30
- Bacterial diseases, 971–1027. *See also specific agents; specific diseases*
public health significance, 46–50
botulism, 46
campylobacteriosis, 47
chlamydiosis (psittacosis), 47–48
Clostridium perfringens infection, 46–47
Erysipelothrix rhusiopathiae infection, 48
Escherichia coli infection, 48–49
listeriosis, 49
mycobacteriosis, 49–50
salmonellosis, 50
Staphylococcus aureus infection, 50
- Bacteriocins, for *Campylobacter*, 743
- Bacteriophages, for colibacillosis, 785
- Baits, rodenticide, 1114, 1115t
- BALT (bronchial-associated lymphoid tissue), 63
- Bankruptcy gut. *See* Hemorrhagic enteritis (HE)
- Baylisascaris* spp., 1125
- B cells, 63–65, 67–69
- Beak and feather disease (BFD), 264–275
chemical composition, 266
classification, 265–266
clinical signs, 270–271
definitions and synonyms, 264–265
diagnosis, 273–275
economic significance, 265
etiology, 265–268
history, 265
immunity, 273
incidence and distribution, 269
incubation period, 270
intervention strategies, 275
management procedures, 275
morbidity and mortality, 270–271
morphology, 266
natural and experimental hosts, 269
pathobiology and epizootiology, 269–275
pathogenesis, 273
pathogenicity, 268
pathology, 271–273
gross lesions, 271
microscopic lesions, 271–272, 272f
ultrastructural observations, 272–273, 272f
public health significance, 265
serology, 274
strain classification, 266–268
antigenicity, 266–267
genetic and molecular characteristics, 267–268
immunogenicity or protective characteristics, 267
susceptibility to physical and chemical agents, 266
transmission, carriers, and vectors, 269–270
treatment, 275
vaccination, 275
virus replication, 266
- Beak necrosis, 1026
- Beak trimming, 19
- Bed bugs, 1108, 1109f
- Belladonna toxicity, 1305
- Benzimidazoles
for nematodes, 1133
toxicity, 1291
- BFD. *See* Beak and feather disease
- BFPyV (Budgerigar Fledgling polyomavirus), 440
- Big-liver-and-spleen disease. *See* Avian hepatitis E virus
- Binding agents for mycotoxins, 1284
- Biocontainment, 33–38
chemoprophylaxis, 33
immunization, 34–38
- Bioexclusion, 6, 9–23
company perspective, 10–11
country perspective, 10
disease status and, 11
hatchery, 17–19
breeder codes, 19
chick sexers, 19
design and location, 18
sanitation, 18–19
storage facilities, 19
surgical procedures, 19
- OIE-listed diseases, 10
- poultry house, 11–17
built-up litter and unclean buildings, 13
cleanout and disinfection, 12–13
culling, 13–14
decontamination, 12–13
disinfectants, 13
down time, 12
feed and drinking water, 15, 15f
feed and water medication, 15–16
house access
animals, 16–17
insect, mite, and tick control, 17
people, 16
management of house environment, 11–12
mortality, 14
nest and egg hygiene, 14–15
turnaround time, 12
- primary control zone (poultry house and hatchery), 11–19
region/state perspective, 10
secondary control zone (farm or site), 19–22, 22f
tertiary control zone (complex), 22–23
- Biosecurity, 9–23
APMVs, 112
avian intestinal spirochetosis, 1006
avian metapneumovirus, 112, 119
avian nephritis virus, 473
bioexclusion, 9–23
Campylobacter infection, 742–743
circovirus, 275
classification of diseases and, 11
common practices, 44
company perspective, 10–11
conceptual, 7
country perspective, 10
disease status and, 11
E. coli, 781
global perspective, 9–10
influenza virus and, 203–204
Newcastle disease, 99, 104
OIE-listed diseases, 10
primary control zone (poultry house and hatchery), 11–19
principles of disease prevention and procedural, 7–8
region/state perspective, 10
secondary control zone (farm or site), 19–22, 22f
structural, 7
tertiary control zone (complex), 22–23
viral arthritis, 360–361
- Biotin, 1220, 1220f
- Biotoxins, 1304
algae, 1304
rose chafers, 1304
- Bird flu. *See* Influenza
- Birnaviridae. *See* Infectious bursal disease (IBD)
- Birnavirus
chicken proventricular necrosis virus, 1328–1332
- Biting midges, 1107
- Black flies, 1107
- Blackhead. *See* Histomoniasis
- Black locust toxicity, 1304
- Bladder pod toxicity, 1304
- Blindness, in Marek's disease, 530–531
- Blood parasites, necropsy examination and, 32
- Blood samples, 27–28, 27f
- Bloonavirus, 219
- Blow flies, 1108
- Blue bugs/fowl ticks (*Argas persicus*), 26, 1105
- Bluecomb disease. *See* Turkey coronavirus enteritis
- Blue-wing disease, 363, 976
- B-lymphocytes, in Newcastle disease, 102
- Bocavirus, 400f
- Bone fractures, spontaneous, 1242–1243
- Bone marrow, 63
- Bone marrow granuloma, in tuberculosis, 1013, 1014f, 1015f
- Bordetella avium*, 834–844, 1320
- Bordetellosis, 834–844
antigenic structure, 836
biochemical properties, 835, 836t
classification, 834–835
clinical signs, 839, 839f
colony morphology, 835, 835f
definition and synonyms, 834
diagnosis, 842
differential diagnosis, 843
economic significance, 834
etiology, 834–838
growth requirements, 835
immunity
active, 841–842
passive, 842
incidence and distribution, 838
incubation period, 839
isolation and identification of agent, 842
management procedures, 843
morbidity and mortality, 839
morphology, 835, 835t
natural and experimental hosts, 838–839
pathobiology and epizootiology, 838
pathogenesis, 841
pathology
gross, 839–840, 840f
microscopic and ultrastructural, 840–841, 840f–841f
public health significance, 834
serology, 842
strain classification, 836–837
susceptibility to chemical and physical agents, 835
toxins, 836, 837–838
transmission and carriers, 839
treatment, 843–844
vaccination, 843
virulence factors, 837–838
- Boric acid toxicity, 1298
- Borrelia anserina*, 1018–1020, 1018f–1019f
- Botulism, 953–957
clinical signs, 955, 955f
colony morphology, 954
diagnosis, 956
differential diagnosis, 956
etiology, 953–954
growth requirements, 954
history, 953
incidence and distribution, 954
incubation period, 955
isolation and identification of causative agent, 956
management procedures, 956
morbidity and mortality, 955
morphology and staining, 954
natural and experimental hosts, 954
pathogenesis, 955–956
pathogenicity, 954
public health significance, 46
susceptibility to chemical and physical agents, 954
transmission, 955
treatment, 956–957
vaccination, 956

- competitive exclusion, 743
 feed additives, 743
 phage therapy, 743
 vaccination, 743
 necropsy examination hints, 32
 overview, 737
 pathobiology and epizootiology, 737–741
 pathogenesis of infectious process, 740–741
 pathology, 740
 public health significance, 47
 nature of the disease in humans, 47
 occurrence, 47
 preventive measures, 47
 reservoirs and sources of infection, 47
 transmission, 738–739
 horizontal, 738–739
 vertical, 739
 vectors and carriers, 738–739
 Canary circovirus (CaCV), 265–267
 Canary pox, 334f, 339, 340–341, 345
Candida albicans, 1026–1027
 Candidate genes, 73–74
 Candidiasis, 1088–1090
 clinical signs, 1089
 definition and synonyms, 1088
 diagnosis, 1090
 etiology, 1088
 history, 1088
 incidence and distribution, 1089
 pathology, 1089–1091
 gross lesions, 1089, 1089f
 microscopic lesions, 1089–1090
 significance, 1088
 treatment and control, 1090
 Cannibalism, 1233–1234
Capillaria anatis, 1121, 1122f, 1122t
Capillaria annulata, 1121, 1123f
Capillaria bursata, 1121, 1122f, 1122t
Capillaria caudinflata, 1121, 1122f, 1122t
Capillaria contorta, 1121, 1123f
Capillaria obsignata, 1121, 1122f–1123f, 1122t, 1133
Capillaria spp., 1121, 1122f–1123f, 1122t
 Capillarids, necropsy examination and, 32
 Captan toxicity, 1299
 Carbamate toxicity, 1300–1301
 Carbarstone, for histomoniasis, 1178t
 Carbohydrates, 1207
 Carbon monoxide toxicity, 1302
 Carbon tetrachloride toxicity, 1303
 Carolina jessamine, 1304
 Carriers, removal of, 20
 Case history, 25–26
 Cassava toxicity, 1304
 Castor bean toxicity, 1304
 Cataracts, 1258
 Cationic detergents, 1298
 Cats, access to poultry house, 17
 CD4 cells, 66–67
 CD8 cells, 66–67
 CEF cells. *See* Chicken embryo fibroblast (CEF) cells
 Ceftiofur, for *Riemerella anatipestifer*, 828
 CEK cells. *See* Chicken embryo kidney (CEK) cells
 CEL cells. *See* Chicken embryo liver (CEL) cells
 Cell cultures
 arboviruses, 474
 avian encephalomyelitis, 487
 avian metapneumovirus, 114, 117
 avian nephritis virus, 469
 chicken infectious anemia virus, 252, 253
 Chlamydia, 1066
 duck hepatitis virus type 1, 423–424
 duck virus enteritis, 433
 egg drop syndrome virus, 303
 enterovirus-like viruses, 397
 FAcV, 294
 Gallid herpesvirus type 1, 166
 infectious bursal disease, 223–224
 influenza virus, 191
 inoculation of, 33
 leukosis/sarcoma viruses, 565, 565f
 Marek's disease, 524, 525–526, 525f, 546
 Newcastle disease virus, 96
 pigeon herpesvirus 1, 466
 poxvirus, 339, 342
 reticuloendotheliosis, 595, 596, 596f
 rotavirus, 385
 viral arthritis, 354
 Cell fusion, by Newcastle disease virus, 92
 Cell-mediated immunity (CMI), 66–67
 avian metapneumovirus, 116
 hemorrhagic enteritis, 314
 infectious bronchitis, 147
 infectious bursal disease effect on, 230–231
 infectious laryngotracheitis, 170
 Newcastle disease, 101–102
 paratyphoid infections, 700–701
 pullorum disease and fowl typhoid, 689
 reticuloendotheliosis, 602
 turkey coronavirus enteritis, 380
 viral arthritis, 358–359
 Cellulitis, coliform, 768–772, 771f
 CELO (chicken embryo lethal orphan) virus, 289, 300, 316, 319
 Central chromatolysis, in avian encephalomyelitis, 489–490, 490f
 Cephalosporins, for *Riemerella anatipestifer*, 828
 Cervical dislocation, 28
 Cestodes, 1135–1143
 Amoebotaenia cuneata, 1137f–1139f, 1138, 1139
 Choanotaenia infundibulum, 1135, 1137f–1139f, 1138, 1139, 1143
 classification, 1136
 Davainea proglottina, 1136–1137, 1136f, 1138, 1139–1140, 1143
 diagnosis and identification, 1137–1138, 1137f–1139f
 Fimbriaria fasciolaris, 1142, 1142f
 Hymenolepsis cantaniana, 1137f, 1138, 1140
 Hymenolepsis carioca, 1136, 1137f–1139f, 1138, 1140
 Hymenolepsis megalops, 1135, 1142, 1142f
 key to species, 1138
 Metroliaesthes lucida, 1141–1142, 1141f–1142f
 morphology and life cycle, 1136–1137, 1136f–1138f
 number of species described, 1136
 overview, 1135–1136, 1135t, 1136f
 prevention and control, 1143
 Raillietina cesticillus, 1135, 1136f, 1137, 1137f–1139f, 1138, 1140, 1143
 Raillietina echinobothrida, 137f–1139f, 1138, 1141
 Raillietina georgiensis, 1139f, 1141, 1141f–1142f
 Raillietina tetragona, 1137f–1139f, 1138, 1140
 table of species, 1135t
 treatment, 1143
 CF test. *See* Complement fixation (CF) test
Cheilospirura hamulosa, 1125, 1126f
Cheilospirura spinosa, 1125, 1127f
Cheilospirura spp., 1125, 1126f–1127f
 Chemoprophylaxis, 33
 Chick edema disease, 1303
 Chicken anemia agent (CAA). *See* Chicken infectious anemia
 Chicken anemia virus (CAV). *See* Chicken infectious anemia
 Chicken body louse (*Menacanthus stramineus*), 1103–1104, 1104f
 Chicken embryo fibroblast (CEF) cells
 Gallid herpesvirus type 1, 166
 infectious bursal disease, 221, 223–224
 infectious bursal disease and, 231
 influenza virus, 191
 Israel turkey meningoencephalitis, 479
 Newcastle disease virus, 96
 viral arthritis, 354
 Chicken embryo kidney (CEK) cells
 Gallid herpesvirus type 1, 166
 infectious bronchitis virus, 143
 infectious bursal disease, 221, 223
 Newcastle disease virus, 96
 Chicken embryo lethal orphan (CELO) virus, 289, 300, 316, 319
 Chicken embryo liver (CEL) cells
 egg drop syndrome virus, 303
 enterovirus-like viruses, 397, 397f
 FAcV, 294
 Gallid herpesvirus type 1, 166, 170–171
 quail bronchitis virus, 317
 rotavirus, 385
 Chicken embryo lung cells, for Gallid herpesvirus type 1, 166
 Chicken embryos
 APMV, 111
 arboviruses, 474
 avian encephalomyelitis, 486–487, 487
 avian hepatitis E virus, 495
 avian metapneumovirus, 114, 117
 avian nephritis virus, 469
 chicken infectious anemia virus, 253
 Chlamydia, 1066
 duck hepatitis virus type 1, 423
 enterovirus-like viruses, 396–397
 Gallid herpesvirus type 1, 166
 infectious bronchitis virus, 142–143, 143f
 infectious bursal disease, 223
 inoculation for virus isolation, 32–33
 leukosis/sarcoma viruses, 564, 564f
 Marek's disease, 524–525
 Newcastle disease virus, 96
 poxvirus, 338, 342
 quail bronchitis virus, 317
 reticuloendotheliosis, 597
 rotavirus, 385
 turkey coronavirus enteritis, 378f
 viral arthritis, 354
 Chicken head louse (*Cuclotogaster heterographa*), 1104–1105
 Chicken hepatoma cell line (LMH cells), 294
 Chicken infectious anemia (CIA), 248–264
 chemical composition, 250
 classification, 249
 clinical signs, 254–255
 as cofactor in other diseases, 260
 definition and synonyms, 248
 diagnosis, 260–263
 antibody-based detection, 262
 DNA-based detection, 260–263
 serology, 262–263, 262f
 virus isolation, 260–261
 differential diagnosis, 263
 economic significance, 248
 etiology, 249–253
 hematology, 254
 history, 248–249
 immunity, 259
 active, 259
 immunosuppression, 259–260
 passive, 259
 immunosuppression by, 1321
 incidence and distribution, 253
 incubation period, 254
 intervention strategies, 263–264
 laboratory host systems, 252–253
 cell culture, 253
 chicken embryos, 253
 chicks, 253
 management procedures, 263
 morbidity and mortality, 255
 morphology, 249, 249f
 natural and experimental hosts, 253
 overview, 248
 pathobiology and epizootiology, 253–260
 pathogenesis, 258–259
 age resistance, 258–259
 genetic resistance, 259
 route of infection, 259
 virus dose, 259

- beak necrosis in, 1026
Borrelia anserina in, 1018–1020, 1018f–1019f
 botulism in, 953–957
 candidiasis in, 1088–1090
 chicken infectious anemia in, 248–264
 chlamydiosis in, 1061, 1064
Citrobacter in, 1020
 coccidiosis in, 1149–1163
 colibacillosis in, 751–785
 contact dermatitis in, 1257
 coryneform bacteria in, 1020
 cryptosporidiosis in, 1169–1170, 1169f–1170f
 cystic right oviduct in, 1256, 1256f
 deep pectoral myopathy in, 1244–1245
 degenerative joint disease in, 1242
 dermatophytosis in, 1091
 eastern equine encephalitis in, 475–477, 476f
 enterovirus-like viruses in, 396–399, 397f–398f
 erysipelas in, 986, 989
 fatty liver-hemorrhagic syndrome in, 1252–1253, 1252f
Flavobacterium in, 1020
 fowl cholera in, 807–823
 fowl typhoid in, 678–693
 gangrenous dermatitis in, 957–960, 958f–959f
 gastrocnemius tendon rupture in, 1245–1246, 1245f
Helicobacter in, 1021
 histomoniasis in, 1172, 1175, 1177–1178
 hypoglycemia-spiking mortality syndrome of broiler chickens in, 1325–1327, 1326f
 inclusion body hepatitis in, 295–296, 296f, 298, 298f
 infectious bronchitis in, 139–153
 infectious bursal disease in, 219–235
 infectious coryza in, 859–868
 infectious laryngotracheitis in, 161–174
 influenza in, 181–206
 keratoacanthoma in, 617–619, 618f–619f
Klebsiella spp. in, 1021
 leucocytozoonosis in, 1187–1188
 leukosis/sarcoma group of neoplastic diseases in, 552–588
 macrorhabdosis in, 1092–1093, 1093f
 Marek's disease in, 515–552
 multicentric histiocytosis in, 621–622, 622f
 multicausal enteric diseases in, 1322–1325
Mycoplasma gallisepticum infection in, 877–893
Mycoplasma iowae infection in, 908, 909
Mycoplasma synoviae infection in, 900–906
 necrotic enteritis in, 949–953
Neisseria in, 1023
 Newcastle disease in, 89–107
 nutritional diseases in, 1205–1227
 ochroconosis in, 1091
Ornithobacterium rhinotracheale infection in, 828–834
 osteochondrosis in, 1244
 osteoporosis in, 1240–1241
 oviductal adenocarcinoma in, 609
 parvovirus in, 399–405
 poxvirus in, 333–346
Proteus spp. in, 1023
 proventriculitis and proventricular dilatation of broiler chickens in, 1328–1332
Pseudomonas spp. in, 1024–1025, 1024f–1025f
 pullorum disease in, 678–693
 pulmonary hypertension syndrome in, 1246–1249
 reoviruses in, 362–363
 reticuloendotheliosis in, 593–604
Riemerella anatipestifer in, 825
 rotated tibia in, 1244
 rotavirus in, 382f, 385–390, 388f
 sarcocystosis in, 1190–1191
 segmented filamentous bacteria in, 1025
 seminoma in, 611
 splenomegaly virus in, 290
 spondylolisthesis in, 1243, 1243f
 staphylococcosis in, 971–977
 streptococcosis in, 977–980
 sudden death syndrome in, 1250–1251
 tapeworms of, 1138–1141
 tibial dyschondroplasia in, 1238–1240, 1238f
 toxoplasmosis in, 1193–1194
 transmissible viral proventriculitis in, 1328–1332
 turkey viral hepatitis in, 483
 ulcerative enteritis in, 944–949
 urolithiasis and visceral urate deposition in, 1254–1255, 1255f
 valgus and varus deformation in, 1241–1242, 1241f
Vibrio in, 1026
 viral arthritis in, 352–361
 West Nile virus in, 480–481
 zygomycosis in, 1092
 Chick sexers, 19
 Chiggers (*Neoschoengastia americana*), 1102, 1102f
Chilomastix gallinarum, 1180, 1181f
Chlamydia psittaci. See Chlamydiosis
 Chlamydiosis, 1055–1068
 antigenic structure and toxins, 1057–1058
 biochemical properties, 1057
 in chickens, 1061, 1064
 classification, 1055, 1056t
 definition and synonyms, 1055
 diagnosis, 1065–1067
 ELISA, 1065
 isolation, 1065–1066
 microscopy, 1065
 nucleic-acid amplification techniques, 1066–1067
 serology, 1067
 specimen collection and storage, 1065
 differential diagnosis, 1067
 in ducks and geese, 1061, 1064
 etiology, 1055–1060
 history, 1055
 immunity, 1064–1065
 incidence and distribution, 1060–1061
 intervention strategies, 1067–1068
 management procedures, 1067
 ovotransferrin, 1068
 state regulations, 1068
 treatment, 1068
 vaccination, 1068
 morphology and staining, 1055–1057, 1057f
 natural and experimental hosts, 1061
 pathobiology and epidemiology, 1060–1065
 in pheasants, quail, guinea fowl, peacocks and partridges, 1064
 in pigeons, 1064
 public health significance, occurrence, 47
 preventive measures, 47
 reservoirs and sources of infection, 47
 strain classification, 1058–1060
 antigenicity, 1058
 genetic, molecular, 1058–1059
 pathogenicity, 1059
 virulence factors, 1059–1060, 1060f
 susceptibility to chemical and physical agents, 1057
 transmission, carriers and vectors, 1061–1062
 in turkeys, 1060, 1062–1064, 1063f
Chlamydophila psittaci. See Chlamydiosis
 Chloramphenicol, for fowl cholera, 821–822
 Chlorate toxicity, 1299
 Chlordane toxicity, 1300
 Chlorine
 deficiency, 1223, 1223f
 toxicity, 1298
 Chlortetracycline
 for avian intestinal spirochetosis, 1007
 for chlamydiosis, 1068
 for enterococcosis, 983
 for fowl cholera, 821–822
 for *Mycoplasma gallisepticum*, 892
 for *Mycoplasma meleagridis*, 899
 for *Mycoplasma synoviae*, 906
 for *Ornithobacterium rhinotracheale*, 834
Choanotaenia infundibulum, 1135, 1137, 1137f–1139f, 1138, 1139, 1143
 Cholangiocellular tumors, 612–613, 612f–613f
 Choline deficiency, 1221, 1221f
 Chondrodystrophy, 903, 1208, 1219, 1220, 1221
 Chondroma and chondrosarcoma, 580, 582, 621, 621f
 Chorioallantoic membrane, inoculation for virus isolation, 32–33
 Chromium toxicity, 1294
 Chronic respiratory disease (CRD) of chickens, 877, 884
 Chukar partridges. See Partridges
 CIA. See Chicken infectious anemia
Cimex lectularius, 1108, 1109f
 chicken infectious anemia, 248–264
 classification, 265–266
 clinical signs, 270–271
 definitions and synonyms, 264–265
 diagnosis, 273–275
 differential diagnosis, 275
 economic significance, 265
 etiology, 265–268
 history, 265
 immunity, 273
 active, 273
 passive, 273
 incidence and distribution, 269
 incubation period, 270
 intervention strategies, 275
 management procedures, 275
 morbidity and mortality, 270–271
 morphology, 266
 natural and experimental hosts, 269
 overview, 247
 pathobiology and epizootiology, 269–275
 pathogenesis, 273
 pathogenicity, 268
 pathology, 271–273
 gross lesions, 271
 microscopic lesions, 271–272, 272f
 ultrastructural observations, 272–273, 272f
 public health significance, 265
 serology, 274
 strain classification, 266–268
 antigenicity, 266–267
 genetic and molecular characteristics, 267–268
 immunogenicity or protective characteristics, 267
 susceptibility to physical and chemical agents, 266
 transmission, carriers, and vectors, 269–270
 treatment, 275
 vaccination, 275
 virus replication, 266
 Circovirus-like infection of geese, 421
 Circulatory system diseases, 1246–1252
 aortic rupture, 1251–1252, 1251f
 dilated cardiomyopathy, 1249–1250
 pulmonary hypertension syndrome (PHS)
 clinical signs, 1247, 1247f
 intervention strategies, 1249
 pathogenesis and etiology, 1248–1249
 pathology, 1247, 1248, 1247f

- morphology and staining, 957
 pathobiology and epizootiology, 958–959
 public health significance, 957
 treatment and prevention, 961–962
- necrotic enteritis, 949–953
 clinical signs, 950
 definitions and synonyms, 949
 diagnosis, 952–953
 economic significance, 949
 etiology, 949–950
 history, 949
 intervention strategies, 953
 pathobiology and epizootiology, 950–952
 pathogenesis, 951–952
 pathology, 950–951, 951f
 public health significance, 949
 strain classification and toxins, 949–950, 950t
 transmission, carriers, vectors, 950
- overview, 943–944
- ulcerative enteritis, 944–949
 biochemical characteristics, 945
 classification, 944
 clinical signs, 945–946
 diagnosis, 946–948
 differential diagnosis, 948
 etiology, 944–945
 growth requirements, 945
 history, 944
 immunity, 946
 incidence and distribution, 945
 incubation period, 945
 management procedures, 948
 morphology and staining, 944–945, 944f
 mortality rate, 946
 natural and experimental hosts, 945
 pathology
 gross lesions, 946, 947f
 histopathology, 946
 susceptibility to chemical and physical agents, 945
 transmission, 945
 treatment, 948–949
- Clostridium botulinum*, 46, 943, 953–957. *See also* Botulism
- Clostridium chauvoei*, 944
- Clostridium colinum*, 943, 944–948
- Clostridium difficile*, 944
- Clostridium novyi*, 944
- described, 943–944, 949–953, 957–958
 public health significance, 46–47
 nature of disease in humans, 46
 occurrence, 46–47
 reservoirs and sources of infection, 47
- Clostridium piliforme*, 943
- Clostridium septicum*, 943, 957–958
- Clostridium sordelli*, 944
- Clostridium sporogenes*, 944
- Clostridium tertium*, 944
- Clostridium welchii*, 957
- Clotting, 28
- CMI. *See* Cell-mediated immunity
- CNS disease
 Marek's disease, 535, 535f, 537, 538f
 neoplastic diseases, 614–616
- Coal-tar derivatives, toxicity of, 1298
- Cobalamin (vitamin B₁₂), 1221
- Cobalt toxicity, 1293
- Coccidiosis, 1148–1166
 anticoccidials, table of preventative, 1159t
 in chickens, 1149–1163
 diagnosis, 1150t, 1157–1159
Eimeria acervulina, 1150t, 1151, 1152f
Eimeria brunetti, 1150t, 1153, 1154f
Eimeria hagani, 1150t, 1153
Eimeria maxima, 1150t, 1152f, 1153
Eimeria mitis, 1150t, 1152f, 1155
Eimeria mivati, 1150t, 1153
Eimeria necatrix, 1150t, 1154f, 1155–1156
Eimeria praecox, 1150t, 1156
Eimeria tenella, 1150t, 1154f, 1156
 epidemiology, 1157
 etiology, 1149–1156
 incidence and distribution, 1149
 life cycle, 1151f
 natural and experimental hosts, 1157
 prevention and control, 1159–1163
 transmission and vectors, 1157
 vaccination, 1161
- classification and taxonomic relationships, 1148–1149
- in ducks, 1166
- in geese, 1165–1166
Eimeria anseris, 1166
Eimeria truncata, 1165–1166
- life cycle, 1149
- necropsy examination hints, 32
- oocyst morphology, 1148, 1148f
- overview, 1148
- in pigeons, 1166
- Salmonella* colonization and, 698
- in turkeys, 1162t, 1163–1165
Eimeria adeneides, 1162t, 1163–1164
Eimeria dispersa, 1162t, 1164
Eimeria gallopavonis, 1162t, 1164
Eimeria innocua, 1165
Eimeria meleagridis, 1162t, 1164
Eimeria meleagrimitis, 1162t, 1164–1165
Eimeria subrotunda, 1165
 etiology, 1163
 prevention and control, 1165
- Cochlosoma anatis* infection, 1180, 1182–1185
 clinical signs and pathogenicity, 1184
 etiology and classification, 1182–1183
 incubation period, 1183
 life cycle, 1183
 morphology, 1182–1183, 1183f
 natural and experimental hosts, 1184
 overview, 1182
 prevention, 1185
 site of infection, 1184
 transmission, 1183
 treatment, 1184–1185
- Codex Alimentarius Commission, 10
- Codiostomum struthonis*, 1126
- Coenonia*, 1020
- COFAL test, 586, 587–588, 587t
- Coffee senna toxicity, 1304
- Co-inheritance of alleles, 72
- Colibacillosis, 751–785
 antigenic structure, 755
 F (pilus) antigen, 755
 H (flagellar) antigen, 755
 K (capsular) antigen, 755
 O (somatic) antigen, 755
 biochemical properties, 754
 classification, 753, 753t
 clinical signs, 765
 colisepticemia, 775–777
 of ducks, 777
 enteric-origin, 776
 hemorrhagic, 776
 of layers, 776–777
 neonatal, 776
 respiratory-origin, 775–776
 colisepticemia sequelae, 777–779
- osteoarthritis and synovitis, 777–778
 panophthalmitis, 777
 turkey osteomyelitis complex, 778–779
- colony morphology, 754
 definitions and synonyms, 751
 diagnosis, 780–781
 diagnostic characteristics, 753t
 differential diagnosis, 781
 economic significance, 751
 etiology, 752–762
 growth requirements, 754, 754t
 history, 752
 immunosuppression and, 1321
 incidence and distribution, 762
 incubation period, 765
 intervention strategies, 781–785
 isolation and identification of causative agent, 780–781
 localized forms, 766–775
 coliform cellulitis, 768–772, 771f
 coliform omphalitis/yolk sac infection, 766–768, 767f
 diarrheal disease, 772–774, 773f
 salpingitis/peritonitis, 774
 swollen head syndrome, 772
 venereal colibacillosis (acute vaginitis), 773–774
 management procedures, 781–782
 morbidity and mortality, 765
 morphology and staining, 754
 natural and experimental hosts, 762–764
 host susceptibility factors, 763–764, 764t
 Ø157:H7 strain, 754
 pathobiology and epidemiology, 762–780
 pathogenesis, 779–780
 pathology, 765–779, 766t
 public health significance, 751–752
 strain classification, 755–757
 antigenicity, 755–756
 molecular typing, 756–757
 pathogenicity, 757
 susceptibility to chemical and physical agents, 754–755
 transmission, carriers, and vectors, 764–765
 treatment, 784–785
 vaccination, 782–784
 immunopotential, 783–784
 inactivated vaccines, 782
 live vaccines, 782–783
- passive immunization, 783
- recombinant and mutant vaccines, 783
- virulence factors, 757–762
 adhesins, 757–759
 genomic location of genes, 760–762
 invasins, 760
 iron acquisition mechanisms, 759
 protectins, 759–760
 regulation of virulence, 762
 table of, 758t
 toxins, 755, 759
- Colicins, 772
- Coligranuloma, 779, 779f
- Collyrichum faba*, 1144
- Compartmentalization, 10
- Competitive exclusion
Campylobacter colonization, 743
 necrotic enteritis, 952
 paratyphoid infections, 704–705
- Complement fixation (CF) test
 for *Chlamydia*, 1067
 for eastern equine encephalitis, 477
 for leukosis/sarcoma group of neoplastic diseases, 585–586
- Complement system, 63
- Complex, disease control and, 22–23
- Concanavalin A (ConA), 69
- Condorpox, 336
- Conjunctival-associated lymphoid tissue (CALT), 63, 64f
- Conjunctivitis
 in avian metapneumovirus, 115f, 116
 in fowl cholera, 816, 817f
 in infectious laryngotracheitis, 167–168, 169f
 in Marek's disease, 533
 in *Mycoplasma gallisepticum* infection, 882, 883–884, 885, 885f
 in Newcastle disease, 99, 100f
- Connective tissue tumors
 differential diagnosis, 591
 pathology, 580–582, 581f
 gross, 580–582, 581f
 microscopic, 581f, 582
 pathogenesis, 582
 ultrastructural, 582
- Contact dermatitis, 1257–1258, 1257f
- Copper
 deficiency, 1225
 excess, 1225
 toxicity, 1293

- Cryptosporidium meleagridis*, 1167–1168, 1167t, 1170
 Culling, 13–14
 Curled-toe paralysis, 1218, 1218f
 Cutaneous disease, poxvirus as, 338f, 340–341, 342
 Cyanide, 1304, 1305
Cyathostoma bronchialis, 1126–1127, 1127f
 Cyclopiazonic acid, 1281
Cyrnea colini, 1125–1126, 1127f
 Cysticercoid, 1136, 1136f, 1137
 Cystic right oviduct, 1256, 1256f
 Cytokines, 67, 69–70
 Cytopathic effect (CPE)
 arboviruses, 474
 astrovirus, 393
 avian nephritis virus, 469
 chicken infectious anemia, 249, 261, 261f
 duck hepatitis virus type 1, 423
 duck virus enteritis, 433
 in eastern equine encephalitis, 477
 goose hemorrhagic polyomavirus, 441
 infectious bronchitis virus, 143
 Newcastle disease virus, 96
 poxvirus, 339, 342
 viral arthritis, 359, 359f
 West Nile virus, 481
 Cytotoxic T cells
 in Marek's disease, 545
 in reticuloendotheliosis, 602
 Cytotoxic T lymphocytes (CTL), 66, 67
 Cytotoxin, chlamydial, 1058
- Dactylariosis. *See* Ochroconosis
 DAdV-1. *See* Duck adenovirus type 1
 DAdV-2. *See* Duck adenovirus type 2
 DAEC (diffuse-adherence *Escherichia coli*), 48
 Darkling beetle, 1105–1107, 1106f
Daubentonia toxicity, 1305
Davainea proglottina, 1136–1137, 1136f, 1138, 1139–1140, 1143
 DDE toxicity, 1300
 DDGS (distillers dried grain solubles), 1283
 DDT toxicity, 1300
 DDVP (dichlorvos), 1300
 Dead bird disposal, 22, 22f
 Death camas toxicity, 1305
 Decalcification solution, 32
- Deep pectoral myopathy, 1244–1245
 Degenerative joint disease, 1242
 Dehydration, 1235–1236
 Delayed type hypersensitivity, in tuberculosis, 1013–1015
Deletrocephalus dimidiatus, 1127
 Deoxynivalenol, 1272–1273
 Dependovirus, 400f
 Depluming mite (*Knemidocoptes laevis*), 1101–1102
 Depopulation, for disease control, 20
 Dermal squamous cell carcinoma. *See* Keratoacanthoma
Dermanyssus gallinae (poultry red mite), 26, 52, 1101, 1101f.
 See also Avian mite dermatitis
 Dermatitis
 aspergillosis, 1081
 biotin deficiency, 1220
 candidiasis, 1089
 contact, 1257–1258, 1257f
 gangrenous, 957–960
 Dermatophytosis (flavus)
 described, 1091
 public health significance, 51
 nature of disease in humans, 51
 occurrence, 51
 reservoirs and sources of infection, 51
 Detoxification of mycotoxins, 1284
 DFA. *See* Direct fluorescent antibody
 DIA (dot immunobinding assay), for *Ornithobacterium rhinotracheale*, 833
 Diacetoxyscirpenol, 1272, 1273f
 Diagnosis, 23–33
 blood samples, 27–28, 27f
 case history, 25–26
 in disease outbreak, 39
 examination of field birds, 24
 external examination, 26–27
 flock profiling, 25, 26f
 laboratory procedures, 30
 bacterial cultures, 30
 respiratory virus isolation, 30
 Salmonella cultures, 30
 monitoring and surveillance, 23–24
 necropsy
 brain exposure and removal, 30–31, 31f
 communication of results, 33
 gross examination, 30
 histopathologic examination, tissues for, 32
 laboratory procedures, 30
 precautions, 28
 progressive examination hints, 32–33
 specimen disposal, 33
 techniques, 28–30, 29f
 performance parameters, 24
 procedures, 25–33
 serologic monitoring, 24–25
 Diarrhea
 in astrovirus infection, 393–394
 in avian nephritis virus infection, 470
 in cryptosporidiosis, 1170–1171
 in *E. coli* infection, 772–773
 in enterovirus-like virus infection, 397–398
 in hexamitiasis, 1181
 in infectious bursal disease, 226
 in multicausal enteric diseases, 1324–1325
 in parvovirus of chickens and turkeys, 402, 403
 in rotavirus infection, 381, 386–389
 in turkey coronavirus enteritis, 378, 379
 Diazinon toxicity, 1300
Dicheilonema rhea, 1128
 Dichlorvos, 1300
 Diclazuril, for coccidiosis, 1160, 1161, 1165
 DID. *See* Double immunodiffusion (DID) test
 Dieldrin toxicity, 1300
 Diet
 carbohydrates, 1207
 essential inorganic elements, 1221–1227
 fats, 1207
 least-cost formulization, 1205
 proteins and amino acids, 1205–1207
 vitamins, 1207–1221
 water, 1205
 Diffuse-adherence *Escherichia coli* (DAEC), 48
 Digestive system diseases
 neoplasia, 611–613
 alimentary tract, 611–612, 611f
 liver, 612–613
 choleangiocellular tumors, 612–613, 612f–613f
 hepatocellular tumors, 612, 612f
 pancreas, adenocarcinoma of, host resistance, 8
 risk, 8
 Disease resistance, genetics of, 70–79
 Disinfectants, 13
 toxicity, 1298–1299
 chlorine, 1298
 coal-tar derivatives, 1298
 formaldehyde, 1298–1299
 phenolics, 1298
 quaternary ammonium, 1298
 Disinfection, in candidiasis, 1090
Dispharynx nasuta, 1128, 1128f
 Disposal
 of dead birds, 22, 22f
 of necropsy specimen, 33
 Dissecting aneurysm, 1251–1252
 Distillers dried grain solubles (DDGS), 1283
 DNA fingerprinting
 Avibacterium paragallinarum, 862
 E. coli, 768
 Salmonella, 680
 DNA microarrays
 Campylobacter, 742
 described, 75
 DNA probes
 for chicken infectious anemia virus, 262
 for Marek's disease, 547
 for *Mycoplasma gallisepticum*, 888
 for *Mycoplasma synoviae*, 905
 for *Salmonella*, 703
 DNA vaccination
 described, 36
 for infectious bursal disease, 234
 Dogs, access to poultry house, 17
 Dot immunobinding assay (DIA), for *Ornithobacterium rhinotracheale*, 833
 Double immunodiffusion (DID) test
 for adenoviruses, 292, 300
 egg drop syndrome virus, 305, 306
 Doves, APMVs in, 109
 Down time, 12
 Doxycycline, for *Mycoplasma meleagridis*, 899
 Drinkers, 15, 15f
 Drugs. *See also* specific drugs during disease outbreak, 39–40
 Duck adenovirus type 1 (DAdV-1), 301. *See also* Egg drop syndrome
 Duck adenovirus type 2 (DAdV-2), 290, 294, 297
 Duck circovirus (DuCV), 265, 269, 274

- transmission, carriers, and vectors, 424–425
- treatment, 429
- vaccination, 428–429
- breeders, 428
- ducklings, 428–429
- Duck hepatitis virus type 2, 429–430
- Duck hepatitis virus type 3, 430–431
- Ducks
- Aeromonas* infection in, 1018
- APMVs in, 107–108, 109
- astrovirus in, 391
- aviadenovirus infection in, 297
- avian intestinal spirochetosis in, 999
- Bacillus* in, 1018
- Borrelia anserina* in, 1018
- chlamydiosis in, 1061, 1064
- Citrobacter* infection in, 1020
- Coenonia* infection in, 1020
- eastern equine encephalitis in, 475
- egg drop syndrome virus in, 301, 303, 306
- Gallibacterium* in, 1020–1021
- intracellular infection in, 1027
- lead poisoning in, 1295f–1296f
- macrorhabdosis in, 1092
- Marek's disease virus in, 529
- Proteus* infection in, 1023
- Pseudomonas* in, 1024–1025
- reoviruses in, 364–365
- reticuloendotheliosis virus in, 597
- rotavirus in, 383, 386
- seminoma in, 611, 611f
- tapeworms of, 1142, 1142f
- Vibrio* infection in, 1026
- Duck virus enteritis (duck plague), 431–440
- chemical composition, 434
- classification, 432
- clinical signs, 435
- definition and synonyms, 431
- diagnosis, 439
- differential diagnosis, 439
- economic significance, 432
- etiology, 432–433
- history, 432
- immunity
- active, 438–439
- passive, 439
- incidence and distribution, 434
- incubation period, 435
- intervention strategies, 439–440
- laboratory host systems, 433
- management procedures, 439
- natural and experimental hosts, 434
- pathobiology and epizootiology, 434–439
- pathology
- gross lesions, 435–437, 436f–437f
- microscopic lesions, 437–438, 438f
- serology, 439
- strain classification, 433
- susceptibility to chemical and physical agents, 433
- transmission, carriers, and vectors, 435
- vaccination, 440
- virus isolation and identification, 439
- virus replication, 433
- DuCV (duck circovirus), 265–269, 274
- Dyschondroplasia, 1238–1240
- clinical signs, 1238
- intervention strategies, 1239–1240
- pathogenesis and etiology, 1239
- pathology, 1238–1239, 1238f
- Dysgerminoma, 608
- EAEC (enteroaggregative *Escherichia coli*), 48, 757
- Ear diseases, 1258–1259
- Earthworms, role in histomoniasis, 1174
- Eastern equine encephalitis (EEE), 474–477, 474f, 476f
- clinical signs and pathology, 475–477, 476f
- chickens, 475–477, 476f
- chukar partridges, 475
- ducks, 475
- pheasants, 475
- turkeys, 475, 476f
- diagnosis, 477
- differential diagnosis, 477
- history, 474
- incidence and distribution, 474
- intervention strategies, 477
- natural and experimental hosts, 474
- pathobiology and epizootiology, 474
- public health significance, 44–45, 473
- serology, 477
- transmission, carriers, and vectors, 474–475
- Echidnophaga gallinacea* (sticktight flea), 1103, 1103f
- Echinura uncinata*, 1128, 1128f
- EDS. *See* Egg drop syndrome
- EDTA (ethylenediaminetetraacetic acid), 1329
- EGF (epidermal growth factor), 337
- Egg-bound, 1256
- Egg drop syndrome, 301–309
- chemical composition, 302
- classification, 301
- clinical signs, 304–305, 304f
- definition and synonyms, 301
- etiology, 301–303
- history, 301
- immunity, 305
- incidence and distribution, 303
- laboratory host systems, 303
- morphology, 301–302, 302f
- natural and experimental hosts, 303
- pathobiology and epizootiology, 303–305
- pathogenesis of the infectious process, 305
- pathology, 305
- gross lesions, 305
- microscopic lesions, 305, 306f–308f
- strain classification, 302–303
- susceptibility to physical and chemical agents, 302
- transmission, carriers, and vectors, 303–304
- virus replication, 302
- Egg production decline, 1257
- with aviadenovirus infection, 297
- with egg drop syndrome, 304–305, 304f
- with infectious bronchitis, 139, 145–146, 146f
- with influenza, 196, 197
- with Newcastle disease, 90, 99, 101
- with poxvirus, 341
- Egg room, 21
- Eggs
- fumigation, 14
- hygiene, 14–15
- storage, 14, 19
- washing, 14–15
- EHEC (enterohemorrhagic *Escherichia coli*), 48–49, 757, 773
- EIA. *See* Enzyme immunoassay
- EIEC (enteroinvasive *Escherichia coli*), 48, 757, 773
- Eimeria acervulina*, 1150t, 1151, 1152f
- Eimeria adeneides*, 1162t, 1163–1164
- Eimeria anseris*, 1166
- Eimeria brunetti*, 946, 948f, 1150t, 1153, 1154f
- Eimeria dispersa*, 1162t, 1164
- Eimeria gallopavonis*, 1162t, 1164
- Eimeria innocua*, 1165
- Eimeria labbeana*, 1166
- Eimeria maxima*, 1150t, 1152f, 1153
- Eimeria meleagridis*, 1162t, 1164
- Eimeria meleagrimitis*, 1162t, 1164–1165
- Eimeria mitis*, 1150t, 1152f, 1155
- Eimeria mivati*, 1150t, 1153
- Eimeria necatrix*, 1150t, 1154f, 1155–1156
- Eimeria praecox*, 1150t, 1156
- Eimeria subrotunda*, 1165
- Eimeria tenella*, 1150t, 1154f, 1156, 1172
- Eimeria truncata*, 1165–1166
- Electron microscopy
- astrovirus, 392, 393f
- avian encephalomyelitis, 486
- avian hepatitis E virus, 494, 494f
- avian leukosis/sarcoma viruses, 555, 556f
- avian metapneumovirus, 113, 113f
- chicken infectious anemia virus, 249, 249f, 262, 262f
- chicken proventricular necrosis virus, 1329, 1329f
- duck hepatitis type I, 426
- duck virus enteritis, 432, 432f, 433
- eastern equine encephalitis virus, 474f
- egg drop syndrome virus, 301–302, 302f
- enterovirus-like viruses, 395–399, 396f
- goose hemorrhagic polyomavirus, 441f
- hemorrhagic enteritis, 310
- infectious bronchitis virus, 140, 140f
- infectious bursal disease, 220f
- infectious laryngotracheitis virus, 161, 162f, 163f
- influenza virus, 187f
- Marek's disease, 517f
- Mycoplasma gallisepticum*, 877, 878f
- parvovirus of chickens and turkeys, 399, 401, 401f, 403–404
- Pasteurella multocida*, 808f
- poxvirus, 333, 334f, 342
- reovirus, 351f, 364
- reticuloendotheliosis virus, 594, 594f
- rotavirus, 382, 382f, 384f, 387, 390
- turkey coronavirus, 377, 377f
- Elementary bodies (Borrel bodies), of fowlpox virus, 333, 341
- Elementary body (EB), chlamydial, 1055–1057, 1057f,
- Elementary body agglutination, for *Chlamydia*, 1067
- ELISA. *See* Enzyme-linked immunosorbent assay
- ELVs. *See* Enterovirus-like viruses
- Emerging diseases, 1319–1332
- enteric diseases, multicausal, 1322–1325
- etiologies, 1323–1324
- intervention strategies, 1325
- pathogenesis, 1324–1325
- hypoglycemia-spiking mortality syndrome of broiler chickens, 1325–1327, 1326f
- diagnosis, 1327
- etiology, 1325–1327
- history, 1325
- incidence and distribution, 1325
- pathogenesis and epidemiology, 1327
- treatment, prevention, and control, 1327
- respiratory diseases, multicausal, 1320–1322
- environmental factors, role of, 1321
- immunosuppressive agents, effects of, 1320–1321
- interactions among pathogens, 1320
- vaccination reactions, 1321–1322
- transmissible viral proventriculitis (TVP), 1328–1332
- classification, 1328
- clinical signs, 1330
- definition and synonyms, 1328
- diagnosis, 1331–1332
- differential diagnosis, 1330
- economic significance, 1328
- etiology, 1328–1329
- history, 1328
- incidence and distribution, 1328
- incubation period, 1329–1330
- isolation and identification of agent, 1331–1332
- laboratory host systems, 1329
- morbidity and mortality, 1330
- morphology, 1329, 1329f
- natural and experimental hosts, 1329
- pathogenesis and epizootiology, 1329–1331
- pathology, 1330–1331, 1330f–1331f
- prevention and control, 1332
- public health significance, 1328

- Enteroaggregative *Escherichia coli* (EAEC), 48, 757
Enterobacter, 1020
 Enterobacterial repetitive intergenic consensus (ERIC), 756, 813
 Enterococcosis, 981–985
 clinical signs, 982
 diagnosis, 981f, 983, 983f
 etiology, 981, 981f, 981t
 history, 981
 pathobiology and epidemiology, 982
 pathology, 982–983
 treatment, 983
Enterococcus avium, 981t
Enterococcus cecorum, 981t, 984–985
Enterococcus durans, 981t, 984
Enterococcus faecalis, 981–983, 981f, 981t, 983f
Enterococcus faecium, 981–983, 981t
Enterococcus hirae, 981t, 984
 Enterogenous cysts, 611
 Enterohemorrhagic *Escherichia coli* (EHEC), 48–49, 757, 773
 Enteroinvasive *Escherichia coli* (EIEC), 48, 757, 773
 Enteropathogenic *Escherichia coli* (EPEC), 48, 757, 773
 Enterotoxigenic *Escherichia coli* (ETEC), 48, 757
 Enterovirus, 395
 Enterovirus-like viruses (ELVs), 395–399. *See also* Duck hepatitis virus type 1; Turkey viral hepatitis
 chemical composition, 395
 classification, 395
 clinical signs, 397–398
 diagnosis, 398–399
 differential diagnosis, 399
 etiology, 395–397
 immunity, 398
 incidence and distribution, 397
 intervention strategies, 399
 laboratory host systems, 396–397
 morphology, 395, 396f
 natural and experimental hosts, 397
 overview, 395
 pathobiology and epizootiology, 397–398
 pathogenesis, 398
 pathogenicity, 397
 pathology, 398
 gross lesions, 398
 microscopic lesions, 398
 serology, 399
 susceptibility to physical and chemical agents, 396
 transmission, carriers, and vectors, 397
 virus isolation and identification, 398–399
 virus replication, 395–396, 396f
 Entomobirnavirus, 219
 Environment
 disease control and complex, 23
 farm/site, 20
 poultry house, 11–12
 induced disorders
 asphyxiation, 1234–1235
 heat stress, 1234
 Marek's disease and, 532
 multicausal respiratory disease and, 1321
 Environmental Protection Agency (EPA), 13
 Enzyme immunoassay (EIA)
 for *Campylobacter*, 742
 for reticuloendotheliosis, 603, 604
 for *Salmonella*, 703, 704
 Enzyme-linked immunosorbent assay (ELISA)
 antibody level measurement with, 70
 for arizonosis, 712
 for aspergillosis, 1086
 for astrovirus, 394
 for aviadenovirus, 300
 for avian encephalomyelitis virus, 487, 493
 for avian hepatitis E virus infection, 500
 for avian intestinal spirochetosis, 1005
 for avian metapneumovirus, 117, 118, 418
 for avian nephritis virus, 472
 for *Bordetella avium*, 842
 for *Campylobacter*, 742
 for chicken infectious anemia, 262–263
 for chlamydiosis, 1065
 for circovirus, 273, 274
 for circovirus-like infection, 421
 for duck hepatitis virus type 1, 427
 for duck virus enteritis, 439
 for *E. coli*, 781
 for eastern equine encephalitis, 477
 for egg drop syndrome virus, 306
 for erysipelas, 993, 994
 flock profiling with, 25, 26f
 for Gallid herpesvirus type 1, 171
 for goose hemorrhagic polyomavirus, 443
 for hemorrhagic enteritis virus, 315
 for infectious bronchitis virus, 149–151
 for infectious bursal disease, 229–230, 232–233
 for infectious laryngotracheitis, 170
 for influenza virus, 189, 202
 for leukosis/sarcoma group of neoplastic diseases, 586, 587–588, 587t, 588–589, 589
 for Marek's disease, 547
 for *Mycoplasma gallisepticum*, 889
 for *Mycoplasma meleagridis*, 899
 for *Mycoplasma synoviae*, 905
 for mycotoxicosis diagnosis, 1282
 for Newcastle disease virus, 102, 103
 for *Ornithobacterium rhinotracheale*, 829, 833
 for parvovirus of chickens and turkeys, 401, 405
 for parvovirus of waterfowl, 449
 for poxvirus, 342–343
 for pullorum disease, 690, 691
 for reovirus, 360
 for reticuloendotheliosis, 602
 for *Riemerella anatipestifer* infection, 827
 for rotavirus, 390–391
 for toxoplasmosis, 1194
 for tuberculosis, 1016
 for turkey coronavirus, 381
 for West Nile virus, 481–482
 EPA (Environmental Protection Agency), 13
 EPEC (enteropathogenic *Escherichia coli*), 48, 757, 773
 Epidemiology, disease control and, 8–9
 Epidermal growth factor (EGF), 337
 Epididymitis, *E. coli*, 774–775
 Epithelioma, intracellular keratinizing, 619, 620f
Epomidiostomum uncinatum, 1126, 1127f
 Equipment, sanitation of, 21
 Eradication
 avian metapneumovirus, 112
 infectious laryngotracheitis, 174
 leukosis/sarcoma group of neoplastic diseases, 591–592
 monitoring and surveillance, 23
 Mycoplasma meleagridis infection, 899
 pullorum disease and fowl typhoid, 692
 quail bronchitis virus, 319–320
 success of program, 11
 Ergotism, 1271–1272
 etiology and toxicology, 1271
 experimental disease, 1272
 metabolism and residues, 1272
 natural disease, 1272
 ERIC (enterobacterial repetitive intergenic consensus), 756, 813
 Erysipelas
 antigenic structure, 987
 biochemical properties, 987
 classification, 986
 clinical signs, 990
 colony morphology, 987
 definition and synonyms, 986
 diagnosis, 993
 differential diagnosis, 993
 economic significance, 986
 etiology, 986–989
 growth requirements, 986–987
 history, 986
 immunity, 992–993
 incidence and distribution, 989
 incubation period, 990
 isolation and identification of agent, 993
 management procedures, 994
 morbidity and mortality, 990
 morphology and staining, 986
 natural and experimental hosts, 989
 pathobiology and epidemiology, 989–993
 pathogenesis, 992
 pathology
 gross, 990–991
 microscopic, 991–992, 991f–992f
 public health significance, 48, 986
 nature of disease in humans, 48
 occurrence, 48
 reservoirs and sources of infection, 48
 serology, 993
 strain classification, 987
 susceptibility to chemical and physical agents, 987
 transmission, carriers, and vectors, 989–990
 treatment, 994
 vaccination, 992, 994
 virulence factors, 988–989
Erysipelothrix rhusiopathiae, 48, 986
Erysipelothrix tonsillarum, 986
 Erythroblastosis
 clinical signs, 570
 differential diagnosis, 590
 incubation period, 569
 pathology, 573–575
 gross, 573–575, 574f
 microscopic, 575, 575f
 pathogenesis, 575
 ultrastructure, 575
 Erythromycin
 for avian intestinal spirochetosis, 1007
 for fowl cholera, 822
 for infectious coryza, 868
 for *Mycoplasma gallisepticum*, 893
 Erythrovirus, 400f
Escherichia albertii, 752–754, 753t
Escherichia coli. *See also* Colibacillosis
 AEEC (attaching and effacing), 759, 773, 773f
 APEC (avian pathogenic), 48
 DAEC (diffuse-adherence), 48
 EAEC (enteroaggressive), 48, 757
 EHEC (enterohemorrhagic), 48–49, 757, 773
 EIEC (enteroinvasive), 48, 757, 773
 EPEC (enteropathogenic), 48, 757, 773
 ETEC (enterotoxigenic), 48, 757
 ExPEC (extraintestinal pathogenic), 48
 genetic resistance to, 77–78
 interaction with respiratory pathogens, 1320
 NMEC (neonatal meningitis), 757, 762
 public health significance, 48–49
 nature of disease in humans, 48
 occurrence, 48–49
 reservoirs and sources of infection, 49
 STEC (Shiga toxin), 48
 turkey coronavirus and, 379–380
 UPEC (uropathogenic), 757
Escherichia fergusonii, 752–754, 753t
 Essential oils, for colibacillosis, 785
 ETEC (enterotoxigenic *Escherichia coli*), 48, 757
 Ethambutol, for tuberculosis, 1017
 Ethinone toxicity, 1292
 Ethoxyquin toxicity, 1297
 Ethylenediaminetetraacetic acid (EDTA), 28
 Ethylene glycol toxicity, 1303

- laboratory host systems, 294
 management procedures, 300
 morphology, 291, 292f, 293f
 pathogenicity, 294
 pathology, 296f, 298–299, 298f–299f
 public health significance, 291
 serology, 300
 strain classification, 292, 294
 susceptibility to chemical and physical agents, 292
 transmission, 295
 vaccination, 300
 virus isolation, 299
 virus replication, 292
- Fahey-Crawley virus, 352, 362
- Falcon herpesvirus, 465
- False layer, 1256
- Famphur toxicity, 1300
- Fannia* spp., 1108, 1108f
- Farms, disease control and, 19–22, 22f
 access control, 20–21
 equipment, 21
 people, 20–21
 vehicles, 21
- dead bird disposal, 22, 22f
- egg room, 21
- environment of, 20
- fumigation room, 21–22
- functional units, 20
- isolation, 19–20, 20f
- one age of fowl/farm, 20
- placement, transfers and depletions, 21
- spray vaccination, 37
- Fats, dietary, 1207
- Fatty acids, 1207
- Fatty liver-hemorrhagic syndrome (FLHS), 1252–1253, 1253f
- FDA (Food and Drug Administration), 39
- Feather dystrophy, 271, 273
- Feather folliculoma, 619, 619f
- Feather pecking, 1233–1234
- Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA), 13
- Feed
 antimicrobial administration in, 40–41
 disease control and, 15
 manufacturing and management for mycotoxicosis prevention, 1283
 medication in, 15–16
 toxin levels in, 1288t
- Feed additives
 for *Cochlosoma anatis* infection, 1185
 for histomoniasis, 1178t, 1179
- Feeders, 15, 16
- Fenbendazole, for nematodes, 1133
- Fenthion toxicity, 1300
- Fertilizer toxicity, 1303
- Fibrosarcoma, 580–582, 581f
- Field birds, examination of, 24
- FIFRA (Federal Insecticide, Fungicide, and Rodenticide Act), 13
- Fimbriae, of *E. coli*, 757, 759
- Fimbriaria fasciolaris*, 1142, 1142f
- Finch circovirus (FiCV), 265–267
- Fish meal, 1292
- Fixative, 32
- Flagellin, 682, 755
- Flaviviridae, 419, 474
- Flavobacterium*, 1021
- Flavus. *See* Dermatophytosis
- Fleas, 1103, 1103f
- Flesh flies, 1108
- FLHS (fatty liver-hemorrhagic syndrome), 1252–1253, 1253f
- Flies
 biting, 1107
 nonbiting, 1107–1108, 1107f–1108f
- Flip-over. *See* Sudden death syndrome
- Flock health, 4–5
 disposition during disease outbreak, 40
 population dynamics, 5
 resistance and resilience, 4–5
 tracking, 24
- Flock profiling, 25, 26f
- Fluorescence staining, for *Chlamydia* detection, 1066
- Fluorescent antibody (FA) test
 for infectious bursal disease, 229
 for Marek's disease, 547
 for poxvirus, 343
 for turkey coronavirus, 380
 for ulcerative enteritis, 946, 948
- Fluoride toxicity, 1293
- Fluoroquinolones
 for fowl cholera, 822
 for *Mycoplasma gallisepticum*, 893
 for *Mycoplasma meleagridis*, 899
 for *Salmonella*, 706
- Folic acid, 1220–1221
- Food and Drug Administration (FDA), 39
- Formaldehyde, 980, 1298–1299
- Formalin fixative, 32
- Fowl cholera, 807–823
 classification, 808
 clinical signs
 acute, 815, 816f
 chronic, 816, 816f–817f
 colony morphology, 808–810, 809f
 diagnosis, 820–821
 differential diagnosis, 821
 etiology, 808–814
 growth requirements, 808
 history, 807–808
 immunity, 819–820
 incidence and distribution, 814
 management procedures, 822
 morphology and staining, 808, 808f–809f
 natural and experimental hosts, 814–815
 pathogenesis and epizootiology, 814–820
 pathogenicity, 813
 pathology
 acute lesions, 816–817, 817f–819f
 chronic lesions, 817, 818f, 820f
 physiologic properties, 810, 810t
 resistance to chemical and physical agents, 811
 subgrouping, 811–813, 811t
 toxicity, 813–814
 transmission, carriers, and vectors, 815
 treatment, 821–822
 vaccination, 819–820, 822–823
- Fowl paralysis, 530–531, 530f–531f, 532, 538f, 548–549
- Fowlpox, 333–346
- Fowl tick (*Argas persicus*), 1105, 1105f
- Fowl typhoid, 678–693
 antigenic structure, 680–681
 biochemical properties, 680
 classification, 679
 clinical signs, 684
 colony morphology, 679, 690
 diagnosis, 689–691
 differential diagnosis, 690
 economic significance, 678
 etiology, 679–682
 growth requirements, 679
 history, 678–679
 identification of cultures, 690, 690t
 immunity, 689
 incidence and distribution, 682–683
 intervention strategies, 690–693
 isolation and identification of agent, 689
 management procedures, 691–692
 national control program, 692
 non-gallinarum reactors, 691–692
 serologic tests, 691
 morbidity and mortality, 684
 morphology, 679
 natural and experimental hosts, 683
 pathobiology and epidemiology, 682–689
 pathogenesis, 688–689
 pathology, 684–688
 gross lesions, 684–687
 histopathology, 687–688
 public health significance, 678
 serology, 690, 691
 susceptibility to chemical and physical agents, 680
 transmission, 683–684
 treatment, 692–693
 vaccination, 692
 virulence factors, 681–682
- FreeCalc (program), 24
- Frey's medium, modified, 900, 901t
- Fumigation
 of eggs, 14
 fumigant toxicity, 1298–1299
- Fumigation room, 21–22
- Fumonisin, 1274–1275
- Functional genomics, 75
- Fungal infections, 1077–1093
 aspergillosis, 1078–1088
 candidiasis, 1088–1090
 dermatophytosis, 1091
 macrorhabdosis, 1092–1093, 1093f
 ochroconosis, 1091–1092
 public health significance, 50–52
 cryptococcosis, 50–51
 dermatophytosis, 51
 histoplasmosis, 51–52
 zygomycosis, 1092
- Fungi, necropsy examination and, 32
- Fungicide toxicity, 1299
 captan, 1299
 organic mercurials, 1299
 thiram, 1299
- Furazolidone
 for histomoniasis, 1178t
 toxicity, 1289
- Fusarium* mycotoxins, 1272–1276
 fumonisins, 1274–1275
 fusarochromanone, 1275
 incidence and distribution, 1272
 moniliformin, 1273–1274, 1275f
 trichothecenes, 1272–1273, 1273f–1274f
 zearalenone, 1275–1276
- Galactomannan, of *Aspergillus* spp., 1087
- Gallibacterium*, 1020–1021
- Gallid herpesvirus type1 (GaHV-1), 161–174. *See also* Infectious laryngotracheitis (ILT)
- Gallus adeno-like (GAL), 289
- GALT (gut-associated lymphoid tissue), 63
- Gangrenous dermatitis, 957–960
 antigenic structure and toxins, 957
 biochemical properties, 957
 clinical signs, 958
 colony morphology, 957
 definition, 957
 diagnosis, 959–960
 economic significance, 957
 etiology, 957–958
 growth requirements, 957
 history, 957
 incidence and distribution, 958
 morphology and staining, 957
 pathobiology and epizootiology, 958–959
 public health significance, 957
 treatment and prevention, 961–962
- Gases, toxic, 1302
- Gastrocnemius tendon rupture, 1245–1246, 1245f
- Gastrointestinal diseases. *See* Digestive system diseases; Enteric diseases
- GE. *See* Gizzard erosion
- Geese
Aeromonas infection in, 1018
 APMVs in, 108, 109
 avian adenovirus infection in, 297
 avian intestinal spirochetosis in, 999, 1004
 avian metapneumovirus in, 418
Borrelia anserina in, 1018
 chlamydiosis in, 1064
 circovirus-like infection in, 421
 coccidiosis in, 1165–1166
Coenonia infection in, 1020
 duck virus enteritis in, 434–435, 437
 egg drop syndrome virus in, 303, 306
 erysipelas in, 990, 991
 fowl cholera in, 808, 814
Gallibacterium in, 1020–1021
 goose hemorrhagic polyomavirus in, 440–443
 goose herpesvirus in, 420
Helicobacter in, 1021
 hemorrhagic nephritis enteritis of

- for *Salmonella*, 706
toxicity, 1290
- GHPV (goose hemorrhagic polyomavirus), 440–443
- GHV (goose herpesvirus), 420
- Githagenin toxicity, 1304
- Gizzard erosion (GE), 290
clinical signs, 297
pathology, 299, 299f
- Gizzard impaction, 1253
- Gland of Harder, 63, 64f
- Gliosis, in avian encephalomyelitis, 489, 489f–490f
- Gliotoxin, 1080, 1089–1090
- Glucomannan, 1284
- Glucosinolate toxicity, 1306
- Gongylonema inguicola*, 1128, 1128f
- Goose circovirus (GoCV), 265–269, 274
- Goose hemorrhagic polyomavirus (GHPV), 440–443
- Goose herpesvirus (GHV), 420
- Goose parvovirus, 444–451. *See also* Parvovirus
- Goose venereal disease, 1026–1027
- Gout
articular, 1255–1256, 1256f
visceral, 1254–1255, 1254f
- Granulomas, 1027
- Granulosa-theca cell tumor, 606–607, 607f
- Green muscle disease, 1244–1245
- GuCV (gull circovirus), 265
- Guinea fowl
Aegyptianella in, 1017
aviadenovirus infection in, 298
avian metapneumovirus in, 115
Avibacterium paragallinarum in, 863
chlamydiosis in, 1061, 1064
enterovirus-like viruses in, 397, 398
fowl typhoid in, 683, 687
Helicobacter in, 1021
macrorhabdosis in, 1092
Newcastle disease virus variants in, 107
pullorum disease in, 683
Riemerella anatipestifer in, 825
seminoma in, 611
- Gull circovirus (GuCV), 265
- Gumboro disease. *See* Infectious bursal disease (IBD)
- Gut-associated lymphoid tissue (GALT), 63
- Gyrovirus*, 247
- HA. *See* Hemagglutinin
- Haematosiphon inodorus*, 1108
- Haemophilus gallinarum*. *See* *Avibacterium paragallinarum*
- Haemophilus paragallinarum*. *See* *Avibacterium paragallinarum*
- Haemoproteus* spp., 1189–1190
- Hafnia*, 1021
- Halofuginone
for coccidiosis, 1165
for leucocytozoonosis, 1188
toxicity, 1291
- Harderian gland, infectious bursal disease effect on, 231
- Hatchery, 17–19
breeder codes, 19
chick sexers, 19
design and location, 18
problems related to, 1235
sanitation, 18–19
spray vaccination in, 36–37
storage facilities, 19
surgical procedures, 19
- Hawaiian forest birds, poxviruses of, 336, 339, 341, 346
- HE. *See* Hemorrhagic enteritis
- Health surveys, 24
- Heart, 27
- Heart attack. *See* Sudden death syndrome
- Heart disease
dilated cardiomyopathy, 1249–1250
in eastern equine encephalitis, 475–477, 476f
in enterococcosis, 982
in erysipelas, 991f
in hydropericardium syndrome, 296–298
in pullorum disease, 685–688, 685f–686f, 688f
in sodium excess, 1224f
- Heat stress, 1234
- Helicobacter*, 1021
- Helicopter disease, 363, 402
- Helper T cells, 67
- Helper virus, for reticuloendotheliosis virus, 594, 595, 601
- Hemagglutinin (HA), 303, 306
Avibacterium paragallinarum, 863, 865
Bordetella avium, 837
circovirus, 273, 274
duck hepatitis virus type 1, 426
duck virus enteritis, 439
egg drop syndrome virus, 302
FAdV-1 and, 292
- Mycoplasma gallisepticum*, 879
Newcastle disease, 102–103
Newcastle disease virus, 92
poxvirus, 337, 343
- Hemagglutinin inhibition (HI)
for APMVs, 108
for circovirus, 273, 274
for eastern equine encephalitis, 477
for egg drop syndrome virus, 303, 305–307, 309
for infectious bronchitis virus, 140, 142, 149–151
for infectious coryza, 861, 867
for influenza virus, 189, 202–203
for Israel turkey meningoencephalitis, 479
for *Mycoplasma gallisepticum*, 889
for *Mycoplasma meleagridis*, 899
for *Mycoplasma synoviae*, 905
for Newcastle disease virus, 102–103
for West Nile virus, 481
- Hemangioma
clinical signs, 570
differential diagnosis, 591
incubation period, 569–570
pathology, 577–578, 578f
- Hemangiopericytoma, 617, 617f
- Hemlock toxicity, 1305
- Hemolysis, by Newcastle disease virus, 92
- Hemorrhage
in APMV infections-, 110
in *Borrelia anserina* infection, 1019
in chicken infectious anemia, 255–256, 256f–258f
in duck hepatitis type I infection, 425, 425f
in duck virus enteritis infection, 435–437, 436f
in encephalomalacia, 1214
in erysipelas, 990–992
in fatty liver-hemorrhagic syndrome, 1252–1253, 1252f
in fowl cholera, 818f
in hemangioma, 577
in hemorrhagic enteritis, 309–316
in hydropericardium syndrome, 298
in infectious bursal disease, 227, 227f, 232
in infectious laryngotracheitis, 168, 169f
in influenza virus infection, 197–200, 198f–199f
in Newcastle disease, 99, 100f
in rotavirus, 387
- in ulcerative enteritis, 946, 947f
in vitamin K deficiency, 1215–1216
- Hemorrhagic-aplastic anemia
syndrome, 256
- Hemorrhagic enteritis (HE), 309–316
chemical composition, 310
classification, 310
clinical signs, 312
definitions and synonyms, 309
diagnosis, 314–315
differential diagnosis, 315
economic significance, 309
etiology, 310–311
history, 309–310
immunity, 314
active, 314
passive, 314
immunosuppression by virus, 1320–1321
incidence and distribution, 311
incubation period, 312
intervention strategies, 315–316
laboratory host systems, 311
management procedures, 315
morbidity and mortality, 312
morphology, 310
natural and experimental hosts, 311
pathobiology and epidemiology, 311–314
pathogenesis, 313–314
pathogenicity, 311
pathology, 312–313
gross lesions, 312, 312f
microscopic lesions, 312–313, 312f–313f
public health significance, 309
serology, 314–315
strain classification, 311
susceptibility to physical and chemical agents, 310–311
transmission, carriers, and vectors, 311–312
treatment, 316
vaccination, 315–316
virus isolation, 314
virus replication, 310
- Hemorrhagic fatty liver syndrome (HFLS), 500
- Hemorrhagic nephritis enteritis of geese (HNEG), 440–443
chemical composition, 440
classification, 440
clinical signs, 442
diagnosis, 443
differential diagnosis, 443
- history, 440
immunity, 443
incidence and distribution, 441
incubation period, 442
intervention strategies, 443
laboratory host system, 441
management procedures, 443
morbidity and mortality, 442
morphology, 440
natural and experimental hosts, 441–442
pathobiology and epizootiology, 441–442
pathogenesis of infectious process, 442–443
pathology, 442, 442f
strain classification, 441
susceptibility to chemical and physical agents, 441
transmission, carriers, and vectors, 442
vaccination, 443
virus replication, 441
- Hemorrhagic septicemia, 776
- Hepacivirus, 474
- Hepatitis
hepatitis-splenomegaly syndrome, 494–500
inclusion body hepatitis, 363
turkey viral hepatitis, 482–485, 484f–485f
in young chicks, 363
- Hepatitis E virus. *See* Avian hepatitis E virus
- Hepatitis-hydropericardium syndrome. *See* Hydropericardium syndrome (HS)
- Hepatitis-splenomegaly syndrome, 494–500, 1237. *See also* Avian hepatitis E virus
- Hepatocellular tumors, 612, 612f
- Hepatoma, 612, 612f
- Hepevirus, 494
- Heptachlor toxicity, 1300
- Herbicide toxicity, 1299
chlorates, 1299
diquat, 1299
paraquat, 1299
- Herd immunity, in Newcastle disease vaccination, 106
- Heritability, 72
- Herpesvirus
duck virus enteritis, 431–440
Gallid herpesvirus type 1 (GaHV-1), 161–174

- reservoirs and sources of infection, 52
- Hjarre's disease, 751, 752, 779
- HNEG. *See* Hemorrhagic nephritis enteritis of geese
- Horizontal gene transfer, 42
- Host factors for disease resistance, 61–79. *See also* Immunity
- Host range, 9
- Host resistance, 8
- House flies (*Musca domestica*), 1107, 1107f
- HS. *See* Hydropericardium syndrome
- Humoral immunity, 67–69, 68t
 - in avian hepatitis E virus infection, 497
 - in avian metapneumovirus infection, 116–117
 - in *Campylobacter* infection, 741
 - in circovirus infection, 273
 - in infectious bronchitis, 147, 149
 - in infectious laryngotracheitis, 170
 - in influenza virus infection, 200–201
 - in Marek's disease, 544–545
 - in Newcastle disease, 102
 - in paratyphoid infections, 700–701
 - in reticuloendotheliosis, 601–602
 - in turkey coronavirus enteritis infection, 380
 - in viral arthritis, 358
- HVT (turkey herpesvirus), 551–552
- Hyaluronidase, erysipelas, 988–989
- Hydropericardium syndrome (HS), 290
 - clinical signs, 296–297
 - pathology, 298–299
- Hygiene, nest and egg, 14
- Hymenolepis cantaniana*, 1137, 1137f, 1138, 1140
- Hymenolepis carioca*, 1136, 1137, 1137f–1139f, 1138, 1140
- Hymenolepis megalops*, 1135, 1142, 1142f
- Hyperkeratinization of skin, 1224–1225
- Hypoglycemia-spiking mortality syndrome of broiler chickens, 1325–1327, 1326f
 - diagnosis, 1327
 - etiology, 1325–1327
 - history, 1325
 - incidence and distribution, 1325
 - pathogenesis and epidemiology, 1327
 - treatment, prevention, and control, 1327
- IBD. *See* Infectious bursal disease
- IBH. *See* Inclusion body hepatitis
- Ichtadenovirus, 289t, 290
- ICPI (intracerebral pathogenicity index), Newcastle disease and, 90, 91, 105–106
- IFA. *See* Indirect fluorescent antibody (IFA) test
- IgA. *See* Immunoglobulin A
- IgG. *See* Immunoglobulin G
- IgM. *See* Immunoglobulin M
- IgY, 102
- ILT. *See* Infectious laryngotracheitis
- Iltovirus, 161
- Imidazoles, 1291–1292
- Imidazothiazole toxicity, 1292
- Immune system
 - anatomy of, 62–63, 62f, 64f
 - assays to measure immunity, 69–70
 - features of, 63–69, 65f
 - adaptive immunity, 66–67, 66t
 - humoral immunity, 67–69, 68t
 - innate immunity, 63–65
 - maternal transfer of immunity, 69
 - overview, 61–62
- Immunity. *See also* Vaccination
 - adaptive, 66–67, 66t
 - aspergillosis, 1085
 - assays to measure, 69–70
 - antibody levels, 70
 - cytokines, 69–70
 - macrophages, 69
 - natural killer cells, 69
 - T cells, 69–70
 - astrovirus, 394
 - aviadenovirus, 299
 - avian encephalomyelitis, 491–492
 - avian hepatitis E virus, 497–498
 - avian intestinal spirochetosis, 1004
 - avian malaria, 1189
 - avian metapneumovirus, 116–117
 - Bordetella avium*, 841–842
 - Borrelia anserina* infection, 1020
 - Campylobacter* infection, 741
 - cell-mediated (CMI), 66
 - chicken infectious anemia, 259
 - in chlamydiosis, 1064–1065
 - circovirus, 273
 - cryptosporidiosis, 1171
 - cytokines, 67
 - cytotoxic T cells, 67
 - duck hepatitis virus type 1, 426
 - duck virus enteritis, 438–439
 - egg drop syndrome virus, 305
 - enterovirus-like viruses, 398
 - fowl cholera, 819–820
 - fowl typhoid, 689
 - helper T cells, 67
 - hemorrhagic enteritis, 314
 - hemorrhagic nephritis enteritis of geese, 443
 - histomoniasis, 1177
 - humoral, 67–69, 68t
 - infectious bronchitis, 147, 149
 - infectious bursal disease, 229–230
 - infectious coryza, 865
 - infectious laryngotracheitis, 170
 - influenza virus, 200–201
 - innate, 63–65
 - leukosis/sarcoma group of neoplastic diseases, 584
 - Marek's disease, 543–546
 - maternal transfer, 69
 - mucosal, 68
 - Mycoplasma gallisepticum* infection, 887–888
 - Mycoplasma iowae* infection, 909
 - Mycoplasma meleagridis* infection, 898
 - Mycoplasma synoviae* infection, 905
 - necrotic enteritis, 952
 - Newcastle disease, 101–102
 - Ornithobacterium rhinotracheale*, 832
 - paratyphoid infections, 700–701
 - parvovirus of chickens and turkeys, 404
 - parvovirus of waterfowl, 449
 - pigeon herpesvirus, 467
 - pullorum disease, 689
 - quail bronchitis virus, 319
 - reticuloendotheliosis, 601–602
 - Riemerella anatipestifer* infection, 826–827
 - rotavirus, 389–390
 - sarcocystosis, 1192
 - staphylococcosis, 976
 - Trichomonas gallinae*, 1180
 - trichomoniasis, 1180
 - turkey coronavirus enteritis, 380
 - turkey viral hepatitis, 484
 - ulcerative enteritis, 946
 - viral arthritis, 358–359
 - West Nile virus, 481
- Immunization. *See* Vaccination
- Immunoblotting, poxvirus, 343
- Immunodepression, in reticuloendotheliosis, 602
- Immunodiffusion tests
 - for avian encephalomyelitis virus, 492
 - for poxvirus identification, 343
- Immunofluorescence. *See also specific tests*
 - for aviadenovirus, 299–300
 - for avian encephalomyelitis, 487
 - for avian metapneumovirus, 418
 - for avian nephritis virus, 471–472
 - for chicken infectious anemia virus, 262
 - for duck virus enteritis, 439
 - for enterovirus-like viruses, 396–397, 397f
 - for parvovirus of waterfowl, 449
 - for rotavirus, 387, 391
 - for turkey coronavirus enteritis, 378f
 - for West Nile virus, 481
- Immunoglobulin(s)
 - classes of, 67–68, 68t
 - genes, 69
 - level measurement, 70
 - structure of, 68, 68f
- Immunoglobulin A (IgA)
 - in infectious bronchitis, 147
 - maternal transfer of, 69
 - in Newcastle disease, 102
 - properties of, 67–68, 68t
- Immunoglobulin G (IgG)
 - in infectious bronchitis, 147
 - in infectious bursal disease, 231
 - in influenza, 201
 - maternal transfer of, 69
 - in Newcastle disease, 102
 - in parvovirus of chickens and turkeys, 404
 - properties of, 67–68, 68t
 - in rotavirus, 390
 - structure of, 68f
- Immunoglobulin M (IgM)
 - in infectious bronchitis, 147
 - in infectious bursal disease, 231
 - in influenza, 200
 - in Newcastle disease, 102
 - in parvovirus of chickens and turkeys, 404
 - properties of, 67–68, 68t
- Immunohistochemistry
 - for avian intestinal spirochetosis, 1004
 - for avian nephritis virus, 471
 - for chicken infectious anemia virus, 262
 - for chlamydiosis, 1065
 - for circovirus, 273
 - for eastern equine encephalitis, 477
 - for Gallid herpesvirus type 1, 171
 - for leukosis/sarcoma group of
- for *Ornithobacterium rhinotracheale*, 832
- for parvovirus of chickens and turkeys, 401, 403, 404f
- for rotavirus, 387
- Immunomagnetic separation (IMS), for *Salmonella*, 703
- Immunoperoxidase staining
 - for enterovirus-like viruses, 396
 - for infectious bronchitis virus, 150
 - for *Mycoplasma meleagridis*, 899
 - for poxvirus, 343
 - for reticuloendotheliosis, 603
 - for rotavirus, 388f
 - for turkey coronavirus, 377f, 380
- Immunosuppression
 - aviadenovirus, 299
 - beak and feather disease virus, 273
 - chicken infectious anemia, 259–260
 - infectious bursal disease, 230–231
 - Marek's disease, 546
 - multicausal respiratory disease and, 1320–1321
 - reovirus in turkeys, 364
 - reticuloendotheliosis, 602
- Immunotherapy, for infectious bursal disease, 235
- Impaction, 1253
- IMS (immunomagnetic separation), for *Salmonella*, 703
- Inactivated vaccines, 35–36
- IncA/C plasmids, 43
- Inclusion body hepatitis (IBH), 290, 363
 - clinical signs, 295–296
 - pathology, 296f, 298, 298f
- Inclusions
 - adenovirus, 289
 - aviadenovirus, 291, 292f–293f, 295, 296f, 298–299
 - Chlamydia* in, 1059–1060, 1060f
 - circovirus, 271–272, 272f
 - duck virus enteritis, 433, 434f
 - egg drop syndrome virus, 305, 307f
 - FAdV, 291, 292f–293f, 295, 296f, 298–299
 - Gallid herpesvirus type 1, 171
 - hemorrhagic enteritis, 310
 - parvovirus of chickens and turkeys, 403
 - parvovirus of waterfowl, 448
 - poxvirus, 335, 338f, 341–342
 - quail bronchitis virus, 317, 318f, 319
- Incubation-related problems, 1235

- gross lesions, 145–146, 146f
microscopic lesions, 146–147, 148f
strain classification, 141–142
 genetic, 142
 serotype, 142
 viral evolution and, 142
susceptibility to physical and
 chemical agents, 141
transmission, carriers, and vectors,
 144–145
treatment, 153
vaccination, 139, 151–153
 application methods, 152–153
 future vaccines, 153
 reactions, 1321–1322
 types of vaccine, 151–152
virus replication, 140–141
- Infectious bursal disease (IBD),
 219–235
 chemical composition, 220–221
 chicken infectious anemia as
 cofactor in disease, 261–262
 classification, 219
 clinical signs, 226
 diagnosis, 231–233
 differential diagnosis, 232
 etiology, 219–224
 genetic resistance to, 78
 history, 219
 immunity, 229–231
 active, 230
 immunosuppression, 230–231
 passive, 230
 immunization, 230, 233–235
 immunosuppression by, 1320–1321
 incidence and distribution, 225
 incubation period, 226
 intervention strategies, 233–235
 laboratory host systems, 223–224
 cell culture, 223–224
 chicken embryos, 223
 management procedures, 233
 morbidity and mortality, 226
 morphology, 219, 220f
 natural and experimental hosts,
 225–226
 overview, 219
 pathobiology and epidemiology,
 225–231
 pathogenesis of the infectious
 process, 229
 pathogenicity, 224
 pathology, 226–229
 gross lesions, 226–227, 227f
 microscopic lesions, 227–229, 228f
- serology, 232–233
strain classification, 222–223
susceptibility to physical and
 chemical agents, 222
transmission, carriers, and vectors,
 226
treatment, 235
virus isolation, 231–232
virus replication, 221–222
- Infectious coryza, 859–868
 biochemical properties, 860–861,
 861t
 classification, 860
 clinical signs, 864
 colony morphology, 860
 definitions and synonyms, 859
 diagnosis, 865–867
 differential diagnosis, 867
 economic significance, 859
 etiology, 860–863
 growth requirements, 860
 history, 859
 immunity, 865
 incidence and distribution, 863
 incubation period, 864
 intervention strategies, 867–868
 isolation and identification of agent,
 865–866, 866f
 management procedures, 867
 morbidity and mortality, 864
 morphology, 860
 natural and experimental hosts, 863
 pathobiology and epizootiology,
 863–865
 pathology, 864–865
 gross, 864, 865f
 microscopic, 864–865
 public health significance, 859
 serology, 866–867
 strain classification, 861–863
 antigenicity, 861–862
 immunogenicity or protective
 characteristics, 862
 molecular techniques, 862
 pathogenicity, 862–863
 susceptibility to chemical and
 physical agents, 861
 transmission, carriers, and vectors,
 863–864
 treatment, 868
 vaccination, 867–868
 field protocols and regimes, 868
 types of vaccines, 867–868
 virulence factors, 863
- Infectious laryngotracheitis (ILT),
 chemical composition, 162–165
 classification, 161
 clinical signs, 167–168
 diagnosis, 170–171
 differential diagnosis, 171
 economic significance, 161
 eradication, 174
 etiology, 161–167
 genome organization, 162–163, 164f
 histopathology, 170
 history, 161
 immunity, 170
 active, 170
 passive, 170
 incidence and distribution, 167
 incubation period, 167
 intervention strategies, 172–174
 laboratory host systems, 166
 cell culture, 166
 chicken embryos, 166
 management procedures, 172
 morbidity and mortality, 168
 morphology, 161, 162f, 163f
 natural and experimental hosts, 167
 overview, 161
 pathobiology and epidemiology,
 167–170
 pathogenesis of the infections
 process, 168
 pathogenicity, 166–167
 pathology, 168
 gross lesions, 168, 169f
 microscopic lesions, 168
 serology, 171
 strain classification, 165–166
 susceptibility to physical and
 chemical agents, 165
 transmission, carriers, and vectors,
 167
 treatment, 174
 vaccination, 172–174
 experimental vaccines, 173
 live attenuated, 172–173
 programs, 173–174
 recombinant vaccines, 173
 virus isolation, 170–171
 virus replication, 165
- Infectious stunting syndrome, 1323
- Influenza, 181–206
 chemical composition, 187
 classification, 187
 clinical signs, 196–197
 definitions and synonyms, 181
 diagnosis, 201–203
 direct detection of viral proteins
 sample selection and storage,
 201–202
 serology, 202–203
 virus identification, 202
 virus isolation, 202
 differential diagnosis, 203
 economic significance, 181–182, 183t
 etiology, 187–193
 genetic resistance to, 78–79
 history, 182, 184–187, 185t–186t
 immunity, 200–201
 active, 200–201
 passive, 201
 incidence and distribution, 193–194
 incubation period, 196
 intervention strategies, 203–206
 laboratory host systems, 190–191
 cell culture, 191
 chicken embryos, 190–191
 management procedures, 203–204
 biosecurity, 203–204
 decreasing host susceptibility, 204
 diagnosis and surveillance, 204
 education and behavioral change,
 203
 elimination of infected poultry, 204
 morbidity and mortality, 197
 morphology, 187, 187f
 natural and experimental hosts, 194
 overview, 181–182
 pathobiology and epizootiology,
 193–201
 pathogenesis of the infectious
 process, 200
 pathogenicity, 191–193, 192t
 pathology, 197–200
 gross lesions, 197–199, 198f–199f
 microscopic lesions, 199–200
 public health significance, 45, 182,
 184t
 nature of disease in humans, 45
 occurrence, 45
 preventive measures, 45
 reservoirs and sources of
 infection, 45
 strain classification, 189–190
 antigenicity, 189
 antigenic variation, 189–190
 genetic/molecular characteristics,
 190
 immunogenicity/protective
 characteristics, 190
 pathotype, 190
 strain nomenclature, 189
 susceptibility to physical and
 transmission and carriers, 194–196
 treatment, 206
 vaccination, 204–206
 virus replication, 187
 in waterfowl, 418–419
- Innate immunity, 63–65
 Campylobacter infection, 741
 Chlamydia and, 1065
 infectious bronchitis, 147
 Marek's disease, 543–544
 Newcastle disease, 101
- In ovo* infection, Marek's disease,
 542
- In ovo* vaccination
 for avian metapneumovirus, 119
 delivery systems, 36, 36f
 description of, 36
 for reovirus, 361
- Insect control measures, 17
- Insecticides, 1109
 in poultry house, 17
 toxicity, 1299–1301
 carbamate, 1300–1301
 nicotine, 1301
 organochlorides, 1299–1300
 organophosphates, 1300–1301
 pyrethrum and pyrethroids, 1301
 rotenone, 1301
- Insertional mutagenesis,
 reticuloendotheliosis and,
 596
- In situ* hybridization (ISH)
 for astrovirus, 394
 for aviadenovirus, 300
- Integrated pest management (IPM)
 for arthropod pests, 1109
 for mite control, 1102
 for rodents, 1109–1115
- Integumentary system diseases
 gangrenous dermatitis, 957–960
 keratoacanthoma, 617–619,
 618f–619f
 Marek's disease, 533, 534f, 536
 neoplastic, 617–620
 adenoma, 619
 feather folliculoma, 619, 619f
 hemangiopericytoma, 617, 617f
 intracutaneous keratinizing
 epithelioma, 619, 620f
 keratoacanthoma, 617–619,
 618f–619f
 lipoma, 617
 liposarcoma, 617
 mast cell tumors, 619–620
 squamous cell carcinoma, 617

- Aulonocephalus lindquisti*, 1125, 1125f
Baylisascaris spp., 1125
Capillaria spp., 1121, 1122f–1123f, 1122t
Cheilospirura spp., 1125, 1126f–1127f
Codistomum struthonis, 1126
Cyathostoma bronchialis, 1126–1127, 1127f
Cyrnea colini, 1125–1126, 1127f
Deletrocephalus dimidiatus, 1127
 development and life cycles, 1120
Dicheilonema rhea, 1128
Dispharynx nasuta, 1128, 1128f
Echinura uncinata, 1128, 1128f
Epomidiostomum uncinatum, 1126, 1127f
Gongylonema inguivicola, 1128, 1128f
Hadjelia truncate, 1126
Heterakis spp., 1123–1124, 1124f
Libyostrongylus douglasi, 1128–1129
 morphology, 1119–1120
Ornithostrongylus quadriadiatus, 1129, 1129f
 overview, 1117–1119
Oxyspirura spp., 1129, 1129f
Sicarius spp., 1129
Singhifilaria hayesi, 1129, 1130f
 species reported from chickens, 1118t
 species reported from non-chicken commercial birds, 1118t
 species reported from wild birds, 1119t
Strongloides avium, 1129, 1130f
Subulura spp., 1124f, 1129–1130
Syngamus trachea, 1130–1131, 1131f
Tetrameres spp., 1131–1132, 1131f–1132f
 treatment and control, 1132–1133
Trichostrongylus tenuis, 1132, 1132f
Vaznema zschokkei, 1132
 trematodes, 1143–1144
 control, 1144
 identification, 1144
 life cycle, 1144, 1144f
 morphology, 1143, 1143f
 pathogenicity, 1144
 Interstitial cell tumors, 611
 Intracerebral pathogenicity index (ICPI), Newcastle disease and, 90, 91, 95, 97, 105–106
 Intracutaneous keratinizing epithelioma, 619, 620f
 Intramuscular injection, vaccination by, 36, 37–38
 Intraocular vaccination, 37
 Intussusception, 1253–1254
 Invasins, 760
 Iodine
 deficiency, 1224–1225
 toxicity, 1293
 Ionophores
 for coccidiosis, 1160, 1161
 toxicity, 1290–1291, 1290f–1291f
 IPM. *See* Integrated pest management
 Iprnidazole, for histomoniasis, 1178t
 Iron
 acquisition by *E. coli*, 759
 deficiency, 1225
 toxicity, 1298
 ISH. *See in situ* hybridization
 Isoniazid, for tuberculosis, 1017
 Israel turkey meningoencephalitis, 478–479
 clinical signs and pathology, 478–479
 control, 479
 diagnosis, 479
 differential diagnosis, 479
 history, 478
 incidence and distribution, 478
 pathogenesis and epizootiology, 478
 transmission, carriers, and vectors, 478
 Itraconazole, for aspergillosis, 1088
 Ivermectin toxicity, 1292
 Jimsonweed toxicity, 1305
 Josamycin, for *Mycoplasma meleagridis*, 899
 Keratoacanthoma, 617–619, 618f–619f
 Ketotifen, for infectious bursal disease, 235
 Kidney disease, with infectious bronchitis virus, 144, 146, 146f, 147
 Killed vaccines, 35–36
Klebsiella, 1021
Knemidocoptes mutans (scaly leg mite), 1101, 1102f
 Knockdown syndrome, 1290, 1291f
 Korean fowl plague. *See* Newcastle
 Laboratory procedures, 30
 Lactase, 1207
 LAMP. *See* Loop-mediated isothermal amplification
 Lasalocid, for coccidiosis, 1161, 1165
 Latent infection
 Marek's disease, 522–523, 539f, 540–541
 pigeon herpesvirus 1, 466
 Latex agglutination test, for duck virus enteritis, 439
 Lathyrism, 1306
Lawsonia intracellularis, 1021–1022
 Lead toxicity, 1295–1297, 1296f–1297f
 Leiomyoma, 608, 609f, 611, 620, 620f
 Leiomyosarcoma, 611, 620
 Lesser mealworms, 1105–1107, 1106f
Leucaena leucocephala toxicity, 1305
 Leucocytozoonosis, 1185–1188
 diagnosis, 1188
Leucocytozoon caulleryi, 1187–1188
Leucocytozoon sabrezi, 1188
Leucocytozoon schoutedeni, 1188
Leucocytozoon simondi, 1185–1186, 1187f
Leucocytozoon smithi, 1186–1187, 1187f
 treatment and control, 1188
 Leukemia, in Marek's disease, 536
 Leukosis/sarcoma group of neoplastic diseases, 553–592, 553t
 clinical signs, 570
 connective tissue tumors, 580–582, 581f
 gross, 580–582, 581f
 microscopic, 581f, 582
 pathogenesis, 582
 ultrastructural, 582
 definition and synonyms, 553–554
 diagnosis, 585–591
 differential diagnosis, 589–591
 connective tissue tumors, 591
 erythroblastosis, 590
 hemangioma, 591
 lymphoid leukosis, 589–590
 myeloblastosis, 590
 myelocytomatosis, 590–591
 osteopetrosis, 591
 renal tumors, 591
 economic significance, 554
 erythroblastosis, 573–575, 574f–575f
 gross, 573–575, 574f
 microscopic, 575, 575f
 pathogenesis, 575
 ultrastructure, 575
 chemical composition, 556–558
 lipids, 557
 nucleic acids, 556–557
 proteins, 557–558
 classification, 555, 557t
 endogenous leukosis viruses, 559–561, 560f, 560t
 laboratory host systems, 564–565
 cell culture, 565, 565f
 chick inoculation, 564
 embryos, 564, 564f
 morphology, 555–556, 555f–556f
 pathogenicity, 565–566
 strain classification, 561–564
 antigenicity, 561–562, 562t
 molecular characteristics, 562
 nomenclature, 563–564, 563t
 pathogenicity, 562–563
 susceptibility to chemical and physical agents, 561
 virus replication, 558–559
 defectiveness and phenotypic mixing, 559, 559t
 penetration of host cell, 558
 synthesis and integration of DNA, 558
 transcription, 558–559
 genetic resistance, 584–585, 585t, 592
 hemangioma, 577–578, 578f
 history, 554–555
 immunity, 584
 incidence and distribution, 566–567
 of disease, 566–567
 of infection, 567
 incubation period, 569–570
 isolation and identification of agent, 585–589, 587t
 lymphoid leukosis, 571–573, 572f, 574f
 gross, 571–572, 571f, 574f
 microscopic, 572, 572f
 pathogenesis, 572–573
 ultrastructural, 576
 myeloblastosis, 574f, 575–576, 576f
 gross, 576
 microscopic, 574f, 576, 576f
 pathogenesis, 576
 ultrastructural, 576
 myelocytomatosis, 574f, 576–577, 577f
 gross, 576–577
 microscopic, 574f, 577, 577f
 pathogenesis, 577
 ultrastructure, 577
 nephroma and nephroblastoma, 578–582, 579f
 gross, 578, 579f
 microscopic, 578, 579f, 580
 pathogenesis, 580
 ultrastructural, 580
 nonneoplastic conditions, 570–571
 osteopetrosis, 582–583, 582f–583f
 gross, 582, 582f, 583f
 microscopic, 582–583, 583f
 pathogenesis, 583
 ultrastructural, 583
 pathobiology and epidemiology, 566–585
 pathology, 570–584, 574f
 connective tissue tumors, 580–582, 581f
 erythroblastosis, 573–575, 574f–575
 hemangioma, 577–578, 578f
 lymphoid leukosis, 571–573, 572f, 574f
 myeloblastosis, 574f, 575–576, 576f
 myelocytomatosis, 574f, 576–577, 577f
 nephroma and nephroblastoma, 578–582, 579f
 nonneoplastic conditions, 570–571
 osteopetrosis, 582–583, 582f–583f
 prevention and control, 591–593
 eradication, 591–592
 selection for genetic resistance, 592
 public health significance, 554
 serology, 589
 transmission, 567–569, 568f
 vaccination, 591
 Levamisole
 for nematodes, 1133
 toxicity, 1292
 Leydig cell tumors, 611
Libyostrongylus douglasi, 1128–1129
 Lice, 1103–1105
 Chicken head louse, 1104–1105
 chickens body louse, 1103–1104, 1104f
 external examination for, 26
 shaft louse, 1104, 1105f
 Ligament failure and avulsion, 1246
 Lignosol toxicity, 1297
 Lily of the valley toxicity, 1305
 Limberneck. *See* Botulism
 Lincomycin
 for avian intestinal spirochetosis, 1007
 for *Mycoplasma meleagridis*, 899
 for *Mycoplasma synoviae*, 906

- methods of generating candidate, 35t
 for *Mycoplasma gallisepticum*, 890–892
 for *Riemerella anatipestifer*, 827–828
 Local immunity, in Newcastle disease, 102
 Loop-mediated isothermal amplification (LAMP)
 for avian leukosis viruses, 588
 for infectious bursal disease, 232
 for Marek's disease, 547
 for reticuloendotheliosis, 603
 for *Riemerella anatipestifer*, 827
 LPS. *See* Lipopolysaccharide
 Lung, adenocarcinoma of, 614, 614f
 Lymphodegenerative syndromes, Marek's disease, 526, 527t, 536–537, 537f, 548
 Lymphoid leukosis
 clinical signs, 570
 differential diagnosis, 589–590
 incubation period, 569
 pathology, 571–573
 gross, 571–572, 571f, 574f
 microscopic, 572, 572f
 pathogenesis, 572–573
 ultrastructural, 572
 Lymphoma
 Marek's disease, 532–533, 534f, 541–542
 reticuloendotheliosis, 599–600, 599f, 600f, 601
 Lymphoproliferative syndromes, in Marek's disease, 526, 527t, 532–536, 541–542
 Lyophilization, and infectious bronchitis virus, 141
 Lysergic acid, 1271
 Lysine deficiency, 1207, 1207f, 1213f

Macrodactylus subsoinosus, 1304
 Macrophages, 63–64, 67, 69
 in Marek's disease, 544
 in Newcastle disease, 101
 Macrorhabdosis, 1092–1093, 1093f
 Magnesium
 deficiency, 1223
 excess, 1223
 toxicity, 1293
 Major histocompatibility complex (MHC), 61, 64–67, 73–74, 76–79
 Malabsorption syndrome, 363, 1323, 1324, 1325
 Malaria, avian, 1188–1189
 Mammals, *Mycobacterium avium* in, 1011–1012, 1012t
 Manganese deficiency, 1224
 Marble spleen disease (MSD), 309–316
 Marek's disease, 515–552
 chicken infectious anemia virus dual infection, 260
 classification, 515–516
 clinical signs, 530–531, 530f–531f
 definition and synonyms, 515
 diagnosis, 546–549
 antibody detection, 547
 antigen detection, 547
 differential diagnosis, 548
 DNA probes, 547
 pathotyping, 548
 PCR, 547
 step 1 (clinical data and gross pathology), 547–548
 step 2 (histology, cytology and histochemistry), 548
 step 3 (virologic criteria), 548
 virus isolation, 546–547
 economic significance, 515
 etiology, 515–526
 genetic resistance, 550–551
 genetic resistance to, 76
 history, 515
 immunity, 543–546
 cell-mediated, 545
 humoral, 544–545
 immunoevasion, 545–546
 immunosuppression, 546
 initiation of response, 543
 innate responses, 543–544
 vaccinal, 545
 immunosuppression by, 1321
 incidence and distribution, 526, 528
 incubation period, 530
 laboratory host systems, 524–526
 cell cultures, 524
 chickens, 524
 embryos, 524–525
 lymphoblastoid cell lines, 525–526
 management procedures, 551
 morbidity and mortality, 531–532
 morphology, 516, 517f
 natural and experimental hosts, 528–529
 pathogenesis, 538–543, 539f
 factors influencing, 542
 nontumor diseases, 542–543
 in ovo infection, 542
 phase 1 (early productive-restrictive infection),

- phase 2 (latent infection), 539f, 540–541
 phase 3 (cytolytic infection), 541
 phase 4 (lymphoma development), 541–542
 pathology, 532–538
 gross, 532–533, 532f, 534f
 eye, 533, 534f
 integument, 533, 534f
 nerves, 532
 visceral organs, 532–533, 534f
 microscopic, 535f–538f, 536–538
 blood, 536
 brain, 535
 eye, 536
 integument, 536
 local lesions, 538
 lymphodegenerative syndromes, 536–537, 537f
 nerves, 533, 535
 tumor transplants, 538
 vascular syndromes, 537–538, 538f
 visceral organs, 535, 536f
 public health significance, 515
 scientific significance, 515
 serotype 2, 552
 strain classification, 523–524
 pathotypes, 523–524
 serotypes, 523
 susceptibility to chemical and physical agents, 523
 syndromes associated with, 526, 527t
 transmission, 529–530
 vaccinal immunity, 545
 vaccination, 549–550
 administration, 549
 efficacy, factors affecting, 549–550
 strategies, 550
 types, 549
 viral DNA, 516–518
 physical properties, 516
 structural organization, 516–518
 viral genes and proteins, 518–521, 518t
 with homologues in
 alphaherpesviruses, 518–521
 immediate early and early genes with homology to HSV, 518–519
 1.8 kb gene family, 520–521
 late genes, 519
 latency associated transcripts (LATs), 519
 Meq (Marek's EcoQ), 519–520

- pp38/pp24, 520
 telomerase RNA, 521
 v-IL8, 520
 viral lipase, 520
 viral vectors, 521
 virus replication, 521–523
 latent infection, 522–523
 productive infection, 522
 transforming infection, 523
 virus stock production and stability, 523
 MAS. *See* Malabsorption syndrome
 Mastadenovirus, 289, 289t
 Mast cell tumors, 619–620
 Maternal antibodies
 in avian metapneumovirus infection, 119
 in *Borrelia anserina* infection, 1020
 in hemorrhagic enteritis, 314
 in infectious bronchitis, 149
 interference from, 70
 in Marek's disease, 531
 in *Mycoplasma meleagridis* infection, 898
 in Newcastle disease, 102
 in parvovirus of chickens and turkeys, 404
 in quail bronchitis virus infection, 319
 in rotavirus infection, 390
 in viral arthritis, 352, 361
 in West Nile virus, 481
 Maternal transfer of immunity, 69
 Mean death times (MDT), 95
 Meat meal, 1292
 Medication
 during disease outbreak, 39–40
 feed and water, 15–16
 routes of, 40–41
 Megabacteriosis, 1092–1093, 1093f
 Melanoma, 616, 616f
 Memory cells, 63
 Meningitis, *E. coli*, 777
 Meningoencephalitis, *E. coli*, 777
Menopon gallinae (shaft louse/small body louse), 1104, 1105f
 Mercurials, toxicity of, 1299
 Mercury toxicity, 1297
 Mesosalpinx, neoplasia of, 608, 608f
 Mesothelioma, peritoneal, 613, 613f
 Metaldehyde toxicity, 1302
 Metals and metalloids, toxicity of
 arsenic, 1294
 cadmium, 1294
 chromium, 1294

- mercury, 1297
 tin, 1297
 uranium, 1297
 vanadium, 1297
 Metapneumovirus. *See* Avian metapneumovirus
 Methionine
 deficiency, 1206–1207
 toxicity, 1207, 1292
 Metrics, 24
Metroliasthes lucida, 1141–1142, 1141f–1142f
 Metronidazole, for *Cochlosoma anatis* infection, 1185
 MHC (major histocompatibility complex), 61, 64–67, 73–74, 76–79
 Miconazole
 for aspergillosis, 1088
 for dermatophytosis, 1091
 Microagglutination test
 for arizonosis, 712
 for *Bordetella avium*, 842
 Microarrays
 for *Chlamydia*, 1058
 described, 75
 Microbial feed additives, 1284
 Microimmunofluorescence (MIF), for *Chlamydia*, 1067
 MicroRNAs, 521
Microsporium gallinae, 51, 1091. *See also* Dermatophytosis (flavus)
 MIF (microimmunofluorescence), for *Chlamydia*, 1067
 Milkweed toxicity, 1305
 Mimosine toxicity, 1305
 Mineral oil, as vaccine adjuvant, 35
 Minerals, 1221–1227
 aluminum, 1293
 calcium, 1222, 1293
 chlorine, 1223, 1223f
 cobalt, 1293
 copper, 1225, 1293
 dietary balance of, 1224
 fluorine, 1293
 iodine, 1224–1225, 1293
 iron, 1225
 magnesium, 1222–1223, 1293
 manganese, 1224
 phosphorus, 1222, 1293
 potassium, 1223–1224, 1293
 selenium, 1226–1227, 1294
 sodium, 1223, 1224f, 1293–1294
 sulfate, 1294
 toxicity, 1292–1297

- Mosquito vectors, 1107
of eastern equine encephalitis virus, 474–475
of Israel turkey meningoencephalitis virus, 478
of western equine encephalitis virus, 478
of West Nile virus, 480
- Mouse, 1110f, 1111, 1111t
- MRSA, 972
- MSD (marble spleen disease), 309–316
- Mucor janssenii*, 1027
- Mucormycosis. *See* Zygomycosis
- Mucosal immunity, 68
- Mucosal invasion, by *Salmonella*, 695–696
- Multicentric histiocytosis, 621–622, 622f
- Multidrug resistance
described, 43
in *E. coli*, 752, 761
- Multilocus enzyme electrophoresis (MLEE)
for avian intestinal spirochetosis, 999, 1004, 1005
for *E. coli*, 756
for erysipelas, 988
for *Pasteurella multocida*, 812
for *Salmonella*, 680
- Multilocus sequence typing (MLST)
for avian intestinal spirochetosis, 1004, 1005
for *Chlamydia*, 1059
for *E. coli*, 756
for *Pasteurella multocida*, 811, 813
for *Salmonella*, 680
for *Staphylococcus aureus*, 973
- Multilocus variable number tandem-repeat analysis (MLVA)
for *Chlamydia*, 1059
for *Salmonella*, 680
- Muscovy duck reovirus, 364, 419
- Muscovy ducks, avian
metapneumovirus in, 113, 115
- Muscular dystrophy, 1214
- Musculoskeletal system
myopathy
deep pectoral, 1244–1245
nutritional, 1214, 1216f
neoplastic diseases, 620–621
chondroma and
chondrosarcoma, 621, 621f
leiomyoma and leiomyosarcoma, 620, 620f
osteoma and osteosarcoma, 620,
rhabdomyoma and
rhabdomyosarcoma, 620, 621f
- Mycobacterium avium*. *See* Tuberculosis
- Mycobacterium avium* subsp. *paratuberculosis*, 1010, 1022–1023
- Mycobacterium intracellulare*, 1009
- Mycoplasma anseris*, 911
- Mycoplasma cloacale*, 911
- Mycoplasma columbinasale*, 912
- Mycoplasma columbinum*, 912
- Mycoplasma columborale*, 912
- Mycoplasma gallinaceum*, 875
- Mycoplasma gallinarum*, 875, 911
- Mycoplasma gallisepticum*, 875, 876f, 877–893
antigenic structure, 878–879
biochemical properties, 878
classification, 877
clinical signs, 883–884, 884f
colony morphology, 878
definition and synonyms, 877
diagnosis, 888–890
differential diagnosis, 889–890
economic significance, 877
etiology, 877–881
growth requirements, 877–878
history, 877
immunity, 887–888
incidence and distribution, 881
incubation period, 883
interaction among respiratory pathogens, 1320
isolation and identification of agent, 888–889
management procedures, 890
morbidity and mortality, 884–885
morphology and staining, 877, 878f
natural and experimental hosts, 881–882
pathogenesis, 886–887
pathology, 885–886
gross, 885
microscopic, 885–886, 886f
ultrastructural, 886
serology, 889
strain classification, 879–881
antigenicity, 880
genetic/molecular, 880
immunogenicity, 880
pathogenicity, 880–881
susceptibility to chemical and physical agents, 878
transmission, carriers, and vectors, treatment, 892–893
vaccination, 890–892
virulence factors, 881
- Mycoplasma imitans*, 910–911, 1320
- Mycoplasma iowae*, 875, 907–910
antigenic structure, 907
biochemical properties, 907
classification, 907
clinical signs, 909
colony morphology, 907
diagnosis, 909–910
differential diagnosis, 910
economic significance, 907
etiology, 907–908
growth requirements, 907
history, 907
immunity, 909
incidence and distribution, 908
incubation period, 908
isolation and identification of agent, 909–910
management procedures, 910
morphology and staining, 907
natural and experimental hosts, 908
pathogenesis, 909
pathology, 909
gross, 909
microscopic, 909
ultrastructural, 909
serology, 910
strain classification, 908
susceptibility to chemical and physical agents, 907
transmission, 908
treatment, 910
- Mycoplasma meleagridis*, 875, 893–900
antigenic structure, 894
biochemical properties, 894
classification, 893
clinical signs, 896
colony morphology, 894
definitions and synonyms, 893
diagnosis, 898–899
differential diagnosis, 899
economic significance, 893
eradication, 900
etiology, 893–895
growth requirements, 894
history, 893
immunity, 898
incidence and distribution, 895
interaction among respiratory pathogens, 1320, 1321
isolation and identification of agent, 898–899
- morbidity and mortality, 896
morphology and staining, 893–894
natural and experimental hosts, 895
pathology, 897–898
gross lesions, 897, 897f
microscopic lesions, 897–898
serology, 899
strain classification, 894–895
susceptibility to chemical and physical agents, 894
transmission, 895–896
horizontal, 896
vertical, 895
treatment, 906
- Mycoplasma pullorum*, 911
- Mycoplasma* spp., 875–912
characterization, 875, 876f
classification, 875–876, 876t
- Mycoplasma synoviae*, 875, 900–906
antigenic structure, 901
biochemical properties, 901
classification, 900
clinical signs, 903
colony morphology, 901
diagnosis, 905–906
differential diagnosis, 906
etiology, 900–902
growth requirements, 900–901, 901t
history, 900
immunity, 905
incidence and distribution, 902
incubation period, 903
interaction among respiratory pathogens, 1320, 1321
isolation and identification of agent, 905
management procedures, 906
morbidity and mortality, 903
morphology and staining, 900
natural and experimental hosts, 902
pathogenesis, 904–905
pathology, 903–904
gross, 903–904, 904f
microscopic, 904, 904f
serology, 905
strain classification, 902
susceptibility to chemical and physical agents, 901
transmission, 902
vaccination, 906
virulence factors, 902
- Mycotic disease. *See* Fungal infections
- Mycotoxicoses, 1271–1284
aflatoxins, 1276–1279
experimental disease, 1276–1279, 1278f
metabolism and residues, 1279
natural disease, 1276, 1277f
pharmacological interactions, 1279
- citrinin, 1280
etiology and toxicology, 1280
experimental disease, 1280
natural disease, 1280
- cyclopiazonic acid, 1281
- definition and synonyms, 1271
- diagnosis, 1282–1283
- economic significance, 1271
- ergotism, 1271–1272
etiology and toxicology, 1271
experimental disease, 1272
metabolism and residues, 1272
natural disease, 1272
- Fusarium* mycotoxins, 1272–1276
fumonisins, 1274–1275
fusarochromanone, 1275
incidence and distribution, 1272
moniliformin, 1273–1274, 1275f
trichothecenes, 1272–1273, 1273f–1274f
zearalenone, 1275–1276
- kojic acid, 1282
- ochratoxins, 1279–1280
etiology and toxicology, 1279
experimental disease, 1279–1280
metabolism and residues, 1280
natural disease, 1279
- oosporein, 1280–1281
etiology and toxicology, 1280
experimental disease, 1280–1281, 1281f
natural disease, 1280
- overview, 1271
- patulin, 1282
- penicillic acid, 1281–1282
- prevention, 1283–1284
antifungal agents, 1284
detoxification with binding agents, 1284
feed manufacturing and management, 1283
public health significance, 1271
- rubratoxins, 1281
- sterigmatocystin, 1281
- tenuazonic acid and alternaria toxins, 1282
- treatment, 1283
- Myeloblastosis
clinical signs, 570

- history, 949
intervention strategies, 953
pathobiology and epizootiology, 950–952
pathogenesis, 951–952
pathology, 950–951, 951f
public health significance, 949
strain classification and toxins, 949–950, 950t
transmission, carriers, vectors, 950
- Neisseria*, 1023
- Nematodes, 1117–1133
Amidostomum spp., 1125, 1125f–1126f
Aproctella stoddardi, 1124–1125, 1124f
Ascaridia spp., 1120–1121, 1121f
Aulonocephalus lindquisti, 1125, 1125f
Baylisascaris spp., 1125
Capillaria spp., 1121, 1122f–1123f, 1122t
Cheilospirura spp., 1125, 1126f–1127f
Codistomum struthonis, 1126
Cyathostoma bronchialis, 1126–1127, 1127f
Cyrnea colini, 1125–1126, 1127f
Deletocephalus dimidiatus, 1127
development and life cycles, 1120
Dicheilonema rhea, 1128
Dispharynx nasuta, 1128, 1128f
Echinura uncinata, 1128, 1128f
Epomidiostomum uncinatum, 1126, 1127f
Gongylonema inguivicola, 1128, 1128f
Hadjelia truncate, 1126
Heterakis spp., 1123–1124, 1124f
Libyostrongylus douglassi, 1128–1129
morphology, 1119–1120
Ornithostrongylus quadriadiatus, 1129, 1129f
overview, 1117–1119
Oxyspirura spp., 1129, 1129f
Sicarius spp., 1129
Singhifilaria hayesi, 1129, 1130f
species reported from chickens, 1118t
species reported from non-chicken commercial birds, 1118t
species reported from wild birds, 1119t
Strongloides avium, 1129, 1130f
Subulura spp., 1124f, 1129–1130
Syngamus trachea, 1130–1131, 1131f
- treatment and control, 1132–1133
Trichostrongylus tenuis, 1132, 1132f
Vaznema zschokkei, 1132
- Neomycin
for colibacillosis, 784
for pullorum disease, 692
- Neonatal meningitis *Escherichia coli* (NMEC), 757, 762
- Neoplastic diseases, 513–622
digestive system, 611–613
alimentary tract, 611–612, 611f
liver, 612–613
 cholangiocellular tumors, 612–613, 612f–613f
 hepatocellular tumors, 612, 612f
 pancreas, adenocarcinoma of, 613, 613f
endocrine system, 616–617
adrenal gland, 616
parathyroid gland, 617
pituitary gland, 616
thymus, 617
thyroid gland, 617
eye, 616
integumentary system, 617–620
adenoma, 619
feather folliculoma, 619, 619f
hemangiopericytoma, 617, 617f
intracutaneous keratinizing epithelioma, 619, 620f
keratoacanthoma, 617–619, 618f–619f
lipoma, 617
liposarcoma, 617
mast cell tumors, 619–620
squamous cell carcinoma, 617
xanthoma, 620
leukosis/sarcoma group, 553–592
lung, 614, 614f
Marek's disease, 515–552
mesothelioma, peritoneal, 613, 613f
multicentric histiocytosis, 621–622, 622f
musculoskeletal system, 620–621
chondroma and chondrosarcoma, 621, 621f
leiomyoma and leiomyosarcoma, 620, 620f
osteoma and osteosarcoma, 620, 621f
rhabdomyosarcoma, 620, 621f
nervous system, 614–616
astrocytoma, 614–615, 614f
melanoma, 616, 616f
neuromas, 615, 616f
pineal body tumor, 615, 615f
overview, 513–514, 604–605
prevalence, 605
renal, 611
reticuloendotheliosis, 593–604
teratoma, 621
transmissible neoplasms, table of, 514t
urogenital system, 605–611
mesosalpinx, 608
leiomyoma, 608, 609f
ovary, 605–608
adenocarcinoma, 605, 606f
arrhenoblastoma, 607–608, 608f
dysgerminoma, 608
granulosa-theca cell tumor, 606–607, 607f
ovarian Sertoli cell tumors, 608, 608f
oviduct, 609–610
adenocarcinoma, 609–610, 609f–610f
testis, 610–611
Leydig cell tumors, 611
seminoma, 610, 611f
Sertoli cell tumor, 610, 611f
- Neoschoengastia americana* (chiggers), 1102, 1102f
- Nephritis. *See* Avian nephritis; Hemorrhagic nephritis enteritis of geese (HNEG)
- Nephroma and nephroblastoma
differential diagnosis, 591
pathology, 578–582
gross, 578, 579f
microscopic, 578, 579f, 580
pathogenesis, 580
ultrastructural, 580
- Nerves, Marek's disease and, 532, 532f, 533, 535, 535f
- Nervous system disease
arizonosis, 709, 709f, 710–711, 710f
aspergillosis, 1082
avian encephalomyelitis, 486–493, 489f–490f
E. coli meningitis, 777
encephalomalacia, 1213–1214, 1215f
Listeria, 1022
Marek's disease, 530–531, 530f–531f, 532, 535, 537, 538f, 548–549
neoplasia, 614–616
astrocytoma, 614–615, 614f
melanoma, 616, 616f
neuromas, 615, 616f
pineal body tumor, 615, 615f
Newcastle disease, 99
ochroconosis, 1091–1092
Nest and egg hygiene, 14–15
Nest boxes, 14
Nesting materials, 14
Neuraminidase (NA)
erysipelas, 989
influenza, 187–191, 188t, 202, 205
Newcastle disease virus, 92
Neuraminidase inhibition (NI)
APMV, 108
influenza virus, 189
Neurofibromas, 615, 615f
Neuromas, 615, 616f
Neurotropic velogenic Newcastle disease, 91
Newcastle disease, 89–107
biologic properties, 92
cell fusion and hemolysis, 92
hemagglutination activity, 92
neuraminidase activity, 92
chemical composition, 92
classification, 89–90
clinical signs, 99–101, 100f
definition and synonyms, 91
diagnosis, 102–104
serology, 103
virus isolation and identification, 102–103
differential diagnosis, 103–104
economic significance, 91
emergence of virulent viruses, 97–98
etiology, 91–95
history, 91
immunity, 101–102
active, 101–102
passive, 102
incidence and distribution, 98
incubation period, 99
interaction with *Mycoplasma* spp., 1320
intervention strategies, 104–107
laboratory host systems, 95–96
animals, 95–96
cell culture, 96
chicken embryos, 96
management procedures, 104–105
international control policies, 104
national control policies, 104–105
morphology, 91, 92f
natural and experimental hosts, 98
overview, 89–91
pathobiology and epidemiology, 98–102
pathogenicity, 96–98
pathology, 101
gross lesions, 101
microscopic lesions, 101
ultrastructural lesions, 101
phylogenetic analysis, 94f, 95
public health significance, 45–46, 91
nature of disease in humans, 45
occurrence, 45–46
preventive measures, 46
reservoirs and sources of infection, 46
strain classification, 93–95
antigenicity, 93, 95
genetic or molecular, 95
immunogenicity, 95
pathogenicity tests, 95
susceptibility to physical and chemical agents, 93
transmission, carriers, and vectors, 98–99
treatment, 107
vaccination, 95, 105–107, 105t
field vaccination protocols and regimens, 106–107
reactions, 1321–1322
strains used in, 105t
types of vaccine, 105–106
virulence determinants, 96–97
F gene, 96–97, 96t
HN gene, 97
replication complex (NP/P/L genes), 97
V gene, 97
virus replication, 92–93
- NI. *See* Neuraminidase inhibition
- Niacin, 844, 1219
- Nicarbazin
for coccidiosis, 1160, 1161
toxicity, 1291
- Nicotinamide adenine dinucleotide (NAD), 860, 862, 1219
- Nicotine toxicity, 1301
- Nidovirales, 376
- Nightshade toxicity, 1305
- Nitarosone
for *Cochlosoma anatis* infection, 1185
for histomoniasis, 1178t
- Nitarosone toxicity, 1291
- Nitrate toxicity, 1297
- Nitric oxide, 544
- Nitric oxide inducing factor

- folic acid, 1220–1221
 niacin, 1219
 pantothenic acid, 1218–1219
 pyridoxine (vitamin B₆), 1219–1220
 riboflavin (vitamin B₂), 1217–1218, 1218f
 thiamin (vitamin B₁), 1216–1217, 1217f
 vitamin A, 1208–1210
 deficiency, 1208–1210, 1209f
 hypervitaminosis A, 1210
 vitamin D, 1210–1213
 deficiency, 1211–1212
 hypervitaminosis D, 1212–1213
 vitamin E, 1213–1214
 deficiency, 1213–1214, 1215f
 vitamin K deficiency, 1215–1216
 water, 1205
 Nystatin, in candidiasis, 1090
- Oak toxicity, 1305
- Ochratoxins, 1279–1280
 etiology and toxicology, 1279
 experimental disease, 1279–1280
 metabolism and residues, 1280
 natural disease, 1279
- Ochroconosis, 1091–1092
- Ocular diseases. *See* Eye diseases
- Oerskovia*, 1023
- Office International des Epizooties (OIE), 9–11
- OIE Terrestrial Animal Health Code (Terrestrial Code), 9–11
- Oil toxicity, 1303–1304
- Oleander toxicity, 1305
- Omphalitis
 aspergillosis, 1081
 E. coli, 766–768, 767f
- Onchosphere, 1136f, 1137
- Onicola canis*, 1133, 1133f
- Onion toxicity, 1305
- Oospora coloran*, 1280
- Oosporein, 1280–1281
 etiology and toxicology, 1280
 experimental disease, 1280–1281, 1281f
 natural disease, 1280
- Ophthalmitis, in aspergillosis, 1081–1082, 1081f, 1085
- Orchitis, *E. coli*, 774–775
- Organ cultures, for infectious
 bronchitis virus, 143
- Organochloride toxicity, 1299–1300
- Organophosphate toxicity, 1292, 1300, 1301
- Ornithobacterium rhinotracheale*
 infection, 828–834
 biochemical properties, 829
 classification, 828
 clinical signs, 830–831
 colony morphology, 829
 definitions and synonyms, 828
 diagnosis, 832–833
 differential diagnosis, 833
 economic significance, 828
 etiology, 828–830
 growth requirements, 829
 history, 828
 immunity, 832
 incubation period, 830
 isolation and identification of agent, 832
 management procedures, 833
 morphology and staining, 828, 829f
 natural and experimental hosts, 830
 pathobiology and epidemiology, 830–832
 pathogenicity, 829
 pathology
 gross lesions, 831, 831f
 microscopic lesions, 831, 832f
 serology, 833
 strain classification, 829–830
 susceptibility to chemical and physical agents, 829
 transmission, 830
 treatment, 833–834
 vaccination, 833
- Ornithobacterium rhinotracheale*, 1320
- Ornithonyssus sylviarum* (northern fowl mites), 26, 52, 1099–1101, 1100f
- Ornithostrongylus quadriadiatus*, 1129, 1129f
- Orthoboric acid toxicity, 1298
- Orthomyxoviridae
 influenza viruses, 181–206
- Oseltamivir, 206
- Osteoarthritis, *E. coli*, 777–778
- Osteochondrosis, 1244
- Osteoma and osteosarcoma, 580, 620, 621f
- Osteomyelitis
 Arcanobacterium, 1018
 aspergillosis, 1081
 enterococcosis, 984, 985f
 staphylococcosis, 974, 975f
- Osteopetrosis
 clinical signs, 570
 differential diagnosis, 591
- incubation period, 570
 pathology, 582–583
 gross, 582, 582f, 583f
 microscopic, 582–583, 583f
 pathogenesis, 583
 ultrastructural, 583
- Osteoporosis, 1240–1241
 clinical signs and pathology, 1240
 intervention strategies, 1240–1241
 pathogenesis and etiology, 1240
- Ostrich
 Aeromonas infection in, 1018
 APMVs in, 107, 109
 aviadenovirus infection in, 298
 Bacillus anthracis in, 1018
 botulism in, 954
 enterovirus-like viruses in, 397
 fowl typhoid in, 683
 Gallibacterium in, 1021
 histomoniasis in, 1175
 influenza in, 186t, 197, 200
 Klebsiella infection in, 1021
 Lawsonia infection in, 1021
 macrorhabdosis in, 1092
 Neisseria infection in, 1023
 Newcastle disease in, 101, 107
 Pseudomonas in, 1024–1025
 reovirus in, 365
 tuberculosis in, 1011
 zygomycosis in, 1092
- Otitis, 1258–1259
 arizonosis, 709, 710f, 711
- Ovary
 lesions in pullorum disease, 686, 687f–688f, 688
 neoplasia of, 605–608
 adenocarcinoma, 605, 606f
 arrhenoblastoma, 607–608, 608f
 dysgerminoma, 608
 granulosa-theca cell tumor, 606–607, 607f
 ovarian Sertoli cell tumors, 608, 608f
- Oviduct
 adenocarcinoma, 609–610, 609f–610f
 cystic right, 1256
 impaction, 1256
- Ovotransferrin, for chlamydiosis, 1068
- Owl herpesvirus, 465
- Oxalate toxicity, 1305
- Oxyspirura mansoni*, 1129, 1129f
- Oxyspirura petrowi*, 1129
- Oxyspirura* spp., 1129, 1129f
- Oxytetracycline
 for avian intestinal spirochetosis, 1007
 for bordetellosis, 844
 for *Borrelia anserina*, 1019
 for fowl cholera, 821–822
 for infectious coryza, 868
 for *Mycoplasma gallisepticum*, 892
 for *Mycoplasma synoviae*, 906
- Pacheco's disease, 161
- Pale bird syndrome, 363, 1323
- PAMP (pathogen-associated molecular patterns), 63
- Pancreas
 adenocarcinoma of, 613, 613f
 adenovirus infection, necrotizing pancreatitis with, 299
 APMV infection and, 110
 avian encephalomyelitis and, 491f
 turkey viral hepatitis and, 483, 484f
- Panophthalmitis, *E. coli*, 777
- Pantothenic acid deficiency, 1218–1219
- Papilloma, 611
- Parakeets. *See also* Budgerigars
 Coxiella burnetii in, 1020
 Gallibacterium in, 1020
- Paralysis, in Marek's disease, 530–531, 530f–531f, 548–549
- Paramyxovirinae, 89
- Paramyxoviruses, 417
 Newcastle disease virus (APMV-1), 89–107
 serotypes, 89, 90t
- Paraquat toxicity, 1299
- Parasites. *See also* External parasites;
 Internal parasites
 external examination for, 26
 public health significance, 52–53
 avian mite dermatitis, 52
 cryptosporidiosis, 52
 toxoplasmosis, 52–53
- Parathion toxicity, 1301
- Parathyroid gland neoplasia, 617
- Paratyphoid infections, 693–706
 antigenic structure, 695
 biochemical properties, 694
 classification and nomenclature, 693
 clinical signs, 700
 colony morphology, 694
 competitive exclusion, 704–705
 diagnosis, 701–704
 culture media, 702–703
 culture methods, 702
 genus and serotype, confirmation of, 703
- rapid detection technologies, 703
 sample selection, 701–702
 serology, 703–704
 distribution of *Salmonella* serotypes, 697
 economic significance, 693
 etiology, 693–696
 gastrointestinal colonization control, 704–705
 growth requirements, 694
 immunity and resistance, 700–701
 incidence in poultry and poultry products, 696–697
 intervention strategies, 704–706
 morphology, 693–694
 natural and experimental hosts, 697–699
 mature poultry, 698
 predisposing factors, 698–699
 young poultry, 697
 pathobiology and epizootiology, 696–701
 pathogenesis, 700
 pathogenicity, 697
 pathology, 700
 public health significance, 693
 risk reduction, 704
 sources, vectors, and transmission, 699–700
 strain classification, 695
 susceptibility to chemical and physical agents, 694–695
 treatment, 706
 vaccination, 705–706
 virulence factors, 695–696
- Parrots
 fowl typhoid in, 683
 Newcastle disease virus variants in, 98, 99
 pullorum disease in, 683
 reovirus in, 365
- Parsley toxicity, 1305
- Partridges
 avian intestinal spirochetosis in, 999
 chlamydiosis in, 1064
 eastern equine encephalitis in, 475
 enterovirus-like viruses in, 397
 Highlands J virus in, 476
 histomoniasis in, 1175
 macrorhabdosis in, 1092
 Mycoplasma imitans in, 910–911
 Newcastle disease virus variants in, 107
 Riemerella anatipestifer in, 825
 rotavirus in, 386

- lesions, 448, 448f
 microscopic lesions, 448, 448f
 susceptibility to chemical and physical agents, 445
 transmission, carriers, and vectors, 446–447
 vaccination, 450–451
 application, 444
 hemagglutination test, for avian encephalomyelitis virus, 492
 immunity
 encephalomyelitis, 492
 leukosis/sarcoma viruses and, 584
 metapneumovirus, 117
 beak and feather disease, 273
 bordetellosis, 842
Borrelia anserina infection, 1020
 chicken infectious anemia, 259
 circovirus, 273
 duck virus enteritis (duck plague), 439
 erysipelas, 993
 fowl cholera, 820
 hemorrhagic enteritis, 314
 histomoniasis, 1177
 infectious bursal disease, 230
 infectious laryngotracheitis, 170
 influenza, 201
Mycoplasma iowae, 909
Mycoplasma meleagridis, 898
 necrotic enteritis, 952
 Newcastle disease, 102
 parvovirus of chickens and turkeys, 404
 rotavirus, 390
 turkey coronavirus enteritis, 380
 Passive immunization, in colibacillosis, 783
Pasteurella multocida, 807–823
 Pathogen-associated molecular patterns (PAMP), 63
 Pathogenicity, Newcastle disease and, 95
 Pathogenicity islands
E. coli, 757, 759–761
Salmonella, 681–682
 Patulin, 1282
 PBB (polybrominated biphenyl), 1303
 PCB (polychlorinated biphenyl), 1303
 PCR. *See* Polymerase chain reaction
 Peacocks, chlamydiosis in, 1064
 PEC (poult enteritis complex), 391, 1222, 1224, 1225
 PEMS (poult enteritis mortality syndrome), 364, 391, 399, 402–403, 773, 1323, 1324
 Pendulous crop, 1253, 1253f
 Penguin, APMVs in, 108, 110
 Penicillic acid, 1281–1282
 Penicillin
 for bordetellosis, 834–844
 for *Borrelia anserina*, 1019
 for erysipelas, 994
 for fowl cholera, 821–822
 for *Ornithobacterium rhinotracheale*, 834
 for *Riemerella anatipestifer*, 828
Penicillium citrinum, 1280
Penicillium puberulum, 1276
Penicillium purpurogenum, 1281
Penicillium rubrum, 1281
Penicillium viridicatum, 1279
 Pentachlorophenol toxicity, 1298
 People
 access to complex, 23
 access to farm by, 20–21
 access to poultry house by, 16
 Performance parameters, 24
 Pericarditis, in colisepticemia, 775
 Peritonitis, *E. coli*, 774
 Perosis, 1208
 PES (poult enteritis syndrome), 385, 390
 Pesticide, defined, 17
 Pestivirus, 474
 Pests
 arthropod, 1105–1109
Alphitobius diaperinus (lesser mealworm/darkling beetle), 1105–1107, 1106f
 bed bugs, 1108, 1109f
 control recommendations, 1108–1109
 flies, 1107–1108, 1107f–1108f
 rodents, 1109–1115
 economic impact, 1110
 exclusion of, 1112–1113
 field identification, 1110f
 house mouse, 1111
 inspections for, 1112
 integrated pest management, 1112
 Norway (brown) rats, 1111
 overview, 1109–1110
 population reduction, 1113–1114, 1114f, 1115t
 public health significance, 1110, 1110t
 reproduction capabilities, 1111
 sanitation and cultural practices, 1113, 1113f
 PFGE. *See* Pulsed-field gel electrophoresis
 PHA (phytohemagglutinin), 69, 70
 Phage therapy, for *Campylobacter*, 743
 Phage typing
Pasteurella multocida, 812
Salmonella spp., 695
Staphylococcus aureus, 973
 Phallus prolapse, 1256
 Pheasants
 avian encephalomyelitis in, 487
 avian intestinal spirochetosis in, 999
 avian metapneumovirus in, 113, 115, 116
Borrelia anserina infection in, 1018–1019
 botulism in, 954, 955
 chlamydiosis in, 1064
 eastern equine encephalitis in, 475
 enterovirus-like viruses in, 397
 erysipelas in, 990, 991
 fowl typhoid in, 683
Gallibacterium in, 1020
 histomoniasis in, 1174, 1175
 marble spleen disease in, 290, 309–316
 Marek's disease in, 529
 Newcastle disease in, 101
 Newcastle disease virus variants in, 107
Pseudomonas in, 1024–1025
 pullorum disease in, 683
 reovirus in, 365
 reticuloendotheliosis virus in, 597
Riemerella anatipestifer in, 825
 rotavirus in, 382, 385–388, 390–391
 tuberculosis in, 1011
 Phenolics, toxicity of, 1298
 Phenotypic distributions of unique genotypes, 72
 Phenoxylherbicide toxicity, 1299
 Phenylarsonic acid toxicity, 1291
Philphthalmus gralli, 1144
 Phosphate transport system (Pst) operon, 762
 Phosphorus
 deficiency, 1213f, 1222
 excess, 1222
 toxicity, 1293, 1301
 Photosensitization, 1305
 PHS. *See* Pulmonary hypertension syndrome
 Phylogenetics, of Newcastle disease virus, 94f, 95
 Phytohemagglutinin (PHA), 69, 70
 Phytotoxins, 1304–1306
 avocado, 1304
 black locust, 1304
 bladder pod, 1304
 cacao, 1304
 Carolina jessamine, 1304
 cassava, 1304
 castor bean, 1304
 coffee senna, 1304
 corn cockle, 1304–1305
 cotton seed meal, 1305
 coyotillo, 1305
Crotalaria spp., 1305
Daubentonia, 1305
 death camas, 1305
Eucalyptus cladocalyx, 1305
 hemlock, 1305
 jimsonweed, 1305
Leucaena leucocephala, 1305
 lily of the valley, 1305
 milkweed, 1305
 nightshade, 1305
 nitrates, 1305
 oak, 1305
 oleander, 1305
 onions, 1305
 oxalates, 1305
 parsley, 1305
 pokeberry, 1305
 potato, 1305
 ragwort, 1305
 rapeseed meal, 1306
 sickle pod, 1304
 sweet pea, 1306
 tannins, 1306
 tobacco, 1306
 velvetweed, 1306
 vetch, 1306
 yellow jessamine, 1306
 yew, 1306
 PiAdV-1 (pigeon adenovirus), 290, 297
 Picornavirus
 avian encephalomyelitis, 486–493
 duck, 431
 enterovirus-like viruses (ELVs), 395–399
 Pigeon adenovirus (PiAdV-1), 290, 297
 Pigeon circovirus (PiCV), 265–267, 269–270, 272, 272f, 274
 Pigeonfly (hippoboscid fly/lousefly) (*Pseudolynchia canariensis*), 1107
 clinical signs, 466
 diagnosis, 467
 differential diagnosis, 467
 distribution in the host, 466
 etiology, 466
 history, 465
 immunity, 467
 incidence and distribution, 465
 incubation period, 466
 morbidity and mortality, 466
 natural and experimental hosts, 466
 overview, 465
 pathobiology and epizootiology, 466–467
 pathology, 466–467
 gross lesions, 467
 histopathology, 467
 serology, 467
 shedding, 466
 transmission, 466
 treatment, , and control, 467
 vaccination, 467
 virus isolation, 467
 Pigeon paramyxovirus type 1 (PPMV-1), 91, 97–99, 107
 Pigeon poxvirus, 339, 341, 343, 344, 345
 Pigeons
 APMVs in, 109
 aviadenovirus infection in, 297
 avian encephalomyelitis in, 487
 chlamydiosis in, 1064
 erysipelas in, 989
Gallibacterium in, 1020
 inclusion body hepatitis in, 296
Listeria in, 1022
 macrorhabdosis in, 1092
Mycobacterium in, 1022
Mycoplasma infections in, 912
 Newcastle disease in, 98, 99, 101, 105, 107
Pasteurella multocida in, 809
Pelistegea in, 1023
 rotavirus in, 382, 384–386
 seminoma in, 611
 visceral urate deposition in, 1254f
 Pineal body tumor, 615, 615f
 Pituitary gland neoplasia, 616
Planococcus, 1023
 Plaque formation, poxvirus, 339
 Plasma cells, 64f
 Plasmids
 antimicrobial resistance and, 42–43, 43f
E. coli, 752, 755, 757, 759–762

- for *Riemerella anatipestifer*, 825, 827
for *Salmonella*, 680, 703
for sarcocystosis, 1192
- Polymorphus boschadis*, 1133, 1134f
- Polyomaviruses, 440–443
- Polytetrafluoroethylene toxicity, 1302
- Population dynamics, 5
- Potassium
deficiency, 1223–1224
toxicity, 1293
- Potassium dichromate toxicity, 1294
- Potato toxicity, 1305
- Poult enteritis complex (PEC), 391, 1323, 1324–1325
- Poult enteritis mortality syndrome (PEMS), 364, 391, 399, 402–403, 773, 1323, 1324
- Poult enteritis syndrome (PES), 385, 390
- Poultry house, 11–17
built-up litter and unclean buildings, 13
cleanout and disinfection, 12–13
culling, 13–14
decontamination, 12–13
disinfectants, 13
down time, 12
feed and drinking water, 15, 15f
feed and water medication, 15–16
house access
animals, 16–17
insect, mite, and tick control, 17
people, 16
management of house environment, 11–12
mortality, 14
nest and egg hygiene, 14–15
turnaround time, 12
- Poultry red mite (chicken mite or roost mite) (*Dermanyssus gallinae*), 1101, 1101f
- Pox, 333–346
chemical composition, 333, 335
clinical signs, 340
definition and synonyms, 333
diagnosis, 342–344
avian embryo inoculation, 342
bird inoculation, 342
cell culture, 342
microscopy, 342
molecular methods, 343–344
genomic fragments as probes, 343
polymerase chain reaction (PCR), 343–344
restriction endonuclease
serology and protection tests, 342–343
ELISA, 343
fluorescent antibody, 343
immunoblotting, 343
immunodiffusion, 343
immunoperoxidase, 343
neutralization, 343
passive hemagglutination, 343
differential diagnosis, 344
economic significance, 333
etiology, 333–337
as expression vectors for genes from mammalian pathogens, 346
genomic differences, 336
history, 333
incidence and distribution, 339–340
incubation period, 340
intervention strategies, 344–345
laboratory host systems, 337–339, 338f
birds, 338, 339
cell culture, 339
cytopathic effects, 339
embryos, 339
plaque formation, 339
management procedures, 344–345
morbidity and mortality, 340–341
morphology, 333, 334f
natural and experimental hosts, 340
nonessential and immunomodulatory genes, 336–337
pathology
gross, 341
microscopic, 341–342
ultrastructural, 342
public health significance, 333
strain classification, 335–336
susceptibility to chemical and physical agents, 335
transmission, 340
vaccination, 344–346
canary pox, 345
fowlpox, 344–345
in-ovo, 345
pigeon pox, 345
prophylactic, 345
quail pox, 345
recombinant fowlpox, 345–346
vaccine takes, 345
virus replication, 335
- PPMV-1 (pigeon paramyxovirus type 1), 91, 97–99, 107
- A Practical Guide for Managing Risk
- Prairie chickens, reticuloendotheliosis virus in, 594, 595, 601
- Prebiotics, for *Salmonella* colonization control, 705
- Predisposition, 9
- Prevalence of a disease, 9
- Primary lymphoid organs, 62–63
- Probiotics
avian intestinal spirochetosis, 1006
for colibacillosis, 785
- Proglottids, 1135, 1136–1137, 1136f, 1142f
- Promoter
chicken infectious anemia virus, 250
fowlpox virus, 345–346
- Prosthogonimus* sp., 1143–1144, 1143f, 1144f
- Prosthorynchus formosus*, 1133, 1134f
- Protectins, 759–760
- Proteins, 1205–1207
- Protein supplements, toxicity from, 1292
- Proteolytic enzymes, of *Aspergillus* spp., 1080
- Proteomics, 75
- Proteus*, 1023
- Protozoal infections, 1147–1194
avian malaria, 1188–1189
coccidiosis, 1148–1166
anticoccidials, table of preventative, 1159t
in chickens, 1149–1163
diagnosis, 1150t, 1157–1159
Eimeria acervulina, 1150t, 1151, 1152f
Eimeria brunetti, 1150t, 1153, 1154f
Eimeria hagani, 1150t, 1153
Eimeria maxima, 1150t, 1152f, 1153
Eimeria mitis, 1150t, 1152f, 1155
Eimeria mivati, 1150t, 1153
Eimeria necatrix, 1150t, 1154f, 1155–1156
Eimeria praecox, 1150t, 1156
Eimeria tenella, 1150t, 1154f, 1156
epidemiology, 1157
etiology, 1149–1156
incidence and distribution, 1149
life cycle, 1151f
natural and experimental hosts, 1157
prevention and control, 1157
- transmission and vectors, 1157
vaccination, 1161
- classification and taxonomic relationships, 1148–1149
- in ducks, 1166
- in geese, 1165–1166
Eimeria anseris, 1166
Eimeria truncata, 1165–1166
- life cycle, 1149
overview, 1148
- in pigeons, 1166
- in turkeys, 1162t, 1163–1165
Eimeria adeneides, 1162t, 1163–1164
Eimeria dispersa, 1162t, 1164
Eimeria gallopavonis, 1162t, 1164
Eimeria innocua, 1165
Eimeria meleagridis, 1162t, 1164
Eimeria meleagritidis, 1162t, 1164–1165
Eimeria subrotunda, 1165
etiology, 1163
prevention and control, 1165
- Cochlosoma anatis* infection, 1180, 1182–1185
clinical signs and pathogenicity, 1184
etiology and classification, 1182–1183
incubation period, 1183
life cycle, 1183
morphology, 1182–1183, 1183f
natural and experimental hosts, 1184
overview, 1182
prevention, 1185
site of infection, 1184
transmission, 1183
treatment, 1184–1185
- cryptosporidiosis, 1167–1171
in chickens, 1169–1170, 1169f–1170f
diagnosis and culture, 1171
history, 1167
human health importance, 1167
incidence and distribution, 1168–1169
life cycle and morphology, 1167–1168, 1168f
prevention and control, 1171
in quail, 1170–1171
taxonomy, 1167, 1167t
in turkeys, 1170
- Haemoproteus*, 1189–1190
- histomoniasis, 1147, 1172–1179, 1173f–1174f, 1177f
clinical pathology, 1176
clinical signs, 1176
diagnosis, 1177–1178
economic significance, 1172
etiology and classification, 1172–1175
history, 1172
immunity, 1177
incidence and distribution, 1175
incubation period, 1176
life cycle, 1174–1175
morbidity and mortality, 1176
morphology, 1172, 1174
natural and experimental hosts, 1175
overview, 1172
pathogenicity, 1175
pathology, 1176–1177
gross lesions, 1176, 1177f
histopathology, 1176–1177
prevention and control, 1178–1179, 1178t
susceptibility to chemical and physical agents, 1175
vectors, 1175–1176
- leucocytozoonosis, 1185–1188
diagnosis, 1188
Leucocytozoon caulleryi, 1187–1188
Leucocytozoon sabrezi, 1188
Leucocytozoon schoutedeni, 1188
Leucocytozoon simondi, 1185–1186, 1187f
Leucocytozoon smithi, 1186–1187, 1187f
treatment and control, 1188
- necropsy examination hints, 32
- overview, 1147
- sarcocystosis, 1190–1192
clinical signs, 1191
diagnosis, 1192
etiology, 1190–1191
immunity, 1192
incidence and distribution, 1190
incubation period, 1191
life cycle, 1191
pathogenicity, 1191
pathology, 1191–1192, 1192f
prevention and control, 1192
transmission, carriers and vectors, 1191
zoonosis, 1192
- toxoplasmosis, 1192–1194

- campylobacteriosis, 47
 chlamydiosis (psittacosis), 47–48
Clostridium perfringens infection, 46–47
Erysipelothrix rhusiopathiae infection, 48
Escherichia coli infection, 48–49
 listeriosis, 49
 mycobacteriosis, 49–50
 salmonellosis, 50
Staphylococcus aureus infection, 50
 biosecurity common practices, 44
 fungal diseases, 50–52
 cryptococcosis, 50–51
 dermatophytosis (favus), 51
 histoplasmosis, 51–52
 overview, 44
 parasitic diseases, 52–53
 avian mite dermatitis, 52
 cryptosporidiosis, 52
 toxoplasmosis, 52–53
 viral diseases, 44–46
 arboviral encephalitis, 44–45
 avian influenza, 45
 Newcastle disease, 45–46
 Pullorum disease, 678–693
 antigenic structure, 680–681
 biochemical properties, 680
 classification, 679
 clinical signs, 684
 colony morphology, 679, 690
 diagnosis, 689–690
 identification of cultures, 690, 690t
 isolation and identification of agent, 689
 serology, 690, 691
 differential diagnosis, 690
 economic significance, 678
 etiology, 679–682
 growth requirements, 679
 history, 678–679
 immunity, 689
 incidence and distribution, 682–683
 intervention strategies, 690–693
 management procedures, 691–692
 area eradication, 692
 elimination of carriers, 691
 national control program, 692
 non-pullorum reactors, 691–692
 serologic tests, 691
 morbidity and mortality, 684
 morphology, 679
 natural and experimental hosts, 683
 pathogenesis, 688–689
 pathology, 684–688
 gross lesions, 684–687, 685f–687f
 histopathology, 687–688, 687f–688f
 public health significance, 678
 susceptibility to chemical and physical agents, 680
 synonyms, 678
 transmission, 683–684
 treatment, 692–693
 vaccination, 692
 virulence factors, 681–682
 Pulmonary hypertension syndrome (PHS), 1246–1249
 clinical signs, 1247, 1247f
 intervention strategies, 1249
 pathogenesis and etiology, 1248–1249
 pathology, 1247–1248, 1247f
 Pulsed-field gel electrophoresis (PFGE)
 for avian intestinal spirochetosis, 1000
 for botulism, 956
 for *Campylobacter*, 742
 for *E. coli*, 756
 for *Mycobacterium avium*, 1008
 for necrotic enteritis, 952
 for *Ornithobacterium rhinotracheale*, 830
 for *Pasteurella multocida*, 812
 for *Salmonella*, 680, 695
 for *Staphylococcus aureus*, 973
 Pulse dosing, of antimicrobials, 41
 Pyrethroid toxicity, 1301
 Pyrethrum, 1301
 Pyridoxine (vitamin B₆), 1219–1220
 Pymethamine, for leucocytozoonosis, 1188
 Q-fever, 1020
 QTL (quantitative trait loci), 71, 74, 76–78
 Quail
 avian encephalomyelitis in, 487
 chlamydiosis in, 1064
 cryptosporidiosis in, 1170–1171
 egg drop syndrome in, 303
 fowl typhoid in, 683
 histomoniasis in, 1175
 leiomyoma in, 608
 macrorhabdosis in, 1092
 Marek's disease in, 529
 ochroconosis in, 1091
 reovirus in, 365
 reticuloendotheliosis virus in, 597
 Riemerella anatipestifer in, 825
 seminoma in, 611
 Sertoli cell tumor in, 610, 611f
 ulcerative enteritis in, 944–949, 947f
 Quail bronchitis, 290, 316–320
 clinical signs, 317
 diagnosis, 319
 etiology, 316
 history, 316
 hosts, 317
 immunity, 319
 incidence and distribution, 316
 incubation period, 317
 laboratory hosts and pathogenicity, 317
 morbidity and mortality, 317
 overview, 316
 pathology, 317–319, 318f
 transmission, carriers, and vectors, 317
 treatment, prevention, and control, 319–320
 Quail pox, 334f, 336, 339, 340, 345
 Quarantine
 APMV 2-9, 112
 handling disease outbreaks, 38–39
 diagnosis, 39
 special precautions, 39
 specimen submission, 39
 Newcastle disease virus and, 104–105
 Quaternary ammonium products (quats), 1298
 Quinacrine toxicity, 1291
 Quinolones
 for coccidiosis, 1160, 1161
 for *Mycoplasma iowae*, 910
 Ragwort toxicity, 1305
Raillietina cesticillus, 1135, 1136f, 1137, 1137f–1139f, 1138, 1140, 1143
Raillietina echinobothrida, 137f–1139f, 1137, 1138, 1141
Raillietina georgiensis, 1139f, 1141, 1141f–1142f
Raillietina ransomi, 1141f, 1142f
Raillietina tetragona, 1137, 1137f–1139f, 1138, 1140
Raillietina williamsi, 1139f, 1141f, 1142f
 Random amplification of polymorphic DNA (RAPD)
 for botulism, 956
 for *Campylobacter*, 742
 for *E. coli*, 756
 for erysipelas, 988
 for *Mycoplasma gallisepticum*, 880, 882
 for *Mycoplasma synoviae*, 902
 for *Ornithobacterium rhinotracheale*, 829
 for *Salmonella*, 695
 Ranikhet disease. *See* Newcastle disease
 Rapeseed meal toxicity, 1306
 Rapid agglutination test
 Mycoplasma meleagridis, 899
 Ornithobacterium rhinotracheale, 832
 RDRP. *See* RNA-dependent RNA polymerase
 Real-time polymerase chain reaction
 for aviadenovirus, 300
 for avian hepatitis E virus infection, 500
 for chicken infectious anemia virus, 262
 for *Chlamydia*, 1058
 for infectious bronchitis virus, 150
 for infectious bursal disease, 232
 up-regulation of induced cytokines, 70
 Real-time reverse transcriptase polymerase chain reaction (RRT-PCR)
 for astrovirus, 394
 for duck hepatitis type I, 427
 for influenza virus, 201, 202
 for Newcastle disease, 103, 104
 for reovirus in turkeys, 364
 for turkey coronavirus, 380
 Recombinant vaccines
 for avian metapneumovirus, 119
 for colibacillosis, 783
 development of, 34–35
 for fowlpox virus, 345–346
 for infectious bronchitis, 153
 for infectious bursal disease, 234
 for Newcastle disease, 106
 Recombination, infectious bronchitis virus and, 142
 Recovery, 9
 Red mites (*Dermanyssus gallinae*), 26, 52, 1101, 1101f
 Renal system tumors, 578–582, 611
 clinical signs, 570
 differential diagnosis, 591
 incubation period, 570
 microscopic, 578, 579f, 580
 pathogenesis, 580
 ultrastructural, 580
 Reoviridae, 382, 382f
 Reoviruses, 351–366
 diseases in chickens, 362–363
 enteric disease, 362–363
 hydropericardium, 363
 inclusion body hepatitis, 363
 respiratory disease, 362
 runting-stunting/brittlebone disease/malabsorption syndrome in broilers, 363
 systemic infections, 363
 diseases in turkeys, 363–364
 enteric disease, 364
 immunosuppression, 364
 myocarditis, 364
 tenosynovitis, 363–364
 in ducks and geese, 364–365
 overview, 351–352, 361–362
 viral arthritis, 352–361
 in waterfowl, 419–420
 Repetitive extragenic palindromic sequence PCR (REP-PCR)
 for *Pasteurella multocida*, 813
 for *Salmonella*, 695
 Replication complication complex, of Newcastle disease virus, 97
 Reproductive system diseases, 1256–1257
 cystic right oviduct, 1256, 1256f
 egg-bound, 1256
 egg problems, 1257
 false layer, 1256
 impacted oviduct, 1256
 internal layer, 1256
 neoplastic, 605–611
 mesosalpinx, 608
 leiomyoma, 608, 609f
 ovary, 605–608
 adenocarcinoma, 605, 606f
 arrhenoblastoma, 607–608, 608f
 dysgerminoma, 608
 granulosa-theca cell tumor, 606–607, 607f
 ovarian Sertoli cell tumors, 608, 608f
 oviduct, 609–610
 adenocarcinoma, 609–610, 609f–610f
 testis, 610–611
 Leydig cell tumors, 611
 seminoma, 610, 611f
 Sertoli cell tumor, 610, 611f

- Reticuloendotheliosis, 336, 345, 593–604
 chemical composition, 594–595
 classification, 594
 clinical signs, 598
 definition, 593
 diagnosis, 602–603
 differential diagnosis, 603–604
 economic significance, 593
 etiology, 593–597
 history, 593
 immunity, 601–602
 incidence and distribution, 597
 incubation period, 598
 laboratory host systems, 596–597
 morphology, 594
 natural and experimental hosts, 597
 pathogenesis, 600–601
 acute reticulum cell neoplasia, 601
 chronic lymphomas, 601
 runting disease syndrome, 601
 virus infection, 600–601
 pathology, 598–600
 acute reticulum cell neoplasia, 600, 600f
 chicken bursal lymphoma, 599, 599f
 chicken nonbursal lymphoma, 599, 600f
 multiple syndromes, 600
 runting disease syndrome, 598–599, 599f
 turkey lymphoma, 599–600
 prevention and control, 604
 public health significance, 593
 scientific significance, 593
 serology, 603
 strain classification, 596
 transmission, 597–598
 contaminated biological materials and, 598
 horizontal, 597–598
 vertical, 598
 vaccination, 604
 virus isolation and identification, 602–603, 603f
 virus replication, 595–596
 cytopathology, 595, 596f
 defective strain, 595
 host range, 595
 insertional mutagenesis, 596
 nondefective strains, 595
 pseudotypes, 595–596
- Reticular dysplasia, 1258
- Retroviruses. *See* Avian leukosis virus (ALV); Reticuloendotheliosis
- Reverse transcriptase polymerase chain reaction (RT-PCR)
 for APMVs, 111
 for astrovirus, 394
 for avian bornavirus, 421
 for avian hepatitis E virus infection, 500
 for avian metapneumovirus, 115, 118, 418
 for avian nephritis virus, 421, 470, 472
 for chicken proventricular necrosis virus (CPNV), 1331–1332
 for duck hepatitis virus type 1, 427
 for eastern equine encephalitis, 477
 for infectious bronchitis virus, 142, 144, 150
 for infectious bursal disease, 232
 for influenza virus, 201, 202
 for Israel turkey meningoencephalitis, 479
 for Newcastle disease, 103, 104
 for reovirus, 359, 360
 for reovirus in turkeys, 364
 for rotavirus, 385–386, 390–391
 for turkey coronavirus, 380
 for West Nile virus, 419, 481
- Reverse transcriptase polymerase chain reaction-restriction enzyme fragment length polymorphisms (RT-PCR-RFLP), infectious bursal disease, 223
- RFLP. *See* Restriction fragment-length polymorphism (RFLP) analysis
- Rhabdomyosarcoma and rhabdomyoma, 620, 621f
- Rheas
 avian intestinal spirochetosis in, 999, 1003–1004, 1003f, 1007
 influenza in, 198, 200
 tuberculosis in, 1011
- Riboflavin (vitamin B₂), 1217–1218, 1218f
- Ribotyping
Campylobacter, 742
 for *Salmonella*, 680, 695
- Ricketts, 1211, 1212f
- Riemerella anatipestifer*, 823–828
 biochemical properties, 824
 classification, 823–824
 clinical signs, 825
 definition and synonyms, 823
 diagnosis, 827
 differential diagnosis, 827
 economic significance, 823
 etiology, 823–825
 growth requirements, 824
 history, 823
 immunity, 826–827
 incidence and distribution, 825
 incubation period, 825
 management procedures, 827
 morphology and staining, 824
 natural and experimental hosts, 825
 pathobiology and epidemiology, 825–827
 pathology
 gross, 825, 826f
 microscopic, 825–826, 826f
 serology, 827
 strain classification, 824–825
 susceptibility to chemical and physical agents, 824
 transmission, carriers, and vectors, 825
 treatment, 828
 vaccination, 827–828
- Rifampicin, for tuberculosis, 1017
- Rif (resistance-inducing factor) test, 587–588, 587t
- Rimantadine, 206
- Risk
 aggregate, 8
 defined, 11, 33
 disease determinants, 8
 risk assessment, 8
- Risk analysis, 10
- Risk ratio, 8
- RNA-dependent RNA polymerase (RDRP)
 astrovirus, 392
 infectious bronchitis virus, 142
 infectious bursal disease, 220, 221
 rotavirus, 383
- Robenidine, for coccidiosis, 1160
- Rodenticide, 1114, 1115t
- Rodenticide toxicity, 1301–1302
- Rodents, 1109–1115
 control of, 17
 economic impact, 1110
 exclusion of, 1112–1113
 field identification, 1110f
 house mouse, 1111
 inspections for, 1112
 integrated pest management, 1112
 Norway (brown) rats, 1111
 population reduction, 1113–1114, 1114f, 1115t
 public health significance, 1110, 1110t
 reproductive capabilities, 1111t
 roof (black) rats, 1112
 sanitation and cultural practices, 1113, 1113f
- Ronidazole, for *Cochlosoma anatis* infection, 1185
- Roof (black) rat, 1110f, 1111t, 1112
- Roost areas, 15
- Rose chafers toxicity, 1304
- Rotated tibia, 1244, 1244f
- Rotavirus, 381–391
 chemical composition, 383
 classification, 382
 clinical signs, 386–387
 diagnosis, 390–391
 differential diagnosis, 391
 etiology, 382–386
 immunity, 389–390
 incidence and distribution, 386
 incubation period, 386–387
 intervention strategies, 391
 laboratory host systems, 385
 cell culture, 385
 chicken embryos, 386
 management procedures, 391
 morbidity and mortality, 387
 morphology, 382–383, 382f
 natural and experimental hosts, 386
 overview, 381–382
 pathobiology and epidemiology, 386–390
 pathogenesis, 388–389, 389f
 pathogenicity, 385–386
 pathology, 387–388
 gross lesions, 387
 microscopic lesions, 387–388, 388f
 serology, 391
 strain classification, 384–385
 antigenicity, 384
 genetic, 384–385, 385f
 susceptibility to physical and chemical agents, 383–384
 transmission, carriers, and vectors, 386
 vaccination, 391
 virus isolation and identification, 390–391
 virus replication, 383, 384f
- Rotavirus-like viruses (RVLVs), 382, 385
- Rotenone toxicity, 1301
- Roundworms. *See* Nematodes
- Rous sarcoma virus (RSV), 555, 559–562, 562t, 564, 564f–565f, 567, 584–587, 589, 591–592
- Roxarsone
 for *Cochlosoma anatis* infection, 1185
 toxicity, 1291
- RRT-PCR. *See* Real-time reverse transcriptase polymerase chain reaction
- RSV. *See* Rous sarcoma virus
- Rubivirus, 473
- Rubrattoxins, 1281
- Runting disease syndrome, 598–599, 599f, 601, 630–631
- Runting-stunting syndrome (RSS), 363, 388, 391, 395, 399, 402–403, 1323, 1324
- RVLVs (rotavirus-like viruses), 382, 385
- Salinomycin
 for coccidiosis, 1160, 1161
 for *Mycoplasma gallisepticum*, 892
- Salmonella* cultures, 30
- Salmonella enterica* subsp. *arizonae*, 706–713
- Salmonella enterica* subsp. *enterica* serovar Enteritidis, 693–701, 704–706
- Salmonella enterica* subsp. *enterica* serovar Gallinarum-Pullorum, 678, 679
- Salmonella enterica* subsp. *enterica* serovar Typhimurium, 693, 696, 698, 701, 705
- Salmonella* Gallinarum, 678–693, 694
- Salmonella* Heidelberg, 698
- Salmonella* Infantis, 698
- Salmonella* infections, 677–713
 arizonosis, 706–713
 chicken infectious anemia as cofactor in disease, 261–262
 fowl typhoid, 678–693
 genetic resistance to, 76–77
 paratyphoid infections, 693–709
 public health significance, 50
 nature of disease in humans, 50
 occurrence, 50
 reservoirs and sources of infection, 50
 pullorum disease, 678–693
- Salmonella* Pathogenicity Island, 691, 692

- for avian intestinal spirochetosis, 1005
- for avian metapneumovirus, 118
- for avian nephritis virus, 472
- for *Avibacterium paragallinarum*, 866–867
- for *Bordetella avium*, 842
- for chicken infectious anemia, 262–263
- for *Chlamydia*, 1067
- for circovirus, 274
- for duck hepatitis virus type 1, 427
- for duck virus enteritis, 439
- for eastern equine encephalitis, 477
- for egg drop syndrome virus, 306–307
- for enterovirus-like viruses, 399
- for erysipelas, 993
- for fowl typhoid, 690, 691
- for hemorrhagic enteritis virus, 314–315
- for infectious bursal disease, 232–233
- for infectious laryngotracheitis, 171
- for influenza, 202–203
- interpretation of serologic data, 24–25
- for Israel turkey meningoencephalitis, 479
- for leukosis/sarcoma group of neoplastic diseases, 589
- for *Mycoplasma gallisepticum*, 889
- for *Mycoplasma iowae*, 910
- for *Mycoplasma meleagridis*, 899
- for *Mycoplasma synoviae*, 905
- for Newcastle disease, 103, 104
- for *Ornithobacterium rhinotracheale*, 833
- for paratyphoid infections, 703–704
- for parvovirus of chickens and turkeys, 405
- for parvovirus of waterfowl, 449
- for pigeon herpesvirus, 467
- for poxvirus, 342–343
- for pullorum disease, 690, 691
- for reticuloendotheliosis, 603
- for *Riemerella anatipestifer* infection, 827
- for rotavirus, 391
- for staphylococcosis, 977
- for toxoplasmosis, 1194
- for tuberculosis, 1016
- for turkey coronavirus, 381
- for viral arthritis, 360
- Serotyping, of *Pasteurella multocida*, 811–812
- Sertoli cell tumor, 608, 608f, 610, 611f
- Serum neutralization, for egg drop syndrome virus, 306–307
- Serum plate agglutination test
- for *Mycoplasma gallisepticum*, 889
- for *Mycoplasma synoviae*, 905
- for *Ornithobacterium rhinotracheale*, 833
- Sex reversal, 1257
- Shaft louse/small body louse (*Menopon gallinae*), 1104, 1105f
- Siadenovirus, 289t, 290, 310
- Sicarius* spp., 1129
- Sicarius uncinipenis*, 1129
- Sicarius waltoni*, 1129
- Sickle pod toxicity, 1304
- Singhifilaria hayesi*, 1129, 1130f
- Single nucleotide polymorphisms (SNPs), 74
- Sinusitis, *Mycoplasma gallisepticum* and, 884, 884f, 885
- Skeletal diseases, 1238–1244
- degenerative joint disease, 1242
- dyschondroplasia, 1238–1240
- clinical signs, 1238
- intervention strategies, 1239–1240
- pathogenesis and etiology, 1239
- pathology, 1238–1239, 1238f
- osteocondrosis, 1244
- osteoporosis, 1240–1241
- clinical signs and pathology, 1240
- intervention strategies, 1240–1241
- pathogenesis and etiology, 1240
- rotated tibia, 1244, 1244f
- spondylolisthesis, 1243, 1243f
- spontaneous bone fractures, 1242–1243
- spraddle legs, 1244, 1244f
- valgus and varus deformities, 1241–1242, 1241f
- Skin disease. *See also* Dermatitis
- contact dermatitis, 1257–1258, 1257f
- dermatophytosis, 1091
- poxvirus as, 338f, 340–341, 342
- Snipe (*Gallinago gallinago*), APMV-11 in, 110
- SNPs (single nucleotide polymorphisms), 74
- Sodium
- deficiency, 1223, 1224f
- toxicity, 1293–1294
- Sodium arsonate toxicity, 1291
- Sodium monofluoroacetate (compound 1080) toxicity, 1301
- Sodium salicylate, for colibacillosis, 785
- Solanine toxicity, 1305
- Source of infection, 9
- Specific pathogen free (SPF) flocks
- APMVs and, 108–109, 111
- astrovirus, 394
- aviadenovirus, 300
- avian metapneumovirus, 418
- avian nephritis virus, 469–471, 473
- chicken infectious anemia, 263, 264
- chicken infectious anemia virus, 254
- enteric viruses, 375
- infectious bronchitis virus, 142
- infectious laryngotracheitis, 161
- Newcastle disease and, 102
- parvovirus of chickens and turkeys, 402–403
- pox virus, 339, 342
- reticuloendotheliosis and, 593
- rotavirus, 391
- Spectinomycin
- for arizonosis, 713
- for *Mycoplasma meleagridis*, 899
- for *Mycoplasma synoviae*, 906
- for *Riemerella anatipestifer*, 828
- SPF. *See* Specific pathogen free (SPF) flocks
- Spinareovirinae, 382
- Spiramycin
- for *Mycoplasma gallisepticum*, 893
- for *Mycoplasma meleagridis*, 899
- Spirochetosis
- avian intestinal, 995–1007
- Borrelia anserina*, 1018–1020, 1018f–1019f
- Spirochela meleagridis*, 1181–1182, 1181f
- Spleen
- anatomy, 64f
- in APMV infection, 110
- in avian hepatitis E virus, 497, 497f
- in *Borrelia anserina* infection, 1019, 1019f
- in erysipelas, 991, 992f
- in marble spleen disease, 309–316, 312f–313f
- in Newcastle disease, 100f, 101
- in paratyphoid infections, 700
- in pullorum disease, 685, 685f, 687
- in quail bronchitis virus infection, 319
- Spondylitis, 778, 778f
- Spondylolisthesis, 1243, 1243f
- Spray vaccination, 36–37
- Spread of disease, 9
- Squamous cell carcinoma
- digestive tract, 611, 612f
- integumentary, 617
- Staphylococcosis, 971–977
- antigen structures, 973
- biochemical properties, 973
- classification, 972–973
- clinical signs, 974
- colony morphology, 973
- diagnosis, 976–977
- differential diagnosis, 977
- economic significance, 972
- etiology, 972–973
- growth requirements, 973
- history, 972
- immunity, 976
- incidence and distribution, 974
- incubation period, 974
- location of infections, 971–972, 972t
- management procedures, 977
- morbidity and mortality, 974
- morphology and staining, 973
- MRSA, 972
- pathobiology and epizootiology, 974–976
- pathology
- gross, 974–976, 975f
- microscopic, 975f, 976
- public health significance, 50, 972
- nature of disease in humans, 50
- occurrence, 50
- reservoirs and sources of infection, 50
- serology, 977
- strain classification, 973
- susceptibility to chemical and physical agents, 973
- toxins, 973
- transmission, 974
- treatment, 977
- vaccination, 976, 977
- virulence factors, 973
- Staphylococcus aureus*, 50, 957, 971–977, 976t
- Staphylococcus epidermidis*, 973, 976, 976t
- Staphylococcus hyicus*, 973
- Stargazing posture, 1216, 1217f
- Starling circovirus (StCV), 265–267
- Starve-out, 1235
- Sticktight flea (*Echidnophaga gallinacea*), 1103, 1103f
- Streptobacillus moniliformis*, 1026
- Streptococcosis, 977–980
- clinical signs, 978
- diagnosis, 979–980
- differential diagnosis, 980
- etiology, 978
- history, 978
- pathobiology and epidemiology, 978
- pathology, 978–979, 979f–980f
- treatment, 980
- Streptococcus bovis*, 978, 980
- Streptococcus dysgalactiae*, 978
- Streptococcus gallinarum*, 978
- Streptococcus mutans*, 978
- Streptococcus pleomorphus*, 978
- Streptococcus zooepidemicus*, 978–980
- Streptomycin
- for fowl cholera, 821–822
- for *Mycoplasma gallisepticum*, 892
- for *Mycoplasma meleagridis*, 899
- for ulcerative enteritis, 948
- Stress, 12
- heat stress, 1234
- Marek's disease and, 532
- Strobila, 1136
- Strongyloides avium*, 1129, 1130f
- Strychnine toxicity, 1301
- Subcutaneous injection, vaccination by, 36, 37–38
- Subulura brumpti*, 1130
- Subulura* spp., 1124f, 1129–1130
- Subulura strongylina*, 1124f, 1130
- Subulura suctoria*, 1124f, 1130
- Sudden death syndrome (SDS), 1250–1251
- Sulfa drugs, for *Riemerella anatipestifer*, 828
- Sulfate toxicity, 1294
- Sulfonamides
- for coccidiosis, 1159, 1160, 1161, 1165, 1166
- for fowl cholera, 821–822
- for infectious coryza, 868
- for leucocytozoonosis, 1188
- for pullorum disease, 692
- toxicity of, 1288–1289
- for ulcerative enteritis, 948
- Sulfur toxicity, 1298
- Surgical procedures, in hatchery, 19
- Surveillance, 23–24
- Sus herpesvirus 1, 467
- Suttonella*, 1026
- Swan circovirus (SwCV), 265–267

- reovirus, 353
 Thiamin (vitamin B₁), 1216–1217, 1217f
 Thimerosal, 867
 Thiram toxicity, 1299
 Thymic atrophy, in Newcastle disease, 101
 Thymidine kinase (TK) gene, pox, 337
 Thymus
 atrophy in chicken infectious anemia, 255, 255f, 257
 described, 61–63, 62f
 neoplasia of, 617
 Thyroid gland, neoplasia of, 617
 Thyroxine, 1224
 Tiamulin
 for avian intestinal spirochetosis, 1007
 for *Mycoplasma gallisepticum*, 892
 for *Mycoplasma meleagridis*, 899
 for *Mycoplasma synoviae*, 906
 Tibia, rotated, 1244, 1244f
 Tibial dyschondroplasia (TD), 1211, 1238–1240, 1238f
 Ticks, 1105
 control measures, 17
 external examination for, 26
 Tilmicosin, for *Mycoplasma gallisepticum*, 893
 Tin toxicity, 1297
 T lymphocytes, in Newcastle disease, 101
 TNF- α (tumor necrosis factor- α), 67
 Tobacco toxicity, 1306
 TOC (turkey osteomyelitis complex), 778–779
 Togaviridae, 473–474, 474f
 Toll-like receptors (TLRs), 63, 77
 Torticollis
 in fowl cholera, 817, 817f
 in *Listeria* infection, 1022
 Toxaphene toxicity, 1300
 Toxic fat syndrome, 1303
 Toxicity, 1287–1306
 amino acids, 1292
 anthelmintics, 1292
 benzimidazoles, 1291
 imidazothiazoles, 1292
 ivermectin, 1292
 organophosphates, 1292
 antimicrobials, anticoccidials, and growth promotants, 1288–1292
 aminoglycosides, 1290
 antiprotozoals, 1291
 nitrofurans, 1289–1290
 sulfonamides, 1288–1289
 antimicrobials and growth promotants
 arsenical and imidazole feed additives, 1291–1292
 antinutrients, 1292
 avicides, 1302
 biotoxins, 1304
 algae, 1304
 rose chafers, 1304
 boric acid and orthoboric acid, 1298
 disinfectants and fumigants, 1298–1299
 chlorine, 1298
 coal-tar derivatives, 1298
 formaldehyde, 1298–1299
 phenolics, 1298
 quaternary ammonium, 1298
 ethoxyquin, 1297
 feed levels of, 1288t
 fungicides, 1299
 captan, 1299
 organic mercurials, 1299
 thiram, 1299
 gases
 aerial endotoxin, 1302
 ammonia, 1302
 carbon monoxide, 1302
 polytetrafluoroethylene, 1302
 herbicides, 1299
 chlorates, 1299
 diquat, 1299
 paraquat, 1299
 household and commercial products
 alcohol, 1302–1303
 antifreeze (ethylene glycol), 1303
 carbon tetrachloride, 1303
 fertilizer, 1303
 naphthalene, 1303
 urea, 1303
 industry-related
 crude petroleum and oils, 1303–1304
 dioxin, 1303
 PCB and PBB, 1303
 insecticides, 1299–1301
 carbamate, 1300–1301
 nicotine, 1301
 organochlorides, 1299–1300
 organophosphates, 1300–1301
 pyrethrum and pyrethroids, 1301
 rotenone, 1301
 iron, 1298
 arsenic, 1294
 cadmium, 1294
 chromium, 1294
 lead, 1295–1297, 1295f–1296f
 mercury, 1297
 tin, 1297
 uranium, 1297
 vanadium, 1297
 minerals, 1292–1297
 aluminum, 1293
 calcium, 1293
 cobalt, 1293
 copper, 1293
 fluorine, 1293
 iodine, 1293
 magnesium, 1293
 phosphorus, 1293
 potassium, 1293
 selenium, 1294
 sodium, 1293–1294
 sulfate, 1294
 zinc, 1294
 molluscicides, 1302
 nitrate and nitrite, 1297
 pentachlorophenol, 1298
 phytotoxins, 1304–1306
 avocado, 1304
 black locust, 1304
 bladder pod, 1304
 cacao, 1304
 Carolina jessamine, 1304
 cassava, 1304
 castor bean, 1304
 coffee senna, 1304
 corn cockle, 1304
 cotton seed meal, 1305
 coyotillo, 1305
Crotalaria spp., 1305
Daubentonia, 1305
 death camas, 1305
Eucalyptus cladocalyx, 1305
 hemlock, 1305
 jimsonweed, 1305
Leucaena leucocephala, 1305
 lily of the valley, 1305
 milkweed, 1305
 nightshade, 1305
 nitrates, 1305
 oak, 1305
 oleander, 1305
 onions, 1305
 oxalates, 1305
 parsley, 1305
 pokeberry, 1305
 rapeseed meal, 1306
 sickle pod, 1304
 sweet pea, 1306
 tannins, 1306
 tobacco, 1306
 velvetweed, 1306
 vetch, 1306
 yellow jessamine, 1306
 yew, 1306
 protein supplements, 1292
 rodenticides, 1301–1302
 sulfur, 1298
 vitamins, 1297
 vitamin A, 1297
 vitamin B₆ (pyridoxine), 1297
 vitamin D₃ (cholecalciferol), 1297
 Toxins
Aspergillus spp., 1080
Bordetella avium, 836, 837
Clostridium botulinum, 953–957
Clostridium perfringens, 949–950
Clostridium septicum, 957
Escherichia coli, 755, 759
Pasteurella multocida, 813–814
Salmonella spp., 695
Staphylococcus aureus, 973
 Toxoplasmosis, 1192–1194
 diagnosis, 1194
 disease course, 1193
 etiology, 1192–1193
 life cycle, 1193
 pathology, 1194
 prevention, 1194
 public health significance, 52–53
 nature of disease in humans, 52
 occurrence, 52–53
 reservoirs and sources of infection, 53
 serology, 1194
 transmission, carriers, and vectors, 1193
 zoonosis, 1192, 1194
 Tracheal organ cultures, for avian metapneumovirus, 117
 Transcriptome profiling, 75
 Transit facility, 23
 Transmissible enteritis. *See* Turkey coronavirus enteritis
 Transmissible viral proventriculitis (TVP), 1328–1332
 classification, 1328
 clinical signs, 1330
 definition and synonyms, 1328
 diagnosis, 1331–1332
 etiology, 1328–1329
 history, 1328
 incidence and distribution, 1328
 incubation period, 1329–1330
 isolation and identification of agent, 1331–1332
 laboratory host systems, 1329
 morbidity and mortality, 1330
 morphology, 1329, 1329f
 natural and experimental hosts, 1329
 pathogenesis and epizootiology, 1329–1331
 pathology, 1330–1331
 gross lesions, 1330, 1330f
 microscopic lesions, 1330–1331, 1331f
 prevention and control, 1332
 public health significance, 1328
 transmission, 1329
 Transmission, types of, 9
 Traps, rodent, 1113–1114, 1114f
 Trematodes, 1143–1144
 control, 1144
 identification, 1144
 life cycle, 1144, 1144f
 morphology, 1143, 1143f
 pathogenicity, 1144
Trichomonas gallinae, 1179–1181
 Trichomoniasis, 1179–1181
 description, 1179, 1179f
 diagnosis, 1180
 immunity, 1180
 incidence and distribution, 1179–1180
 life cycle, 1180
 pathology, 1180
 prevention and control, 1180–1181
Trichostrongylus tenuis, 1132, 1132f
 Trichotheceae, 1272–1273, 1273f–1274f
 TRT (turkey rhinotracheitis). *See* Avian metapneumovirus (aMPV)
 Trypanosomiasis, 1190
 Tryptophan, 1219
 T-2 toxin, 1272–1273, 1273f–1274f
 Tube agglutination
 for arizonosis, 712
 for fowl cholera, 811
 for *Mycoplasma gallisepticum*, 889
 for *Mycoplasma meleagridis*, 899
 Tuberculin test, 1016
 Tuberculosis, 1008–1017
 antibiotic sensitivity, 1009

- strain classification, 378
susceptibility to physical and chemical agents, 377
transmission, carriers, and vectors, 378
treatment, 381
virus isolation, 380
virus replication, 377, 377f–378f
- Turkey coryza. *See* Bordetellosis
- Turkey herpesvirus (HVT), 551–552
- Turkey osteomyelitis complex (TOC), 778–779
- Turkeypox virus, 339, 340, 341
- Turkey rhinotracheitis (TRT). *See* Avian metapneumovirus (aMPV)
- Turkeys
- Acinetobacter* spp. in, 1017
 - adenoviruses in, 290, 294, 296, 297
 - Aegyptianella* in, 1017
 - Aeromonas* spp. in, 1017–1018
 - APMVs in, 107, 109–111
 - Arcanobacterium pyogenes* in, 1018
 - arizonosis in, 706–713
 - aspergillosis in, 1078–1088, 1083f–1084f
 - astrovirus in, 391–394
 - aviadenovirus infection in, 297
 - avian encephalomyelitis in, 487
 - avian intestinal spirochetosis in, 999
 - avian metapneumovirus in, 112–119, 417–418
 - Avibacterium paragallinarum* in, 863
 - Bacillus* spp. in, 1018
 - bordetellosis in, 834–844
 - Borrelia anserina* in, 1018–1019
 - botulism in, 954, 955
 - candidiasis in, 1088–1090
 - Chlamydia* in, 1060, 1062–1064, 1063f
 - Citrobacter* infection in, 1020
 - coccidiosis in, 1162t, 1163–1165
 - Cochlosoma anatis* in, 1182–1185
 - cryptosporidiosis in, 1170
 - dactylarthritis in, 1095
 - deep pectoral myopathy in, 1244–1245
 - degenerative joint disease in, 1242, 1242f
 - dilated cardiomyopathy in, 1249–1250
 - eastern equine encephalitis in, 475, 476f
 - Enterobacter* spp. in, 1020
 - enterovirus-like viruses in, 395, 399
 - erysipelas in, 986–994
 - Flavobacterium* in, 1020
 - fowl cholera in, 807–823
 - fowl typhoid in, 678–693
 - Gallibacterium* in, 1020–1021
 - gangrenous dermatitis in, 957–960
 - Haemoproteus meleagridis* in, 1189–1190
 - Helicobacter* in, 1021
 - hemorrhagic enteritis in, 309–316
 - herpesvirus in, 551–552
 - hexamitiasis in, 1181–1182
 - Highlands J virus in, 476
 - histomoniasis in, 1147, 1172–1179
 - infectious bursal disease in, 222, 224, 225–226
 - influenza in-, 181–206
 - Israel turkey meningoencephalitis in, 478–479
 - Klebsiella* spp. in, 1021
 - leucocytozoonosis in, 1186–1187, 1187f
 - Listeria* in, 1022
 - liver granulomas in, 1027
 - macrorhabdosis in, 1092
 - Marek's disease in, 519
 - Moraxella* spp. in, 1022
 - multicausal enteric diseases in, 1322–1325
 - Mycoplasma gallisepticum* infection in, 877–893
 - Mycoplasma iowae* infection in, 907–910
 - Mycoplasma meleagridis* infection in, 893–900
 - Mycoplasma synoviae* infection in, 900–906
 - necrotic enteritis in, 949–953
 - Neisseria* in, 1023
 - Newcastle disease in, 98, 101, 107
 - nutritional diseases in, 1205–1227
 - ochroconosis in, 1091
 - Ornithobacterium rhinotracheale* infection in, 828–834
 - osteochondrosis in, 1244
 - oviductal adenocarcinoma in, 609
 - parvovirus in, 399–405
 - pododermatitis in, 1257–1258, 1257f
 - poxvirus in, 333–346
 - Proteus* spp. in, 1023
 - Pseudomonas* in, 1024–1025
 - pullorum disease in, 678–693
 - reoviruses in, 363–364
 - enteric disease, 364
 - myocarditis, 364
 - reticuloendotheliosis in, 593–604
 - Riemerella anatipestifer* in, 823, 825
 - rotated tibia in, 1244, 1244f
 - rotavirus in, 382–383, 384f, 385–391, 389f
 - Rothia* spp. in, 1025
 - segmented filamentous bacteria in, 1025–1026
 - spraddle legs in, 1244, 1244f
 - staphylococcosis in, 971–977
 - Streptobacillus* spp. in, 1026
 - streptococcosis in, 977–980
 - tapeworms of, 1141–1142
 - tibial dyschondroplasia in, 1238–1240
 - toxoplasmosis in, 1193
 - trichomoniasis in, 1179–1180
 - tuberculosis in, 1008, 1011
 - turkey coronavirus enteritis in, 376–381
 - turkey viral hepatitis in, 482–485, 484f–485f
 - valgus and varus deformation in, 1241–1242
 - Vibrio* in, 1026
 - viral arthritis in, 351, 354, 356
 - western equine encephalitis in, 477–478
 - West Nile virus in, 481
 - Turkey viral hepatitis (TVH), 482–485, 484f–485f
 - chemical composition, 482
 - classification, 482
 - clinical signs, 483
 - diagnosis, 484
 - etiology, 482
 - history, 482
 - immunity, 484
 - incidence and distribution, 483
 - incubation period, 483
 - intervention strategies, 484
 - laboratory host systems, 482
 - morbidity and mortality, 483
 - morphology, 482
 - natural and experimental hosts, 483
 - overview, 482
 - pathogenesis and epizootiology, 483–484
 - pathology, 483
 - gross lesions, 483, 484f
 - microscopic lesions, 483, 485f
 - susceptibility to physical and chemical agents, 482
 - transmission, carriers, and vectors, 483
- Turnaround time, 12
- TVH. *See* Turkey viral hepatitis
- TVP. *See* Transmissible viral proventriculitis
- Tylosin
 - for *Mycoplasma gallisepticum*, 892–893
 - for *Mycoplasma meleagridis*, 899, 900
 - for *Mycoplasma synoviae*, 906
- Tyzzeria perniciosus*, 1166
- Ulcerative enteritis, 944–949
 - biochemical characteristics, 945
 - classification, 944
 - clinical signs, 945–946
 - diagnosis, 946–948
 - differential diagnosis, 948
 - etiology, 944–945
 - growth requirements, 945
 - history, 944
 - immunity, 946
 - incidence and distribution, 945
 - incubation period, 945
 - management procedures, 948
 - morphology and staining, 944–945, 944f
 - mortality rate, 946
 - natural and experimental hosts, 945
 - pathology
 - gross lesions, 946, 947f
 - histopathology, 946
 - susceptibility to chemical and physical agents, 945
 - transmission, 945
 - treatment, 948–949
- UPEC (uropathogenic *Escherichia coli*), 757
- Uranium toxicity, 1297
- Urate deposition
 - articular, 1255–1256, 1256f
 - visceral, 1254–1255, 1254f
- Ureaplasma*, 875, 911
- Urea toxicity, 1303
- Ureidobenzeneearsonic acid toxicity, 1291
- Urinary system disease, 1254–1256, 1254f–1256f
 - articular urate deposition, 1255–1256, 1256f
 - neoplastic, 578–582
 - uroolithiasis, 1254–1255, 1255f
 - visceral urate deposition, 1254–1255, 1254f
- Urogenital system, neoplastic diseases
- Urolithiasis, 1254–1255, 1255f
- Uropathogenic *Escherichia coli* (UPEC), 757
- Vaccination, 34–38
 - adjuvants, 35, 106
 - APMVs, 111–112
 - arizonosis, 712–713
 - aviadenovirus, 300
 - avian encephalomyelitis, 493
 - avian metapneumovirus, 119
 - booster, 63
 - Bordetella avium*, 843
 - Borrelia anserina*, 1020
 - botulism, 956
 - Campylobacter*, 743
 - characteristics of live and inactivated vaccines, 35t
 - chicken infectious anemia, 263–264
 - Chlamydia*, 1068
 - coccidiosis, 1161
 - delivery systems, 36–38
 - drinking water, 37
 - intraocular, 37
 - nasal drop, 37
 - in ovo vaccination, 36, 36f
 - spray vaccination, 36–37
 - droplet size estimation, 37t
 - on farm, 37
 - in hatchery, 36–37
 - subcutaneous and intramuscular injections, 37–38
 - wing web stab, 37
 - DNA vaccines, 36
 - duck hepatitis virus type 1
 - breeders, 428
 - ducklings, 428–429
 - duck virus enteritis, 440
 - egg drop syndrome, 309
 - erysipelas, 992, 994
 - Escherichia coli*, 782–784
 - failure of, 38
 - fowl cholera, 819–820, 822–823
 - fowl typhoid, 692
 - hemorrhagic enteritis, 315
 - hemorrhagic nephritis enteritis of geese, 443
 - infectious bronchitis, 139, 151–153
 - application methods, 152–153
 - future vaccines, 153
 - types of vaccine, 151–152
 - infectious bursal disease, 230, 233–235
 - infectious coryza, 867–868

- Venereal colibacillosis, 773–774
- Venipuncture, 27, 27f
- Vent pecking, 1233
- Ventriculus lesions, in avian
encephalomyelitis, 488–490,
491f
- Vertebral osteomyelitis, 984, 985f
- Vertical transmission
avian leukosis viruses, 567–569, 568f
Chlamydia, 1062
Marek's disease, 529
Mycoplasma gallisepticum, 883
Mycoplasma iowae, 908
Mycoplasma meleagridis, 895
Mycoplasma synoviae, 902
Ornithobacterium rhinotracheale, 830
reticuloendotheliosis, 598
Salmonella, 699
- Vetch toxicity, 1306
- Veterinarian, calling in a disease
outbreak, 39
- V-factor testing, 866, 866f
- Vibrio*, 1026
- Viral arthritis, 352–361
age-associated resistance, 355
biophysical factors, 353–354
biosecurity, 360–361
classification, 353
clinical signs, 355–356
diagnosis, 359–360
location of virus in tissues, 360
molecular methods, 360
serology, 360
virus isolation, 359
etiology, 353–354
history, 352–353
immunity, 358–359
cell-mediated, 358–359
humoral, 358
local antibodies, 358
incidence and distribution, 353
incubation period, 355
laboratory host systems, 354
cell cultures, 354
chick embryos, 354
morbidity and mortality, 355, 356
morphology, 353
natural and experimental hosts,
354–355
overview, 352
pathobiology and epidemiology,
354–359
pathogenicity, 354
pathology, 356, 358
gross lesions, 356–357, 356f–357f
prevention and control, 360–361
strain classification, 354
susceptibility to physical and
chemical agents, 353
transmission, 355
vaccination, 361
virus replication, 353
- Viral diseases, public health
significance of, 44–46
arboviral encephalitis, 44–45
avian influenza, 45
Newcastle disease, 45–46
- Virilism, 608
- Virulence determinants, of Newcastle
disease virus, 96–97, 96t
- Virulence factors
arizonosis, 711
aspergillosis, 1080
avian intestinal spirochetosis,
997–999
Avibacterium paragallinarum, 863
Bordetella avium, 837–838
botulism, 954
Chlamydia, 1059
Clostridium perfringens, 950
erysipelas, 988–989
Mycoplasma gallisepticum, 881
Mycoplasma synoviae, 902
paratyphoid infections, 695–696
pullorum disease and fowl typhoid,
681–682
Staphylococcus, 973
- Virus identification. *See specific viruses*
- Virus isolation
astrovirus, 393
aviadenovirus, 299
avian encephalomyelitis virus, 492
avian metapneumovirus, 117
avian nephritis, 471
duck hepatitis virus type 1, 427
duck virus enteritis, 439
egg drop syndrome virus, 306
embryo inoculation for, 32–33
enterovirus-like viruses, 398–399
Gallid herpesvirus type 1, 170–171
goose hemorrhagic polyomavirus,
443
hemorrhagic enteritis virus, 314
infectious bronchitis virus, 149–150
infectious bursal disease, 231–232
influenza, 202
Marek's disease, 546–547
Newcastle disease virus, 102
parvovirus of waterfowl, 443–449
pigeon herpesvirus, 467
reticuloendotheliosis, 602
rotavirus, 390
turkey coronavirus, 380
turkey viral hepatitis, 484
viral arthritis, 359
West Nile virus, 481
- Virus neutralization (VN)
for aviadenovirus, 300
for avian encephalomyelitis virus,
492
for avian metapneumovirus, 117, 118
for chicken infectious anemia virus,
263
for duck hepatitis virus type 1, 424,
426–427
for duck virus enteritis, 439
for eastern equine encephalitis, 477
for Gallid herpesvirus type 1, 171
for infectious bronchitis virus, 142,
149–151
for infectious bursal disease, 222,
223, 229–230, 233
for infectious laryngotracheitis, 165,
170
for influenza virus, 189
for Israel turkey
meningoencephalitis, 479
for Marek's disease, 548
for Newcastle disease virus, 102
for parvovirus of waterfowl, 449
for poxvirus, 343
for reovirus, 360
for reticuloendotheliosis virus, 603
- Visceral urate deposition, 1254–1255,
1254f
- Viscerotropic velogenic Newcastle
disease (VVND), 90
- Vitamins, 1207–1221
biotin, 1220, 1220f
choline, 1221, 1221f
cobalamin (vitamin B₁₂), 1221
folic acid, 1220–1221
niacin, 1219
pantothenic acid, 1218–1219
pyridoxine (vitamin B₆), 1219–1220
riboflavin (vitamin B₂), 1217–1218,
1218f
thiamin (vitamin B₁), 1216–1217,
1217f
toxicity, 1297
vitamin A, 1297
vitamin B₆ (pyridoxine), 1297
vitamin D₃ (cholecalciferol), 1297
vitamin A, 1208–1210
deficiency, 1208–1210, 1209f
vitamin D, 1210–1213
deficiency, 1211–1212
hypervitaminosis D, 1212–1213
for tibial dyschondroplasia,
1239–1240
vitamin E, 1213–1214
for colibacillosis, 785
deficiency, 1213–1214, 1215f
vitamin K deficiency, 1215–1216
- VN. *See* Virus neutralization
- Volvulus, 1253–1254
- Warfarin toxicity, 1301
- Water
as *Campylobacter* infection source,
738
disease control and, 15, 15f
medication in, 15–16, 40–51
vaccination using, 37
- Waterfowl diseases, 417–451
adenoviruses, 420–421
avian influenza virus, 418–419
avian metapneumovirus, 417–418
avian paramyxoviruses, 417
botulism, 953–957
circovirus-like infection of geese, 421
duck hepatitis B virus (DHBV), 431
duck hepatitis type 2, 429–430
duck hepatitis type 3, 430–431
duck hepatitis type I, 422–429
classification, 422
clinical signs, 425, 425f
diagnosis
molecular methods, 427
serology, 427
virus isolation and
identification, 427
differential diagnosis, 427–428
epidemiology, 424–425
etiology, 422–424
history and distribution, 422
immunity, 426
laboratory host systems, 423–424
cell culture, 423–424
embryos, 423
management procedures, 428
morbidity and mortality, 425
morphology, 422
natural and experimental hosts,
424
pathogenicity, 424
pathology
biochemical effects, 426
gross lesions, 425, 425f
microscopic/ultrastructural
strain classification, 423
susceptibility to chemical and
physical agents, 422–423
transmission, carriers, and vectors,
424–425
treatment, 429
vaccination, 428–429
breeders, 428
ducklings, 428–429
duck virus enteritis (duck plague),
431–440
clinical signs, 435
definition and synonyms, 431
diagnosis, 439
differential diagnosis, 439
economic significance, 432
etiology, 432–433
chemical composition, 434
classification, 432
morphology, 432–433, 432f
strain classification, 433
susceptibility to chemical and
physical agents, 433
virus replication, 433
history, 432
immunity
active, 438–439
passive, 439
incidence and distribution, 434
incubation period, 435
laboratory host systems, 433
management procedures, 439
morbidity and mortality, 435
natural and experimental hosts,
434
pathology
gross lesions, 435–437,
436f–437f
microscopic lesions, 437–438,
438f
serology, 439
transmission, carriers, and vectors,
435
vaccination, 440
virus isolation and identification,
439
fowl cholera, 814
goose herpes virus (GHV), 420
hemorrhagic nephritis enteritis of
geese (HNEG), 440–443
chemical composition, 440
classification, 440
clinical signs, 442
diagnosis, 443
differential diagnosis, 443

- laboratory host systems, 445–446
- management procedures, 450
- morbidity and mortality, 447–448
- morphology, 444, 446f
- natural and experimental hosts, 446
- pathogenesis of infectious process, 448–449
- pathology
 - gross lesions, 448, 448f
 - microscopic lesions, 448, 448f
- susceptibility to chemical and physical agents, 445
- transmission, carriers, and vectors, 446–447
- vaccination, 450–451
- virus replication, 444
- Proteus* infection, 1023
- Riemerella anatipestifer*, 825
- Vibrio* infection, 1026
- West Nile virus, 419
- Water intake, 1205
- WEE (western equine encephalitis), 44–45, 473, 477–478
- Wenyonella philiplevinei*, 1166
- Western duck sickness. *See* Botulism
- Western equine encephalitis (WEE), 44–45, 473, 477–478
- West Nile virus, 479–482
 - clinical signs and pathology, 480–481
 - chickens, 480–481
 - geese, 480, 480f–481f
 - turkeys, 481
- diagnosis, 481–482
- differential diagnosis, 482
- history, 479
- immunity, 481
- incidence and distribution, 479
- intervention strategies, 482
- natural and experimental hosts, 479–480
- public health significance, 44–45, 473
- serology, 481–482
- transmission, carriers, and vectors, 480
- vaccination, 482
- virus isolation, 481
- in waterfowl, 419
- Whole genome scans, 74
- Wild birds, disease control and, 17
- Wilm's tumor, 578
- Wing web vaccination, 37
- Worker Protection Standards (WPS), 13
- World Organization for Animal Health, 9
- World Trade Organization (WTO), 9–10
- WPS (Worker Protection Standards), 13
- WTO (World Trade Organization), 9–10
- Xanthoma, 620
- Yellow jessamine toxicity, 1306
- Yew toxicity, 1306
- Yolk sac infection, *E. coli*, 766–768, 767f
- Zanamivir, 206
- Zearalenone, 1275–1276
- Zinc
 - deficiency, 1225–1226
 - excess, 1226
 - toxicity, 1294
- Zinc phosphide toxicity, 1302
- Zoalene, for coccidiosis, 1160
- Zoning, 10
- Zoonosis. *See specific diseases*
- Zoos, 17
- Zygomycosis, 1092

Keep up with critical fields

Would you like to receive up-to-date information on our books, journals and databases in the areas that interest you, direct to your mailbox?

Join the **Wiley e-mail service** - a convenient way to receive updates and exclusive discount offers on products from us.

Simply visit www.wiley.com/email and register online

We won't bombard you with emails and we'll only email you with information that's relevant to you. We will ALWAYS respect your e-mail privacy and NEVER sell, rent, or exchange your e-mail address to any outside company. Full details on our privacy policy can be found online.



www.wiley.com/email

ISBN 978-0-4709-5899-5

